

Help for cytotoxic-T-cell responses is mediated by CD40

Nature

393, 478-480

DOI: 10.1038/30996

Citation Report

#	ARTICLE	IF	CITATIONS
1	The original sin of killer T cells. <i>Nature</i> , 1998, 394, 421-422.	13.7	34
2	The ends of an era. <i>Nature</i> , 1998, 394, 422-423.	13.7	11
3	Licence to kill. <i>Nature</i> , 1998, 393, 413-414.	13.7	344
4	Tumor-specific killer cells in paraneoplastic cerebellar degeneration. <i>Nature Medicine</i> , 1998, 4, 1321-1324.	15.2	451
5	The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. <i>Nature</i> , 1998, 395, 462-469.	13.7	894
6	Induction of peripheral CD8+ T-cell tolerance by cross-presentation of self antigens. <i>Immunological Reviews</i> , 1998, 165, 267-277.	2.8	71
7	Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. <i>Nature Medicine</i> , 1998, 4, 1409-1415.	15.2	223
8	The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. <i>Immunological Reviews</i> , 1998, 165, 231-247.	2.8	271
9	A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. <i>European Journal of Immunology</i> , 1998, 28, 4084-4093.	1.6	157
10	Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells. <i>Current Opinion in Immunology</i> , 1998, 10, 444-449.	2.4	109
11	The role of CD4+ T cell responses in antitumor immunity. <i>Current Opinion in Immunology</i> , 1998, 10, 588-594.	2.4	593
12	Cross-presentation: a general mechanism for CTL immunity and tolerance. <i>Trends in Immunology</i> , 1998, 19, 368-373.	7.5	236
13	Induction of MHC-class I restricted human suppressor T cells by peptide priming in vitro. <i>Human Immunology</i> , 1998, 59, 690-699.	1.2	84
14	T-cell help exposed. <i>Trends in Microbiology</i> , 1998, 6, 305.	3.5	0
15	Local Expression of TNF α in Neonatal NOD Mice Promotes Diabetes by Enhancing Presentation of Islet Antigens. <i>Immunity</i> , 1998, 9, 733-743.	6.6	181
16	Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function. <i>Journal of Experimental Medicine</i> , 1998, 188, 2205-2213.	4.2	1,733
17	CD40 \leftrightarrow CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. <i>Seminars in Immunology</i> , 1998, 10, 443-448.	2.7	93
18	The Central Role of CD4+ T Cells in the Antitumor Immune Response. <i>Journal of Experimental Medicine</i> , 1998, 188, 2357-2368.	4.2	1,194

#	ARTICLE	IF	CITATIONS
19	In vivo priming of T cells against cryptic determinants by dendritic cells exposed to interleukin 6 and native antigen. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 14903-14908.	3.3	97
20	The Critical Need for CD4 Help in Maintaining Effective Cytotoxic T Lymphocyte Responses. Journal of Experimental Medicine, 1998, 188, 2199-2204.	4.2	610
21	Papillomavirus vaccines. Frontiers in Bioscience - Landmark, 1998, 3, d1192-1208.	3.0	15
22	Enhancement of tumoricidal activity of alveolar macrophages via CD40-CD40 ligand interaction. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 277, L49-L57.	1.3	21
23	Cancer Vaccines. Journal of Clinical Oncology, 1999, 17, 1047-1047.	0.8	139
24	Rapid Induction of CD40 on a Subset of Granulocyte Colony-Stimulating Factor- Mobilized CD34+ Blood Cells Identifies Myeloid Committed Progenitors and Permits Selection of Nonimmunogenic CD40+ Progenitor Cells. Blood, 1999, 94, 2293-2300.	0.6	30
25	Dendritic Cells Derived In Vitro From Acute Myelogenous Leukemia Cells Stimulate Autologous, Antileukemic T-Cell Responses. Blood, 1999, 93, 780-786.	0.6	233
26	HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. Aids, 1999, 13, 2003-2012.	1.0	44
27	A Critical Role for Cd40-Cd40 Ligand Interactions in Amplification of the Mucosal Cd8 T Cell Response. Journal of Experimental Medicine, 1999, 190, 1275-1284.	4.2	74
28	Th1 but not Th0 cell help is efficient to induce cytotoxic T lymphocytes by immunization with short synthetic peptides. International Immunology, 1999, 11, 2025-2034.	1.8	21
29	CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 9305-9310.	3.3	569
30	Selective Expansion of Cross-Reactive Cd8+ Memory T Cells by Viral Variants. Journal of Experimental Medicine, 1999, 190, 1319-1328.	4.2	110
31	T Helper Cell Type 1-associated and Cytotoxic T Lymphocyte-mediated Tumor Immunity Is Impaired in Interleukin 4-deficient Mice. Journal of Experimental Medicine, 1999, 189, 803-810.	4.2	163
32	Two differently regulated nuclear factor- κ B activation pathways triggered by the cytoplasmic tail of CD40. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 1234-1239.	3.3	97
33	Sensitized Lymphocytes and CD40 Ligation Augment Interleukin-12 Production by Human Dendritic Cells in Response to Toxoplasma gondii. Journal of Infectious Diseases, 1999, 179, 467-474.	1.9	37
34	DNA Vaccination: Transfection and Activation of Dendritic Cells as Key Events for Immunity. Journal of Experimental Medicine, 1999, 189, 169-178.	4.2	340
35	Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes. Journal of Experimental Medicine, 1999, 189, 767-778.	4.2	210
36	The Future of Organ and Tissue Transplantation. JAMA - Journal of the American Medical Association, 1999, 282, 1076.	3.8	72

#	ARTICLE	IF	CITATIONS
37	Mature Dendritic Cells Induce T-Helper Type-1-Dominant Immune Responses in Patients with Metastatic Renal Cell Carcinoma. <i>Urologia Internationalis</i> , 1999, 63, 151-159.	0.6	70
38	CD4 T Cells and Their Role in Antitumor Immune Responses. <i>Journal of Experimental Medicine</i> , 1999, 189, 753-756.	4.2	460
39	Human Interleukin-12 Enhances Interferon- γ -Producing Influenza-Specific Memory CD8+Cytotoxic T Lymphocytes. <i>Journal of Infectious Diseases</i> , 1999, 180, 1477-1486.	1.9	30
40	Co-stimulatory molecules B7-1 and B7-2 as experimental therapeutic targets. <i>Expert Opinion on Therapeutic Targets</i> , 1999, 3, 93-108.	1.0	1
41	Immune regulatory loops determine productive interactions within human T lymphocyte-dendritic cell clusters. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 1532-1535.	3.3	36
42	CD8+ T Cells Mediate CD40-independent Maturation of Dendritic Cells In Vivo. <i>Journal of Experimental Medicine</i> , 1999, 189, 1875-1884.	4.2	140
43	Dendritic Cells Infiltrating Tumors Cotransduced with Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf) and Cd40 Ligand Genes Take up and Present Endogenous Tumor-Associated Antigens, and Prime Naive Mice for a Cytotoxic T Lymphocyte Response. <i>Journal of Experimental Medicine</i> , 1999, 190, 125-134.	4.2	168
44	Anti-Tumor Immunity Induced by in Vivo Adenovirus Vector-Mediated Expression of CD40 Ligand in Tumor Cells. <i>Human Gene Therapy</i> , 1999, 10, 1375-1387.	1.4	83
45	TRANCE, a Tumor Necrosis Factor Family Member Critical for CD40 Ligand-independent T Helper Cell Activation. <i>Journal of Experimental Medicine</i> , 1999, 189, 1025-1031.	4.2	240
46	Combination Immunotherapy of B16 Melanoma Using Anti-Cytotoxic T Lymphocyte-Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation. <i>Journal of Experimental Medicine</i> , 1999, 190, 355-366.	4.2	951
47	The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection. <i>Current Opinion in Immunology</i> , 1999, 11, 504-508.	2.4	67
48	The initiation of autoimmune diabetes. <i>Current Opinion in Immunology</i> , 1999, 11, 663-669.	2.4	29
49	Immunosuppression without immunosuppression? How to be a tolerant individual in a dangerous world. <i>Transplant Infectious Disease</i> , 1999, 1, 65-75.	0.7	13
51	Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS. <i>Trends in Immunology</i> , 1999, 20, 66-71.	7.5	37
52	What is the real role of CD40 in cancer immunotherapy?. <i>Trends in Immunology</i> , 1999, 20, 488-493.	7.5	75
53	Generation of anti-idiotypic immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. <i>British Journal of Haematology</i> , 1999, 107, 648-655.	1.2	67
54	The use of carboxyfluorescein diacetate succinimidyl ester to determine the site, duration and cell type responsible for antigen presentation in vivo. <i>Immunology and Cell Biology</i> , 1999, 77, 539-543.	1.0	30
55	Cross-presentation of tumour antigens: Evaluation of threshold, duration, distribution and regulation. <i>Immunology and Cell Biology</i> , 1999, 77, 552-558.	1.0	21

#	ARTICLE	IF	CITATIONS
56	Interleukin-3 and granulocyte-macrophage colony-stimulating factor enhance the generation and function of dendritic cells. <i>Immunology</i> , 1999, 97, 138-149.	2.0	30
57	Induction of dendritic cell costimulator molecule expression is suppressed by T _H 1 cells in the absence of antigen-specific signalling: role of cluster formation, CD40 and HLA-class II for dendritic cell activation. <i>Immunology</i> , 1999, 98, 171-180.	2.0	29
58	Immunomodulatory effect of a plasmid expressing CD40 ligand on DNA vaccination against human immunodeficiency virus type-1. <i>Immunology</i> , 1999, 98, 436-442.	2.0	24
59	The Majority of Epidermal T Cells in Psoriasis Vulgaris Lesions can Produce Type 1 Cytokines, Interferon- γ , Interleukin-2, and Tumor Necrosis Factor- α , Defining TC1 (Cytotoxic T Lymphocyte) and TH1 Effector Populations: A Type 1 Differentiation Bias is also Measured in Circulating Blood T Cells in Psoriatic Patients. <i>Journal of Investigative Dermatology</i> , 1999, 113, 752-759.	0.3	433
60	Inhibition of a secondary human alloimmune response via the soluble active component of CD154 (CD40L) in severe combined immune-deficient mice engrafted with human lymphocytes. <i>Transfusion</i> , 1999, 39, 818-823.	0.8	6
61	TGF- β 1 regulation of dendritic cells. <i>Microbes and Infection</i> , 1999, 1, 1283-1290.	1.0	186
62	CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. <i>Nature Medicine</i> , 1999, 5, 774-779.	15.2	439
63	Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. <i>Nature Medicine</i> , 1999, 5, 780-787.	15.2	394
64	Transplantation tolerance—where do we stand?. <i>Nature Medicine</i> , 1999, 5, 1245-1248.	15.2	89
65	Approaches to Dendritic Cell-Based Immunotherapy after Peripheral Blood Stem Cell Transplantation. <i>Annals of the New York Academy of Sciences</i> , 1999, 872, 363-371.	1.8	18
66	Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. <i>Immunological Reviews</i> , 1999, 170, 151-172.	2.8	94
67	CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. <i>Nature Medicine</i> , 1999, 5, 548-553.	15.2	381
68	Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. <i>Nature Medicine</i> , 1999, 5, 686-693.	15.2	801
69	Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. <i>Leukemia</i> , 1999, 13, 653-663.	3.3	71
70	CD4+ T-Cells Are Required for the Establishment of Maedi-visna Virus Infection in Macrophages but Not Dendritic Cells in Vivo. <i>Virology</i> , 1999, 258, 355-364.	1.1	23
71	Enrichment of an Antigen-Specific T Cell Response by Retrovirally Transduced Human Dendritic Cells. <i>Cellular Immunology</i> , 1999, 195, 10-17.	1.4	67
72	Dendritic cells: a link between innate and adaptive immunity. <i>Journal of Clinical Immunology</i> , 1999, 19, 12-25.	2.0	190
73	Signaling through CD40 enhances cytotoxic T lymphocyte generation by CD8 + T cells from mice bearing large tumors. <i>Cancer Immunology, Immunotherapy</i> , 1999, 48, 153-164.	2.0	9

#	ARTICLE	IF	CITATIONS
74	Generation of protective immunity against an immunogenic carcinoma requires CD40/CD40L and B7/CD28 interactions but not CD4 + T cells. <i>Cancer Immunology, Immunotherapy</i> , 1999, 48, 336-341.	2.0	20
75	Function and dysfunction of CD4 + T cells in the immune response to melanoma. <i>Cancer Immunology, Immunotherapy</i> , 1999, 48, 363-370.	2.0	27
76	Cell-based vaccination against melanoma – background, preliminary results, and perspective. <i>Journal of Molecular Medicine</i> , 1999, 77, 593-608.	1.7	37
77	Dominant regulation. <i>Immunologic Research</i> , 1999, 20, 1-14.	1.3	11
78	Clonal expansion of antigen-specific CD8+ cytotoxic T lymphocytes is regulated by late exposure to serum to prevent apoptosis. <i>Journal of Immunological Methods</i> , 1999, 225, 39-52.	0.6	4
79	Costimulatory regulation of T cell function. <i>Current Opinion in Cell Biology</i> , 1999, 11, 203-210.	2.6	359
80	Intrathymic deletion of MHC class I-restricted cytotoxic T cell precursors by constitutive cross-presentation of exogenous antigen. <i>European Journal of Immunology</i> , 1999, 29, 1477-1486.	1.6	22
81	Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias. <i>European Journal of Immunology</i> , 1999, 29, 2567-2578.	1.6	110
82	Dendritic cells need T cell help to prime cytotoxic T cell responses to strong antigens. <i>European Journal of Immunology</i> , 1999, 29, 2826-2834.	1.6	27
83	Membrane-bound CD154, but not CD40-specific antibody, mediates NF- κ B-independent IL-6 production in B cells. <i>European Journal of Immunology</i> , 1999, 29, 3855-3866.	1.6	91
84	Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. , 1999, 81, 748-754.		94
85	DISCOVERING THE ORIGINS OF IMMUNOLOGICAL COMPETENCE. <i>Annual Review of Immunology</i> , 1999, 17, 1-17.	9.5	27
86	Immunotherapy: the last 25 years. <i>Cancer Treatment Reviews</i> , 1999, 25, 355-363.	3.4	4
87	CTLA-4 Blockade Reverses CD8+ T Cell Tolerance to Tumor by a CD4+ T Cell– and IL-2-Dependent Mechanism. <i>Immunity</i> , 1999, 11, 483-493.	6.6	282
88	Inhibition of CD40 signaling pathway in antigen presenting cells by T suppressor cells. <i>Human Immunology</i> , 1999, 60, 568-574.	1.2	77
89	Antigen presenting cells integrate opposing signals from CD4+ and CD8+ regulatory T lymphocytes to arbitrate the outcomes of immune responses. <i>Human Immunology</i> , 1999, 60, 553-561.	1.2	11
90	Induction and tolerization of anti-male CD8+ cytotoxic T lymphocytes by in vivo immunization with an H-Y-derived peptide. <i>Human Immunology</i> , 1999, 60, 764-773.	1.2	2
91	Cancer Therapy: New Concepts on Active Immunization. <i>Immunobiology</i> , 1999, 201, 1-21.	0.8	5

#	ARTICLE	IF	CITATIONS
92	BCG immunotherapy of bladder cancer: 20 years on. <i>Lancet</i> , The, 1999, 353, 1689-1694.	6.3	417
93	A stimulating new target for cancer immunotherapy. <i>Lancet</i> , The, 1999, 354, 1225-1227.	6.3	17
94	The Natural Killer T (NKT) Cell Ligand α -Galactosylceramide Demonstrates Its Immunopotentiating Effect by Inducing Interleukin (IL)-12 Production by Dendritic Cells and IL-12 Receptor Expression on NKT Cells. <i>Journal of Experimental Medicine</i> , 1999, 189, 1121-1128.	4.2	588
95	Fc γ Receptor α -mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class II α -restricted Antigen Presentation after Immune Complex Internalization. <i>Journal of Experimental Medicine</i> , 1999, 189, 371-380.	4.2	838
96	IMMUNOPATHOGENESIS OF HEPATITIS B VIRUS INFECTION. <i>Clinics in Liver Disease</i> , 1999, 3, 221-239.	1.0	12
97	The Role of CD4 vs. CD8 T Cells in IDDM. <i>Journal of Autoimmunity</i> , 1999, 13, 290-295.	3.0	66
98	Fc receptors for IgG and antigen presentation on MHC class I and class II molecules. <i>Seminars in Immunology</i> , 1999, 11, 385-390.	2.7	74
99	TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. <i>Journal of Leukocyte Biology</i> , 1999, 65, 715-724.	1.5	188
100	Uptake and presentation of phagocytosed antigens by dendritic cells. <i>Advances in Cellular and Molecular Biology of Membranes and Organelles</i> , 1999, , 363-378.	0.3	0
101	Synthetic Peptide Vaccines Effective in Preventing Virus Infection. <i>Microbiology and Immunology</i> , 1999, 43, 915-923.	0.7	4
102	Dendritic cells: A novel therapeutic modality. <i>Annals of Oncology</i> , 1999, 10, 21-28.	0.6	18
103	Update in transplantation immunology. Costimulatory molecules as targets for the induction of transplantation tolerance. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 322-332.	0.4	7
104	Dendritic Cells. <i>Advances in Immunology</i> , 1999, 72, 255-324.	1.1	269
105	The critical role of CD40/CD40L in the CD4-dependent generation of CD8+ T cell immunity. <i>Journal of Leukocyte Biology</i> , 2000, 67, 607-614.	1.5	91
106	Transfusion Medicine: New Clinical Applications of Cellular Immunotherapy. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 356-375.	0.9	8
107	CD40-CD40 ligand. <i>Journal of Leukocyte Biology</i> , 2000, 67, 2-17.	1.5	1,219
108	IFN- γ Is Necessary But Not Sufficient for Anti-CD40 Antibody-Mediated Inhibition of the Th2 Response to <i>Schistosoma mansoni</i> Eggs. <i>Journal of Immunology</i> , 2000, 164, 779-785.	0.4	13
109	Antigenic Epitopes Regulate the Phenotype of CD8+ CTL Primed by Exogenous Antigens. <i>Journal of Immunology</i> , 2000, 164, 5698-5703.	0.4	15

#	ARTICLE	IF	CITATIONS
110	Promise of costimulatory pathway modifying reagents for transplantation. <i>Current Opinion in Organ Transplantation</i> , 2000, 5, 90-95.	0.8	0
111	The role of costimulatory molecules as targets for new immunosuppressives in transplantation. <i>Current Opinion in Urology</i> , 2000, 10, 57-62.	0.9	27
112	Efficient Induction of Peptide-specific Cytotoxic T Lymphocytes by LPS-Activated Spleen Cells. <i>Microbiology and Immunology</i> , 2000, 44, 123-133.	0.7	3
113	Hybrid cell vaccination for cancer immune therapy: First clinical trial with metastatic melanoma. , 2000, 85, 618-626.		91
114	Genetic immunization of mice with human tyrosinase-related protein 2: Implications for the immunotherapy of melanoma. , 2000, 86, 89-94.		95
115	Interaction within clusters of dendritic cells and helper T cells during initial Th1 / Th2 commitment. <i>European Journal of Immunology</i> , 2000, 30, 1255-1262.	1.6	27
116	Modeling Immune Responses with Handling Time. <i>Bulletin of Mathematical Biology</i> , 2000, 62, 869-890.	0.9	51
117	Modelling T-cell-Mediated Suppression Dependent on Interactions in Multicellular Conjugates. <i>Journal of Theoretical Biology</i> , 2000, 207, 231-254.	0.8	66
118	Class I-restricted presentation of exogenous antigen acquired by Fc γ 3 receptor-mediated endocytosis is regulated in dendritic cells. <i>European Journal of Immunology</i> , 2000, 30, 848-857.	1.6	118
119	Donor cell persistence and activation-induced unresponsiveness of peripheral CD8+ T cells. <i>European Journal of Immunology</i> , 2000, 30, 883-891.	1.6	19
120	Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. <i>European Journal of Immunology</i> , 2000, 30, 3591-3597.	1.6	161
121	Strategies for tolerance induction to composite tissue allografts. <i>Microsurgery</i> , 2000, 20, 448-452.	0.6	35
122	Dendritic cells, tolerance and transplantation. <i>Nephrology</i> , 2000, 5, 125-131.	0.7	2
123	Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising <i>Mycobacterium bovis</i> bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7. <i>Clinical and Experimental Immunology</i> , 2000, 121, 216-225.	1.1	161
124	Absence of CD40-CD40 ligand interactions in X-linked hyper-IgM syndrome does not affect differentiation of T helper cell subsets. <i>Clinical and Experimental Immunology</i> , 2000, 121, 346-352.	1.1	7
125	Selection and characterization of MUC1-specific CD8+T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. <i>Immunology</i> , 2000, 101, 316-324.	2.0	46
126	Effect of Interleukin-7 on the In Vitro Development and Maturation of Monocyte Derived Human Dendritic Cells. <i>Scandinavian Journal of Immunology</i> , 2000, 51, 361-371.	1.3	36
127	Prevention of Autoimmune Type 1 Diabetes via Mucosal Tolerance: Is Mucosal Autoantigen Administration As Safe and Effective As It Should?. <i>Scandinavian Journal of Immunology</i> , 2000, 52, 217-225.	1.3	13

#	ARTICLE	IF	CITATIONS
128	Cytokines and T cells in host defense. <i>Current Opinion in Immunology</i> , 2000, 12, 413-418.	2.4	65
129	Costimulation in antiviral immunity: differential requirements for CD4+ and CD8+ T cell responses. <i>Current Opinion in Immunology</i> , 2000, 12, 448-455.	2.4	129
130	Dendritic cells and prospects for transplantation tolerance. <i>Current Opinion in Immunology</i> , 2000, 12, 528-535.	2.4	94
131	Costimulatory wars: the tumor menace. <i>Current Opinion in Immunology</i> , 2000, 12, 589-596.	2.4	69
132	Dendritic cell activation by danger and antigen-specific T-cell signalling. <i>Experimental Dermatology</i> , 2000, 9, 313-322.	1.4	21
133	The role of dendritic cells in the innate immune system. <i>Microbes and Infection</i> , 2000, 2, 257-272.	1.0	97
134	Development of non-live vectors and procedures (liposomes, pseudo-viral particles, toxin, beads,) Tj ETQq0 0 0 rgBT /Overlock, 10 Tf 50 5	1.1	22
135	Importance of CD4+ T helper cell responses in tumor immunity. <i>Immunology Letters</i> , 2000, 74, 75-79.	1.1	80
136	Recombinant lipid-tagged antibody fragments as functional cell-surface receptors. <i>Nature Medicine</i> , 2000, 6, 223-227.	15.2	28
137	Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. <i>Nature Biotechnology</i> , 2000, 18, 509-514.	9.4	250
138	Epitope affinity for MHC class I determines helper requirement for CTL priming. <i>Nature Immunology</i> , 2000, 1, 145-150.	7.0	76
139	Phage display of peptide epitopes from HIV-1 elicits strong cytolytic responses. <i>Nature Biotechnology</i> , 2000, 18, 873-876.	9.4	94
140	CD27 is required for generation and long-term maintenance of T cell immunity. <i>Nature Immunology</i> , 2000, 1, 433-440.	7.0	662
141	Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. <i>Gene Therapy</i> , 2000, 7, 1859-1866.	2.3	53
142	In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. <i>Gene Therapy</i> , 2000, 7, 1467-1476.	2.3	67
143	Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity. <i>Gene Therapy</i> , 2000, 7, 1672-1679.	2.3	38
144	Donor-derived alloantigen-presenting cells persist in the liver allograft during tolerance induction. <i>Transplant International</i> , 2000, 13, 12-20.	0.8	17
145	Efficient presentation of tumor idiotype to autologous T cells by CD83+ dendritic cells derived from highly purified circulating CD14+ monocytes in multiple myeloma patients. <i>Experimental Hematology</i> , 2000, 28, 931-940.	0.2	46

#	ARTICLE	IF	CITATIONS
146	Active immunization of humans with dendritic cells. , 2000, 20, 167-174.		31
147	Recycled addition of CD4+ T cell-rich population for induction of human autologous cytotoxic T lymphocytes: A practically efficient method. Cytotechnology, 2000, 34, 101-110.	0.7	0
148	Characterization of HIV-1-Specific Cytotoxic T Lymphocytes Expressing the Mucosal Lymphocyte Integrin CD103 in Rectal and Duodenal Lymphoid Tissue of HIV-1-Infected Subjects. Virology, 2000, 270, 317-327.	1.1	33
149	H-2d Mice Born to and Reared by HBeAg-Transgenic Mothers Do Not Develop T Cell Tolerance toward the Hepatitis B Virus Core Gene Products. Virology, 2000, 273, 149-159.	1.1	10
150	CD40 signaling in human dendritic cells is initiated within membrane rafts. EMBO Journal, 2000, 19, 3304-3313.	3.5	175
151	Dynamics of T Lymphocyte Responses: Intermediates, Effectors, and Memory Cells. Science, 2000, 290, 92-97.	6.0	716
152	Immunobiology of Dendritic Cells. Annual Review of Immunology, 2000, 18, 767-811.	9.5	5,918
153	Cross-presentation: inducing CD8 T cell immunity and tolerance. Journal of Molecular Medicine, 2000, 78, 326-332.	1.7	46
154	The role of CD40 in peripheral T cell tolerance and immunity. Journal of Molecular Medicine, 2000, 78, 363-371.	1.7	67
155	Tumour vaccines: a new immunotherapeutic approach in oncology. Annals of Hematology, 2000, 79, 651-659.	0.8	5
156	Immunostimulatory DNA sequences help to eradicate intracellular pathogens. Seminars in Immunopathology, 2000, 22, 147-152.	4.0	5
157	Impaired induction of protective immunity by highly virulent herpes simplex virus type 2 in a murine model of genital herpes. Archives of Virology, 2000, 145, 1989-2002.	0.9	13
158	Blockade of CD86 and CD40 induces alloantigen-specific immunoregulatory T cells that remain anergic even after reversal of hyporesponsiveness. Blood, 2000, 95, 3153-3161.	0.6	59
159	An oral CD40 ligand gene therapy against lymphoma using attenuated Salmonella typhimurium. Blood, 2000, 95, 1258-1263.	0.6	53
160	Ligation of E-cadherin on in vitro-generated immature Langerhans-type dendritic cells inhibits their maturation. Blood, 2000, 96, 4276-4284.	0.6	100
161	Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures. Blood, 2000, 96, 2219-2225.	0.6	55
162	Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood, 2000, 96, 91-99.	0.6	132
163	Efficient priming of protein antigen-specific human CD4+ T cells by monocyte-derived dendritic cells. Blood, 2000, 96, 3490-3498.	0.6	63

#	ARTICLE	IF	CITATIONS
164	Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes. <i>Blood</i> , 2000, 96, 647-654.	0.6	19
165	Impaired function of circulating HIV-specific CD8+ T cells in chronic human immunodeficiency virus infection. <i>Blood</i> , 2000, 96, 3094-3101.	0.6	257
166	Immune Surveillance and Tumor Recognition. <i>Contributions To Oncology / Beitrage Zur Onkologie</i> , 2000, 55, 94-116.	0.1	0
167	Glioma Immunology and Immunotherapy. <i>Neurosurgery</i> , 2000, 46, 778-792.	0.6	118
168	Immune regulation by CD40-CD40-L interactions - 2 Y2K update. <i>Frontiers in Bioscience - Landmark</i> , 2000, 5, d880-893.	3.0	6
169	Neonatal Tumor Necrosis Factor $\hat{\pm}$ Promotes Diabetes in Nonobese Diabetic Mice by Cd154-Independent Antigen Presentation to Cd8+ T Cells. <i>Journal of Experimental Medicine</i> , 2000, 191, 225-238.	4.2	71
170	Cd40-Independent Pathways of T Cell Help for Priming of Cd8+ Cytotoxic T Lymphocytes. <i>Journal of Experimental Medicine</i> , 2000, 191, 541-550.	4.2	182
171	Trance, a Tumor Necrosis Factor Family Member, Enhances the Longevity and Adjuvant Properties of Dendritic Cells in Vivo. <i>Journal of Experimental Medicine</i> , 2000, 191, 495-502.	4.2	306
172	In Vivo Cytotoxic T Lymphocyte Elicitation by Mycobacterial Heat Shock Protein 70 Fusion Proteins Maps to a Discrete Domain and Is Cd4+ T Cell Independent. <i>Journal of Experimental Medicine</i> , 2000, 191, 403-408.	4.2	123
173	Immune regulation by CD40-CD40-L interactions - 2; Y2K update. <i>Frontiers in Bioscience - Landmark</i> , 2000, 5, d880.	3.0	42
174	The Role of CD40-CD154 Interactions in the Regulation of Cell Mediated Immunity. <i>Immunological Investigations</i> , 2000, 29, 111-114.	1.0	42
175	Combination of Interleukin 12 and Interferon $\hat{\pm}$ Gene Therapy Induces a Synergistic Antitumor Response against Colon and Renal Cell Carcinoma. <i>Human Gene Therapy</i> , 2000, 11, 1851-1862.	1.4	34
176	CD40-CD40 Ligand-Independent Activation of CD8+ T Cells Can Trigger Allograft Rejection. <i>Journal of Immunology</i> , 2000, 165, 1111-1118.	0.4	144
177	Archaeosomes Induce Long-Term CD8+ Cytotoxic T Cell Response to Entrapped Soluble Protein by the Exogenous Cytosolic Pathway, in the Absence of CD4+ T Cell Help. <i>Journal of Immunology</i> , 2000, 165, 5177-5185.	0.4	88
178	APC Stimulated by CpG Oligodeoxynucleotide Enhance Activation of MHC Class I-Restricted T Cells. <i>Journal of Immunology</i> , 2000, 165, 6244-6251.	0.4	77
179	Induction of CTL Responses by Simultaneous Administration of Liposomal Peptide Vaccine with Anti-CD40 and Anti-CTLA-4 mAb. <i>Journal of Immunology</i> , 2000, 164, 1230-1235.	0.4	61
180	Host CD40 Ligand Deficiency Induces Long-Term Allograft Survival and Donor-Specific Tolerance in Mouse Cardiac Transplantation But Does Not Prevent Graft Arteriosclerosis. <i>Journal of Immunology</i> , 2000, 165, 3506-3518.	0.4	143
181	CD8 + T-Cell Priming against a Nonsecreted <i>Listeria monocytogenes</i> Antigen Is Independent of the Antimicrobial Activities of Gamma Interferon. <i>Infection and Immunity</i> , 2000, 68, 2196-2204.	1.0	16

#	ARTICLE	IF	CITATIONS
182	IL-2 and IL-15 Regulate CD154 Expression on Activated CD4 T Cells. <i>Journal of Immunology</i> , 2000, 164, 3500-3505.	0.4	66
183	Soluble CD8 Attenuates Cytotoxic T Cell Responses Against Replication-Defective Adenovirus Affording Transprotection of Transgenes In Vivo. <i>Journal of Immunology</i> , 2000, 165, 1470-1478.	0.4	8
184	CD4 Help-Independent Induction of Cytotoxic CD8 Cells to Allogeneic P815 Tumor Cells Is Absolutely Dependent on Costimulation. <i>Journal of Immunology</i> , 2000, 165, 3612-3619.	0.4	53
185	Measles Virus Induces Abnormal Differentiation of CD40 Ligand-Activated Human Dendritic Cells. <i>Journal of Immunology</i> , 2000, 164, 1753-1760.	0.4	159
186	A novel helper role for CD4 T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 12950-12952.	3.3	28
187	Divergent Roles for CD4+ T Cells in the Priming and Effector/Memory Phases of Adoptive Immunotherapy. <i>Journal of Immunology</i> , 2000, 165, 4246-4253.	0.4	101
188	Infection of Dendritic Cells by the Maedi-Visna Lentivirus. <i>Journal of Virology</i> , 2000, 74, 10096-10103.	1.5	88
189	CD40 Ligand-Dependent Activation of Cytotoxic T Lymphocytes by Adeno-Associated Virus Vectors In Vivo: Role of Immature Dendritic Cells. <i>Journal of Virology</i> , 2000, 74, 8003-8010.	1.5	110
190	The Importance of Exogenous Antigen in Priming the Human CD8+ T Cell Response: Lessons from the EBV Nuclear Antigen EBNA1. <i>Journal of Immunology</i> , 2000, 165, 7078-7087.	0.4	119
191	Comparative Analysis of Genetically Modified Dendritic Cells and Tumor Cells as Therapeutic Cancer Vaccines. <i>Journal of Experimental Medicine</i> , 2000, 191, 1699-1708.	4.2	155
192	Immature Dendritic Cells Acquire Cd8+Cytotoxic T Lymphocyte Priming Capacity upon Activation by T Helper Cell-Independent or -Dependent Stimuli. <i>Journal of Experimental Medicine</i> , 2000, 192, 145-150.	4.2	173
193	Induction of Vigorous Helper and Cytotoxic T Cell as well as B Cell Responses by Dendritic Cells Expressing a Modified Antigen Targeting Receptor-Mediated Internalization Pathway. <i>Journal of Immunology</i> , 2000, 165, 4581-4591.	0.4	35
194	Anergic T Cells Inhibit the Antigen-Presenting Function of Dendritic Cells. <i>Journal of Immunology</i> , 2000, 165, 1175-1181.	0.4	154
195	Identification of a MHC Class II-Restricted Human gp100 Epitope Using DR4-IE Transgenic Mice. <i>Journal of Immunology</i> , 2000, 164, 3535-3542.	0.4	124
196	Treatment of Allograft Recipients with Donor-Specific Transfusion and Anti-CD154 Antibody Leads to Deletion of Alloreactive CD8+ T Cells and Prolonged Graft Survival in a CTLA4-Dependent Manner. <i>Journal of Immunology</i> , 2000, 164, 512-521.	0.4	201
197	Langerhans Cells That Have Matured In Vivo in the Absence of T Cells Are Fully Capable of Inducing a Helper CD4 as Well as a Cytotoxic CD8 Response. <i>Journal of Immunology</i> , 2000, 165, 645-653.	0.4	19
198	Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 3485-3490.	3.3	160
199	Th2-Dependent B Cell Responses in the Absence of CD40-CD40 Ligand Interactions. <i>Journal of Immunology</i> , 2000, 164, 248-255.	0.4	18

#	ARTICLE	IF	CITATIONS
200	Tumor-Specific CD4+ T Cells Have a Major "Post-Licensing" Role in CTL Mediated Anti-Tumor Immunity. <i>Journal of Immunology</i> , 2000, 165, 6047-6055.	0.4	306
201	Recruitment of CD40 and Tumor Necrosis Factor Receptor-associated Factors 2 and 3 to Membrane Microdomains during CD40 Signaling. <i>Journal of Biological Chemistry</i> , 2000, 275, 15392-15398.	1.6	185
202	Association of Hepatitis C Virus-Specific CD8+T Cells with Viral Clearance in Acute Hepatitis C. <i>Journal of Infectious Diseases</i> , 2000, 181, 1528-1536.	1.9	348
203	Therapy of Cancer and Autoimmunity: Immuno-modulatory Strategies Based on Modified Dendritic cells. , 2000, , 353-363.		0
204	Genetic Immunotherapy for Cancer. <i>Oncologist</i> , 2000, 5, 87-98.	1.9	26
205	Polyomavirus-Infected Dendritic Cells Induce Antiviral CD8 + T Lymphocytes. <i>Journal of Virology</i> , 2000, 74, 4093-4101.	1.5	30
206	Human Cd4+ T Lymphocytes Consistently Respond to the Latent Epstein-Barr Virus Nuclear Antigen Ebna1. <i>Journal of Experimental Medicine</i> , 2000, 191, 1649-1660.	4.2	323
207	Perspectives in dermatology: dermatologic oncology. <i>Journal of Dermatological Treatment</i> , 2000, 11, s3-s8.	1.1	0
208	Molecular advances to treat cancer of the brain. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 1207-1215.	1.9	5
209	Functional heterogeneity among bone marrow-derived dendritic cells conditioned by Th1- and Th2-biasing cytokines for the generation of allogeneic cytotoxic T lymphocytes. <i>International Immunology</i> , 2000, 12, 335-342.	1.8	33
210	REVIEW: The Application of Dendritic Cell-derived Exosomes in Tumour Immunotherapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2000, 15, 185-194.	0.7	21
211	Cd8+ but Not Cd8 ⁺ Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo. <i>Journal of Experimental Medicine</i> , 2000, 192, 1685-1696.	4.2	1,171
212	Tumor-Specific CD4+T Lymphocytes from Cancer Patients Are Required for Optimal Induction of Cytotoxic T Cells Against the Autologous Tumor. <i>Journal of Immunology</i> , 2000, 164, 3902-3912.	0.4	155
213	Human Dendritic Cells Discriminate Between Viable and Killed <i>Toxoplasma gondii</i> Tachyzoites: Dendritic Cell Activation After Infection with Viable Parasites Results in CD28 and CD40 Ligand Signaling That Controls IL-12-Dependent and -Independent T Cell Production of IFN- γ . <i>Journal of Immunology</i> , 2000, 165, 1498-1505.	0.4	90
214	In Vivo Induction of a High-Avidity, High-Frequency Cytotoxic T-Lymphocyte Response Is Associated with Antiviral Protective Immunity. <i>Journal of Virology</i> , 2000, 74, 5769-5775.	1.5	90
215	Th1 and Th2 Cell Clones to a Poorly Immunogenic Tumor Antigen Initiate CD8+ T Cell-Dependent Tumor Eradication In Vivo. <i>Journal of Immunology</i> , 2000, 165, 5495-5501.	0.4	77
216	Inducible Costimulator Protein (Icos) Controls T Helper Cell Subset Polarization after Virus and Parasite Infection. <i>Journal of Experimental Medicine</i> , 2000, 192, 53-62.	4.2	192
217	Role of Antigen-Presenting Cells in Mediating Tolerance and Autoimmunity. <i>Journal of Experimental Medicine</i> , 2000, 191, 2021-2028.	4.2	148

#	ARTICLE	IF	CITATIONS
218	Cytokine Expression, Natural Killer Cell Activation, and Phenotypic Changes in Lymphoid Cells from Rhesus Macaques during Acute Infection with Pathogenic Simian Immunodeficiency Virus. <i>Journal of Virology</i> , 2000, 74, 1648-1657.	1.5	122
219	CD40 expressed on human melanoma cells mediates T cell co-stimulation and tumor cell growth. <i>International Immunology</i> , 2000, 12, 787-795.	1.8	20
220	CD40 Ligand (CD154) Enhances the Th1 and Antibody Responses to Respiratory Syncytial Virus in the BALB/c Mouse. <i>Journal of Immunology</i> , 2000, 164, 5913-5921.	0.4	53
221	Sustained Expression of CD154 (CD40L) and Proinflammatory Cytokine Production by Alloantigen-Stimulated Umbilical Cord Blood T Cells. <i>Journal of Immunology</i> , 2000, 164, 6206-6212.	0.4	41
222	CD40-Ligated Dendritic Cells Effectively Expand Melanoma-Specific CD8+ CTLs and CD4+ IFN- β -Producing T Cells from Tumor-Infiltrating Lymphocytes. <i>Journal of Immunology</i> , 2000, 164, 6633-6639.	0.4	48
223	Retrovirally Transduced Mouse Dendritic Cells Require CD4+ T Cell Help to Elicit Antitumor Immunity: Implications for the Clinical Use of Dendritic Cells. <i>Journal of Immunology</i> , 2000, 164, 1243-1250.	0.4	61
224	The Role of CD4+ T Cell Help and CD40 Ligand in the In Vitro Expansion of HIV-1-Specific Memory Cytotoxic CD8+ T Cell Responses. <i>Journal of Immunology</i> , 2000, 165, 6133-6141.	0.4	89
225	CD40 Signaling Replaces CD4+ Lymphocytes and Its Blocking Prevents Chronic Rejection of Heart Transplants. <i>Journal of Immunology</i> , 2000, 165, 7316-7322.	0.4	49
226	CpG-DNA Activates In Vivo T Cell Epitope Presenting Dendritic Cells to Trigger Protective Antiviral Cytotoxic T Cell Responses. <i>Journal of Immunology</i> , 2000, 164, 2372-2378.	0.4	123
227	Genetic Characterization of Strain Differences in the Ability to Mediate CD40/CD28-Independent Rejection of Skin Allografts. <i>Journal of Immunology</i> , 2000, 165, 6849-6857.	0.4	128
228	CD8+ T Cell-Dependent Elimination of Dendritic Cells In Vivo Limits the Induction of Antitumor Immunity. <i>Journal of Immunology</i> , 2000, 164, 3095-3101.	0.4	208
229	Soluble Antigen and CD40 Triggering Are Sufficient to Induce Primary and Memory Cytotoxic T Cells. <i>Journal of Immunology</i> , 2000, 164, 725-732.	0.4	92
230	Role of CD40 Ligand and CD28 in Induction and Maintenance of Antiviral CD8+ Effector T Cell Responses. <i>Journal of Immunology</i> , 2000, 164, 3689-3697.	0.4	111
231	Diminished Primary and Secondary Influenza Virus-Specific CD8+ T-Cell Responses in CD4-Depleted Ig α^{γ} / α^{γ} Mice. <i>Journal of Virology</i> , 2000, 74, 9762-9765.	1.5	127
232	Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101 α 0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1 α Expressing Melanoma. <i>Journal of Experimental Medicine</i> , 2000, 191, 625-630.	4.2	196
233	Requirements for Bone Marrow-Derived Antigen-Presenting Cells in Priming Cytotoxic T Cell Responses to Intracellular Pathogens. <i>Journal of Experimental Medicine</i> , 2000, 192, 1135-1142.	4.2	86
234	Consequences of Fas-Mediated Human Dendritic Cell Apoptosis Induced by Measles Virus. <i>Journal of Virology</i> , 2000, 74, 4387-4393.	1.5	116
235	α -Anergic α ™ T cells Modulate the T-cell Activating Capacity of Antigen-presenting Cells. <i>Journal of Autoimmunity</i> , 2000, 14, 335-341.	3.0	53

#	ARTICLE	IF	CITATIONS
236	Potent Adjuvant Effect by Anti-CD40 in Collagen-induced Arthritis. Enhanced Disease is Accompanied by Increased Production of Collagen Type-II Reactive IgG2a and IFN- β . <i>Journal of Autoimmunity</i> , 2000, 14, 295-302.	3.0	29
237	Localization dose and time of antigens determine immune reactivity. <i>Seminars in Immunology</i> , 2000, 12, 163-171.	2.7	198
238	Dendritic Cells in Cancer Immunotherapy. <i>Annual Review of Immunology</i> , 2000, 18, 245-273.	9.5	625
239	Effective Priming of Cytotoxic T Lymphocyte Precursors by Subcutaneous Administration of Peptide Antigens in Liposomes Accompanied by Anti-CD40 and Anti-CTLA-4 Antibodies. <i>Immunobiology</i> , 2000, 201, 527-540.	0.8	6
240	Dendritic Cells Lose Ability to Present Protein Antigen after Stimulating Antigen-Specific T Cell Responses, despite Upregulation of MHC Class II Expression. <i>Immunobiology</i> , 2000, 201, 568-582.	0.8	14
241	Anergic T cells as active regulators of the immune response. <i>Human Immunology</i> , 2000, 61, 633-639.	1.2	41
242	Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminum phosphate. <i>Vaccine</i> , 2000, 18, 1227-1235.	1.7	70
243	Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: Results of a pilot, multicenter, multiple-dose, placebo-controlled study. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, 595-604.	0.6	126
244	The Beta Cell in Autoimmune Diabetes: Many Mechanisms and Pathways of Loss. <i>Trends in Endocrinology and Metabolism</i> , 2000, 11, 11-15.	3.1	60
245	A Proposed Mechanism for the Induction of Cytotoxic T Lymphocyte Production by Heat Shock Fusion Proteins. <i>Immunity</i> , 2000, 12, 263-272.	6.6	126
246	Expression of Intestine-Specific Antigen Reveals Novel Pathways of CD8 T Cell Tolerance Induction. <i>Immunity</i> , 2000, 12, 505-514.	6.6	125
247	CD4 + T Cell-Mediated Tumor Rejection Involves Inhibition of Angiogenesis that Is Dependent on IFN- β Receptor Expression by Nonhematopoietic Cells. <i>Immunity</i> , 2000, 12, 677-686.	6.6	461
248	DNA Vaccines: Immunology, Application, and Optimization. <i>Annual Review of Immunology</i> , 2000, 18, 927-974.	9.5	1,104
249	The Specific Regulation Of Immune Responses By CD8+T Cells Restricted By The MHC Class Ib Molecule, Qa-1. <i>Annual Review of Immunology</i> , 2000, 18, 185-216.	9.5	153
250	The Role of Chemokine Receptors in Primary, Effector, and Memory Immune Responses. <i>Annual Review of Immunology</i> , 2000, 18, 593-620.	9.5	969
251	Virosomes as an Antigen Delivery System. <i>Journal of Liposome Research</i> , 2000, 10, 329-338.	1.5	17
252	Dendritic Cells Promote T-cell Survival or Death Depending Upon Their Maturation State and Presentation of Antigen. <i>Immunological Investigations</i> , 2000, 29, 177-185.	1.0	17
253	Consequences of Cell Death. <i>Journal of Experimental Medicine</i> , 2000, 191, 423-434.	4.2	1,334

#	ARTICLE	IF	CITATIONS
255	Strategies for immunotherapy of cancer. <i>Advances in Immunology</i> , 2000, 75, 235-282.	1.1	138
256	Host factors influencing viral persistence. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2000, 355, 1031-1041.	1.8	24
257	CROSS-PRESENTATION, DENDRITIC CELLS, TOLERANCE AND IMMUNITY. <i>Annual Review of Immunology</i> , 2001, 19, 47-64.	9.5	818
258	Developmental approaches in immunological control of acute myelogenous leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2001, 14, 189-209.	0.7	4
259	Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine. <i>Journal of Experimental Medicine</i> , 2001, 194, 481-490.	4.2	307
260	Dendritic cells and tumor immunity. <i>Seminars in Immunology</i> , 2001, 13, 291-302.	2.7	58
261	Cytotoxic T Cells to an Epitope in the Islet Autoantigen IA-2 Are Not Disease-Specific. <i>Clinical Immunology</i> , 2001, 99, 360-364.	1.4	30
262	Measle Virus-Infected Dendritic Cells Develop Immunosuppressive and Cytotoxic Activities. <i>Immunobiology</i> , 2001, 204, 629-638.	0.8	31
263	Plasmids encoding granulocyte macrophage colony-stimulating factor and CD154 enhance the immune response to genetic vaccines. <i>Vaccine</i> , 2001, 19, 2181-2189.	1.7	20
264	Dendritic cells generated in vivo by a chimeric hematopoietic growth factor, progenipoietin-4, demonstrate potent immunological function. <i>Vaccine</i> , 2001, 19, 3710-3719.	1.7	10
265	Protective CTL response is induced in the absence of CD4+ T cells and IFN- γ by gene gun DNA vaccination with a minigene encoding a CTL epitope of <i>Listeria monocytogenes</i> . <i>Vaccine</i> , 2001, 19, 4297-4306.	1.7	25
266	Functional maturation of dendritic cells by exposure to CD40L transgenic tumor cells, fibroblasts or keratinocytes. <i>Cancer Letters</i> , 2001, 168, 145-154.	3.2	16
267	Therapeutic aspects of tolerance. <i>Current Opinion in Pharmacology</i> , 2001, 1, 392-397.	1.7	14
268	Dendritic cells resurrect antigens from dead cells. <i>Trends in Immunology</i> , 2001, 22, 141-148.	2.9	180
269	The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. <i>Trends in Immunology</i> , 2001, 22, 269-276.	2.9	247
270	The therapeutic use of antibodies for malignancy. <i>Transfusion Clinique Et Biologique</i> , 2001, 8, 255-259.	0.2	5
271	CD40 Is a Cellular Receptor Mediating Mycobacterial Heat Shock Protein 70 Stimulation of CC-Chemokines. <i>Immunity</i> , 2001, 15, 971-983.	6.6	253
272	The role of CD154 (CD40-ligand) in costimulation. <i>Transplantation Proceedings</i> , 2001, 33, 202-206.	0.3	5

#	ARTICLE	IF	CITATIONS
273	CD154 DEFICIENCY AND RELATED SYNDROMES. Immunology and Allergy Clinics of North America, 2001, 21, 65-89.	0.7	10
274	PSORIASIS. Dermatologic Clinics, 2001, 19, 649-657.	1.0	69
275	Innovative Cancer Vaccine Strategies Based on the Identification of Tumour-Associated Antigens. BioDrugs, 2001, 15, 819-831.	2.2	10
276	Role of Dendritic Cell-Derived Cytokines in Immune Regulation. Current Pharmaceutical Design, 2001, 7, 977-992.	0.9	30
277	Mechanisms of tolerance induction: blockade of co-stimulation. Philosophical Transactions of the Royal Society B: Biological Sciences, 2001, 356, 649-657.	1.8	17
278	Expression of the Serpin Serine Protease Inhibitor 6 Protects Dendritic Cells from Cytotoxic T Lymphocyte-Induced Apoptosis. Journal of Experimental Medicine, 2001, 194, 657-668.	4.2	187
279	Role of CD28/CD80-86 and CD40/CD154 Costimulatory Interactions in Host Defense to Primary Herpes Simplex Virus Infection. Journal of Virology, 2001, 75, 612-621.	1.5	55
281	Interactions of viruses with dendritic cells. , 2001, , 505-522.		3
282	Dendritic Cell-Dead Cell Interactions: Implications and Relevance for Immunotherapy. Journal of Immunotherapy, 2001, 24, 294-304.	1.2	22
283	CD8+ LYMPHOCYTES AUGMENT CHRONIC REJECTION IN A MHC CLASS II MISMATCHED MODEL. Transplantation, 2001, 71, 1146-1153.	0.5	35
284	Phase I Trial Of Intravenous Peptide-Pulsed Dendritic Cells in Patients With Metastatic Melanoma. Journal of Immunotherapy, 2001, 24, 66-78.	1.2	164
285	Proinflammatory Cytokines and CD40 Ligand Enhance Cross-Presentation and Cross-Priming Capability of Human Dendritic Cells Internalizing Apoptotic Cancer Cells. Journal of Immunotherapy, 2001, 24, 162-171.	1.2	57
286	MHC Class II-Restricted Tumor Antigens Recognized by CD4+ T Cells: New Strategies for Cancer Vaccine Design. Journal of Immunotherapy, 2001, 24, 195-204.	1.2	36
287	Broadsheet: Dendritic cells and their emerging clinical applications. Pathology, 2001, 33, 479-492.	0.3	17
288	Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy. Blood, 2001, 98, 3359-3366.	0.6	55
289	Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood, 2001, 98, 1667-1677.	0.6	220
290	Phase I Study of Recombinant Human CD40 Ligand in Cancer Patients. Journal of Clinical Oncology, 2001, 19, 3280-3287.	0.8	209
291	Defects in Deletional Tolerance of CD8+ T Cells in Autoimmune Diabetes. , 2001, 4, 123-143.		3

#	ARTICLE	IF	CITATIONS
292	Interactions of Effectors and Regulators Are Decisive in the Manifestations of Type 1 Diabetes in Nonobese Diabetic Mice. , 2001, 4, 171-192.		4
293	CD40 Signaling and Autoimmunity. , 2001, 5, 51-61.		12
294	Immunity to human papillomaviruses: Implications for vaccine design. Perspectives in Medical Virology, 2001, 5, 451-478.	0.1	1
295	Cytokine Regulation of Diabetes in Experimental Models. , 2001, 4, 193-217.		1
296	Targeting Signal 1 Through CD45RB Synergizes with CD40 Ligand Blockade and Promotes Long Term Engraftment and Tolerance in Stringent Transplant Models. Journal of Immunology, 2001, 166, 322-329.	0.4	90
297	Examination of HY Response: T Cell Expansion, Immunodominance, and Cross-Priming Revealed by HY Tetramer Analysis. Journal of Immunology, 2001, 167, 3756-3764.	0.4	63
298	Dendritic cell discoveries provide new insight into the cellular immunobiology of DNA vaccines. Immunology Letters, 2001, 78, 103-111.	1.1	41
299	Dendritic cells and immunotherapy for malignant disease. British Journal of Haematology, 2001, 112, 874-887.	1.2	58
300	Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis. British Journal of Haematology, 2001, 115, 298-308.	1.2	36
301	CD40 expression and function on human dermal microvascular endothelial cells: role in cutaneous inflammation. Clinical and Experimental Dermatology, 2001, 26, 434-440.	0.6	14
302	Erythema Toxicum Neonatorum: An Immunohistochemical Analysis. Pediatric Dermatology, 2001, 18, 177-187.	0.5	48
303	Association of CD40 Ligand Expression on HTLV-I-Infected T Cells and Maturation of Dendritic Cells. Scandinavian Journal of Immunology, 2001, 54, 574-581.	1.3	22
304	Specific killing of P53 mutated tumor cell lines by a cross-reactive human HLA-A2-restricted P53-specific CTL line. International Journal of Cancer, 2001, 93, 855-861.	2.3	23
305	Active immunization against cancer with dendritic cells: The near future. International Journal of Cancer, 2001, 94, 459-473.	2.3	285
306	A MAGE-1 peptide recognized on HLA-DR15 by CD4+ T cells. European Journal of Immunology, 2001, 31, 1910-1916.	1.6	24
307	Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells. European Journal of Immunology, 2001, 31, 3432-3442.	1.6	92
308	Annotated References by Year. , 2001, , 651-770.		0
309	Differential Stimulation of Helper and Cytotoxic T Cells by Dendritic Cells after Infection by Yersinia enterocolitica in Vitro. Cellular Immunology, 2001, 208, 43-51.	1.4	9

#	ARTICLE	IF	CITATIONS
310	Viral Neuraminidase Treatment of Dendritic Cells Enhances Antigen-Specific CD8+ T Cell Proliferation, but Does Not Account for the CD4+ T Cell Independence of the CD8+ T Cell Response during Influenza Virus Infection. <i>Virology</i> , 2001, 286, 403-411.	1.1	14
311	MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment. <i>Glycoconjugate Journal</i> , 2001, 18, 931-942.	1.4	56
312	Regulatory Role of CD4 ⁺ T Cells During the Development of Contact Hypersensitivity Responses. <i>Immunologic Research</i> , 2001, 24, 69-78.	1.3	24
313	Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. <i>International Immunology</i> , 2001, 13, 897-908.	1.8	73
314	Differential CD4+ and CD8+ T-cell responsiveness in hepatitis C virus infection. <i>Hepatology</i> , 2001, 33, 267-276.	3.6	316
315	Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma. <i>Hepatology</i> , 2001, 34, 72-81.	3.6	50
316	Interleukin-4 acts at the locus of the antigen-presenting dendritic cell to counter-regulate cytotoxic CD8+ T-cell responses. <i>Nature Medicine</i> , 2001, 7, 206-214.	15.2	85
317	A fresh look at tumor immunosurveillance and immunotherapy. <i>Nature Immunology</i> , 2001, 2, 293-299.	7.0	650
318	The CD8 response on autopilot. <i>Nature Immunology</i> , 2001, 2, 381-382.	7.0	87
319	Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. <i>Nature Immunology</i> , 2001, 2, 423-429.	7.0	769
320	Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T-cell cross-priming. <i>Nature Medicine</i> , 2001, 7, 807-813.	15.2	88
321	Immunity or tolerance? That is the question for dendritic cells. <i>Nature Immunology</i> , 2001, 2, 988-989.	7.0	99
322	Positive selection in a Schnurri. <i>Nature Immunology</i> , 2001, 2, 989-991.	7.0	6
323	Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. <i>Nature Immunology</i> , 2001, 2, 1010-1017.	7.0	368
324	Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. <i>Cancer Gene Therapy</i> , 2001, 8, 378-387.	2.2	31
325	Induction of effective antitumor immune responses in a mouse bladder tumor model by using DNA of an I± antigen from mycobacteria. <i>Cancer Gene Therapy</i> , 2001, 8, 483-490.	2.2	21
326	Gene delivery by attenuated <i>Salmonella typhimurium</i> : Comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination. <i>Cancer Gene Therapy</i> , 2001, 8, 599-611.	2.2	38
327	Prospects for immunotherapy of acute lymphoblastic leukemia. <i>Leukemia</i> , 2001, 15, 701-706.	3.3	12

#	ARTICLE	IF	CITATIONS
328	Cross-presentation in viral immunity and self-tolerance. <i>Nature Reviews Immunology</i> , 2001, 1, 126-134.	10.6	402
329	Strategies for designing and optimizing new generation vaccines. <i>Nature Reviews Immunology</i> , 2001, 1, 209-219.	10.6	319
330	Dendritic cells presenting pyruvate kinase M1/M2 isozyme peptide can induce experimental allergic myositis in BALB/c mice. <i>Journal of Neuroimmunology</i> , 2001, 117, 108-115.	1.1	16
331	CD40 ligation for immunotherapy of solid tumours. <i>Journal of Immunological Methods</i> , 2001, 248, 139-147.	0.6	63
332	Foreign antigenic peptides delivered to the tumor as targets of cytotoxic T cells. <i>Journal of Immunological Methods</i> , 2001, 258, 141-150.	0.6	23
333	Phenotypic and functional comparison of monocytes from cord blood and granulocyte colony-stimulating factor-mobilized apheresis products. <i>Experimental Hematology</i> , 2001, 29, 1289-1294.	0.2	15
334	Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 14571-14576.	3.3	61
335	Distinct Cytokine Regulation by Cholera Toxin and Type II Heat-Labile Toxins Involves Differential Regulation of CD40 Ligand on CD4+ T Cells. <i>Infection and Immunity</i> , 2001, 69, 4486-4492.	1.0	34
336	Epidermal Powder Immunization Induces both Cytotoxic T-Lymphocyte and Antibody Responses to Protein Antigens of Influenza and Hepatitis B Viruses. <i>Journal of Virology</i> , 2001, 75, 11630-11640.	1.5	70
337	Mature Dendritic Cells Infected with Canarypox Virus Elicit Strong Anti-Human Immunodeficiency Virus CD8+and CD4+ T-Cell Responses from Chronically Infected Individuals. <i>Journal of Virology</i> , 2001, 75, 2142-2153.	1.5	76
338	CD4+ and CD8+ T Cell Priming for Contact Hypersensitivity Occurs Independently of CD40-CD154 Interactions. <i>Journal of Immunology</i> , 2001, 166, 2323-2332.	0.4	36
339	CD40/CD40 Ligand Interactions Are Critical for Elicitation of Autoimmune-Mediated Fibrosis in the Lung. <i>Journal of Immunology</i> , 2001, 166, 3556-3563.	0.4	24
340	The Role of Dendritic Cells, B Cells, and M Cells in Gut-Oriented Immune Responses. <i>Journal of Immunology</i> , 2001, 166, 4843-4852.	0.4	165
341	Targeting Antigen in Mature Dendritic Cells for Simultaneous Stimulation of CD4+and CD8+T Cells. <i>Journal of Immunology</i> , 2001, 166, 5250-5257.	0.4	101
342	Control of Advanced Choroid Plexus Tumors in SV40 T Antigen Transgenic Mice Following Priming of Donor CD8+ T Lymphocytes by the Endogenous Tumor Antigen. <i>Journal of Immunology</i> , 2001, 167, 6947-6956.	0.4	31
343	Longevity of Antigen Presentation and Activation Status of APC Are Decisive Factors in the Balance Between CTL Immunity Versus Tolerance. <i>Journal of Immunology</i> , 2001, 167, 2522-2528.	0.4	60
344	Dendritic Cell-Derived IL-12 Is Not Required for the Generation of Cytotoxic, IFN- γ -Secreting, CD8+CTL In Vivo. <i>Journal of Immunology</i> , 2001, 167, 5027-5033.	0.4	36
345	The TNF Superfamily Members LIGHT and CD154 (CD40 Ligand) Costimulate Induction of Dendritic Cell Maturation and Elicit Specific CTL Activity. <i>Journal of Immunology</i> , 2001, 167, 2479-2486.	0.4	163

#	ARTICLE	IF	CITATIONS
346	Approaching Tolerance in Transplantation. <i>International Archives of Allergy and Immunology</i> , 2001, 126, 11-22.	0.9	6
348	Vehicles for Genetic Vaccines Against Human Immunodeficiency Virus Induction of T Cell-mediated Immune Responses. <i>Current Molecular Medicine</i> , 2001, 1, 123-135.	0.6	7
349	Dendritic cells: immunological features and utilisation for tumour immunotherapy. <i>Expert Opinion on Therapeutic Targets</i> , 2001, 5, 491-506.	1.5	5
350	Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 4587-4592.	3.3	95
351	Lipopolysaccharide Modulation of Dendritic Cells Is Insufficient to Mature Dendritic Cells to Generate CTLs from Naive Polyclonal CD8+T Cells In Vitro, Whereas CD40 Ligation Is Essential. <i>Journal of Immunology</i> , 2001, 167, 6247-6255.	0.4	41
352	Organ-Specific Regulation of the CD8 T Cell Response to <i>Listeria monocytogenes</i> Infection. <i>Journal of Immunology</i> , 2001, 166, 3402-3409.	0.4	368
353	Role of CD40 in a T Cell-Mediated Negative Regulation of Ig Production. <i>Journal of Immunology</i> , 2001, 166, 841-847.	0.4	3
354	<i>Listeria monocytogenes</i> Infection Overcomes the Requirement for CD40 Ligand in Exogenous Antigen Presentation to CD8+ T Cells. <i>Journal of Immunology</i> , 2001, 167, 5603-5609.	0.4	45
355	Human IL-18 Receptor and ST2L Are Stable and Selective Markers for the Respective Type 1 and Type 2 Circulating Lymphocytes. <i>Journal of Immunology</i> , 2001, 167, 1238-1244.	0.4	78
356	The Generation of Both T Killer and Th Cell Clones Specific for the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells. <i>Journal of Immunology</i> , 2001, 167, 1712-1719.	0.4	42
357	CD4 T Cell-Mediated Alloresistance to Fully MHC-Mismatched Allogeneic Bone Marrow Engraftment Is Dependent on CD40-CD40 Ligand Interactions, and Lasting T Cell Tolerance Is Induced by Bone Marrow Transplantation with Initial Blockade of this Pathway. <i>Journal of Immunology</i> , 2001, 166, 2970-2981.	0.4	102
358	Low-Avidity Self-Specific T Cells Display a Pronounced Expansion Defect That Can Be Overcome by Altered Peptide Ligands. <i>Journal of Immunology</i> , 2001, 167, 3818-3828.	0.4	40
359	Redundancy of Direct Priming and Cross-Priming in Tumor-Specific CD8+ T Cell Responses. <i>Journal of Immunology</i> , 2001, 167, 3577-3584.	0.4	75
360	CD40 Signaling Converts a Minimally Immunogenic Antigen into a Potent Vaccine Against the Intracellular Pathogen <i>Listeria monocytogenes</i> . <i>Journal of Immunology</i> , 2001, 166, 5115-5121.	0.4	40
361	IFN- γ -Dependent Inhibition of Tumor Angiogenesis by Tumor-Infiltrating CD4+ T Cells Requires Tumor Responsiveness to IFN- γ . <i>Journal of Immunology</i> , 2001, 166, 2276-2282.	0.4	180
362	CD4+ T Cells Are Required for the Development of Cytotoxic CD8+ T Cells During <i>Mycobacterium tuberculosis</i> Infection. <i>Journal of Immunology</i> , 2001, 167, 6991-7000.	0.4	153
363	Tumor Progression Despite Efficient Tumor Antigen Cross-Presentation and Effective Arming of Tumor Antigen-Specific CTL. <i>Journal of Immunology</i> , 2001, 166, 5557-5566.	0.4	60
364	Immunostimulatory DNA-Based Vaccines Elicit Multifaceted Immune Responses Against HIV at Systemic and Mucosal Sites. <i>Journal of Immunology</i> , 2001, 167, 1584-1591.	0.4	100

#	ARTICLE	IF	CITATIONS
365	Depletion of CD4+ T Cells Precipitates Immunopathology in Immunodeficient Mice Infected with a Noncytotoxic Virus. <i>Journal of Immunology</i> , 2001, 166, 3384-3391.	0.4	23
366	CD40 stimulation accelerates deletion of tumor-specific CD8+ T cells in the absence of tumor-antigen vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 10811-10816.	3.3	80
367	Contribution of CD8+ T Cells to Gamma Interferon Production in Human Tuberculosis. <i>Infection and Immunity</i> , 2001, 69, 3497-3501.	1.0	47
368	Concurrent Naive and Memory CD8+ T Cell Responses to an Influenza A Virus. <i>Journal of Immunology</i> , 2001, 167, 2753-2758.	0.4	53
369	Stimulation via CD40 can substitute for CD4 T cell function in preventing reactivation of a latent herpesvirus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 6325-6329.	3.3	65
370	Multiple Paths for Activation of Naive CD8+ T Cells: CD4-Independent Help. <i>Journal of Immunology</i> , 2001, 167, 1283-1289.	0.4	95
371	Prophylactic Tumor Vaccination: Comparison of Effector Mechanisms Initiated by Protein Versus DNA Vaccination. <i>Journal of Immunology</i> , 2001, 166, 3440-3450.	0.4	39
372	Immunobiology of Cardiac Allograft and Xenograft Transplantation. <i>Pediatric Cardiac Surgery Annual</i> , 2001, 4, 123-157.	0.5	8
373	IL-15 Is Expressed by Dendritic Cells in Response to Type I IFN, Double-Stranded RNA, or Lipopolysaccharide and Promotes Dendritic Cell Activation. <i>Journal of Immunology</i> , 2001, 167, 1179-1187.	0.4	389
374	Cutting Edge: Recombinant Adenoviruses Induce CD8 T Cell Responses to an Inserted Protein Whose Expression Is Limited to Nonimmune Cells. <i>Journal of Immunology</i> , 2001, 166, 4809-4812.	0.4	49
375	The Roles of MHC Class II, CD40, and B7 Costimulation in CTL Induction by Plasmid DNA. <i>Journal of Immunology</i> , 2001, 166, 3061-3066.	0.4	47
376	Regulation of CD40 function by its isoforms generated through alternative splicing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 1751-1756.	3.3	132
377	The role of CD154 in organ transplant rejection and acceptance. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2001, 356, 691-702.	1.8	64
378	Alloantigen-induced specific immunological unresponsiveness. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2001, 356, 665-680.	1.8	24
379	CD40 Ligand Promotes Priming of Fully Potent Antitumor CD4+ T Cells in Draining Lymph Nodes in the Presence of Apoptotic Tumor Cells. <i>Journal of Immunology</i> , 2001, 167, 5678-5688.	0.4	30
380	Anti-CD40 Antibody Induces Antitumor and Antimetastatic Effects: The Role of NK Cells. <i>Journal of Immunology</i> , 2001, 166, 89-94.	0.4	103
381	The Potent Adjuvant Activity of Archaeosomes Correlates to the Recruitment and Activation of Macrophages and Dendritic Cells In Vivo. <i>Journal of Immunology</i> , 2001, 166, 1885-1893.	0.4	71
382	MHC Class I-Restricted Determinants on the Glutamic Acid Decarboxylase 65 Molecule Induce Spontaneous CTL Activity. <i>Journal of Immunology</i> , 2001, 167, 1748-1757.	0.4	43

#	ARTICLE	IF	CITATIONS
383	A Transcriptional Block in the IL-2 Promoter at the \sim 150 AP-1 Site in Effector CD8+ T Cells. <i>Journal of Immunology</i> , 2001, 166, 6530-6536.	0.4	7
384	Direct Analysis of the Dynamics of the Intestinal Mucosa CD8 T Cell Response to Systemic Virus Infection. <i>Journal of Immunology</i> , 2001, 166, 2348-2356.	0.4	136
385	Generation of Tumor-associated Cytotoxic T Lymphocytes Requires Interleukin 4 from CD8+ T Cells. <i>Journal of Experimental Medicine</i> , 2001, 194, 1767-1775.	4.2	61
386	Antigen-Pulsed Dendritic Cell Approach to Melanoma. , 2001, 61, 195-202.		0
387	Generation of Blood-Derived Human Dendritic Cells for Antitumor Immunotherapy. , 2001, 64, 297-303.		2
388	Th1 Cytokine-Conditioned Bone Marrow-Derived Dendritic Cells Can Bypass the Requirement for Th Functions During the Generation of CD8+ CTL. <i>Journal of Immunology</i> , 2001, 167, 3687-3691.	0.4	13
390	An Expanding Role for CD40L and Other Tumor Necrosis Factor Superfamily Ligands in HIV Infection. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 787-801.	1.8	24
391	CD40 stimulation leads to effective therapy of CD40- tumors through induction of strong systemic cytotoxic T lymphocyte immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 5561-5566.	3.3	210
392	Reduced Functional Capacity of CD8+ T Cells Expanded by Post-Exposure Vaccination of β 3-Herpesvirus-Infected CD4-Deficient Mice. <i>Journal of Immunology</i> , 2002, 168, 3477-3483.	0.4	35
393	Activation of CD8 T Cells by Antigen Expressed in the Pituitary Gland. <i>Journal of Immunology</i> , 2002, 169, 6753-6759.	0.4	19
394	Complementary Dendritic Cell-activating Function of CD8+ and CD4+ T Cells. <i>Journal of Experimental Medicine</i> , 2002, 195, 473-483.	4.2	167
395	Tissue-Level Regulation of Th1 and Th2 Primary and Memory CD4 T Cells in Response to <i>Listeria</i> Infection. <i>Journal of Immunology</i> , 2002, 168, 4504-4510.	0.4	53
396	In Vivo Triggering Through 4-1BB Enables Th-Independent Priming of CTL in the Presence of an Intact CD28 Costimulatory Pathway. <i>Journal of Immunology</i> , 2002, 168, 3755-3762.	0.4	84
397	In Situ γ 2 Cell Death Promotes Priming of Diabetogenic CD8 T Lymphocytes. <i>Journal of Immunology</i> , 2002, 168, 1466-1472.	0.4	96
398	Allograft Rejection by Primed/Memory CD8+ T Cells Is CD154 Blockade Resistant: Therapeutic Implications for Sensitized Transplant Recipients. <i>Journal of Immunology</i> , 2002, 169, 4667-4673.	0.4	157
399	Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides. <i>Journal of Immunology</i> , 2002, 169, 350-358.	0.4	386
400	CD40 Ligation in the Presence of Self-Reactive CD8 T Cells Leads to Severe Immunopathology. <i>Journal of Immunology</i> , 2002, 168, 5124-5129.	0.4	23
401	CpG Are Efficient Adjuvants for Specific CTL Induction Against Tumor Antigen-Derived Peptide. <i>Journal of Immunology</i> , 2002, 168, 1212-1218.	0.4	135

#	ARTICLE	IF	CITATIONS
402	Major Histocompatibility Complex Class II Presentation of Cell-associated Antigen Is Mediated by CD8 ⁺ Dendritic Cells In Vivo. <i>Journal of Experimental Medicine</i> , 2002, 195, 683-694.	4.2	50
403	CD28, TNF Receptor, and IL-12 Are Critical for CD4-Independent Cross-Priming of Therapeutic Antitumor CD8 ⁺ T Cells. <i>Journal of Immunology</i> , 2002, 169, 4897-4904.	0.4	19
404	The Role of Sp1 and NF- κ B in Regulating CD40 Gene Expression. <i>Journal of Biological Chemistry</i> , 2002, 277, 8890-8897.	1.6	65
405	Requirement for NK Cells in CD40 Ligand-Mediated Rejection of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Cells. <i>Journal of Immunology</i> , 2002, 168, 73-80.	0.4	20
406	Cutting Edge: Precursor Frequency Affects the Helper Dependence of Cytotoxic T Cells. <i>Journal of Immunology</i> , 2002, 168, 977-980.	0.4	99
407	Cutting Edge: A Crucial Role for B7-CD28 in Transmitting T Help from APC to CTL. <i>Journal of Immunology</i> , 2002, 169, 4094-4097.	0.4	54
408	CD40 Ligation Conditions Dendritic Cell Antigen-Presenting Function Through Sustained Activation of NF- κ B. <i>Journal of Immunology</i> , 2002, 168, 5491-5498.	0.4	150
409	Ox40 Costimulation Enhances the Development of T Cell Responses Induced by Dendritic Cells In Vivo. <i>Journal of Immunology</i> , 2002, 168, 661-670.	0.4	86
410	T Cell Immunity to Lymphoma Following Treatment with Anti-CD40 Monoclonal Antibody. <i>Journal of Immunology</i> , 2002, 168, 2720-2728.	0.4	79
411	Impaired Effector Function of Hepatitis C Virus-Specific CD8 ⁺ T Cells in Chronic Hepatitis C Virus Infection. <i>Journal of Immunology</i> , 2002, 169, 3447-3458.	0.4	596
412	IFN- γ Promote Priming of Antigen-Specific CD8 ⁺ and CD4 ⁺ T Lymphocytes by Immunostimulatory DNA-Based Vaccines. <i>Journal of Immunology</i> , 2002, 168, 4907-4913.	0.4	117
413	The CD154-CD40 T Cell Costimulation Pathway Is Required for Host Sensitization of CD8 ⁺ T Cells by Skin Grafts Via Direct Antigen Presentation. <i>Journal of Immunology</i> , 2002, 169, 1270-1276.	0.4	39
414	The Poststimulation Program of CD4 Versus CD8 T Cells (Death Versus Activation-Induced) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 262 Td	0.4	34
415	Induction of MHC Class I Presentation of Exogenous Antigen by Dendritic Cells Is Controlled by CD4 ⁺ T Cells Engaging Class II Molecules in Cholesterol-Rich Domains. <i>Journal of Immunology</i> , 2002, 168, 1172-1180.	0.4	47
416	Accumulation of Immature Langerhans Cells in Human Lymph Nodes Draining Chronically Inflamed Skin. <i>Journal of Experimental Medicine</i> , 2002, 196, 417-430.	4.2	246
417	Peptide Antigen Priming of Naive, But Not Memory, CD8 T Cells Requires a Third Signal That Can Be Provided by IL-12. <i>Journal of Immunology</i> , 2002, 168, 5521-5529.	0.4	116
418	Cutting Edge: Expression of Functional CD137 Receptor by Dendritic Cells. <i>Journal of Immunology</i> , 2002, 168, 4262-4267.	0.4	216
419	Cutting Edge: The Relative Distribution of T Cells Responding to Chemically Dominant or Minor Epitopes of Lysozyme Is Not Affected by CD40-CD40 Ligand and B7-CD28-CTLA-4 Costimulatory Pathways. <i>Journal of Immunology</i> , 2002, 169, 2832-2836.	0.4	7

#	ARTICLE	IF	CITATIONS
420	Differential Kinetics of Antigen-Specific CD4+ and CD8+ T Cell Responses in the Regression of Retrovirus-Induced Sarcomas. <i>Journal of Immunology</i> , 2002, 169, 3191-3199.	0.4	82
421	Selective Delivery of Augmented IL-2 Receptor Signals to Responding CD8+ T Cells Increases the Size of the Acute Antiviral Response and of the Resulting Memory T Cell Pool. <i>Journal of Immunology</i> , 2002, 169, 4990-4997.	0.4	35
422	Detection of CD4+- and CD8+-T-Cell Responses to Human Papillomavirus Type 1 Antigens Expressed at Various Stages of the Virus Life Cycle by Using an Enzyme-Linked Immunospot Assay of Gamma Interferon Release. <i>Journal of Virology</i> , 2002, 76, 6027-6036.	1.5	29
423	The CD8 ⁺ Dendritic Cell Is Responsible for Inducing Peripheral Self-Tolerance to Tissue-associated Antigens. <i>Journal of Experimental Medicine</i> , 2002, 196, 1099-1104.	4.2	436
424	Compromised Influenza Virus-Specific CD8+-T-Cell Memory in CD4+-T-Cell-Deficient Mice. <i>Journal of Virology</i> , 2002, 76, 12388-12393.	1.5	270
425	The Cross-Priming APC Requires a Rel-Dependent Signal to Induce CTL. <i>Journal of Immunology</i> , 2002, 168, 3283-3287.	0.4	14
426	The Central Role Played by Peptides in the Immune Response and the Design of Peptide-Based Vaccines Against Infectious Diseases and Cancer. <i>Current Drug Targets</i> , 2002, 3, 175-196.	1.0	48
427	Hybrid Cell Vaccination for Cancer Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2002, 465, 347-354.	0.8	17
428	Activation of APCs Through CD40 or Toll-Like Receptor 9 Overcomes Tolerance and Precipitates Autoimmune Disease. <i>Journal of Immunology</i> , 2002, 169, 2781-2787.	0.4	135
429	A Role for CD40 Expression on CD8+ T Cells in the Generation of CD8+ T Cell Memory. <i>Science</i> , 2002, 297, 2060-2063.	6.0	586
430	Constitutive versus Activation-dependent Cross-Presentation of Immune Complexes by CD8+ and CD8 ^α Dendritic Cells In Vivo. <i>Journal of Experimental Medicine</i> , 2002, 196, 817-827.	4.2	285
431	The Balance Between Donor T Cell Anergy and Suppression Versus Lethal Graft-Versus-Host Disease Is Determined by Host Conditioning. <i>Journal of Immunology</i> , 2002, 169, 5581-5589.	0.4	41
432	The Adjuvant Effects of <i>Mycobacterium tuberculosis</i> Heat Shock Protein 70 Result from the Rapid and Prolonged Activation of Antigen-Specific CD8+ T Cells In Vivo. <i>Journal of Immunology</i> , 2002, 169, 5622-5629.	0.4	65
433	Dominance of Virus-Specific CD8 T Cells in Human Primary Cytomegalovirus Infection. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 2577-2584.	3.0	101
434	A push-pull approach to maximize vaccine efficacy: Abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 13020-13025.	3.3	89
435	Uncoupling of Proliferative Potential and Gain of Effector Function by CD8+ T Cells Responding to Self-Antigens. <i>Journal of Experimental Medicine</i> , 2002, 196, 323-333.	4.2	135
436	Maturation and Activation of Dendritic Cells Induced by Lymphocyte Activation Gene-3 (CD223). <i>Journal of Immunology</i> , 2002, 168, 3874-3880.	0.4	149
437	Coadministration of an Interleukin-12 Gene and a <i>Trypanosoma cruzi</i> Gene Improves Vaccine Efficacy. <i>Infection and Immunity</i> , 2002, 70, 4833-4840.	1.0	54

#	ARTICLE	IF	CITATIONS
438	Activation-Induced Nonresponsiveness: A Th-Dependent Regulatory Checkpoint in the CTL Response. <i>Journal of Immunology</i> , 2002, 168, 1190-1197.	0.4	80
439	Prolonged Maturation and Enhanced Transduction of Dendritic Cells Migrated from Human Skin Explants After In Situ Delivery of CD40-Targeted Adenoviral Vectors. <i>Journal of Immunology</i> , 2002, 169, 5322-5331.	0.4	66
440	OX40 Ligation Enhances Primary and Memory Cytotoxic T Lymphocyte Responses in an Immunotherapy for Hepatic Colon Metastases. <i>Molecular Therapy</i> , 2002, 6, 528-536.	3.7	106
441	Dendritic Cells Cultured in Anti-CD40 Antibody-Immobilized Plates Elicit a Highly Efficient Peptide-Specific T-Cell Response. <i>Journal of Immunotherapy</i> , 2002, 25, 176-184.	1.2	12
442	Hematopoietic growth factors, dendritic cell biology, and vaccine therapy of cancer. <i>Current Opinion in Hematology</i> , 2002, 9, 202-206.	1.2	7
443	Donor-derived interferon \hat{I}^3 separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells. <i>Blood</i> , 2002, 99, 4207-4215.	0.6	84
444	In vivo manipulation of dendritic cells to induce therapeutic immunity. <i>Blood</i> , 2002, 99, 1676-1682.	0.6	104
445	Disrupted homeostasis of Langerhans cells and interdigitating dendritic cells in monkeys with AIDS. <i>Blood</i> , 2002, 99, 2859-2868.	0.6	46
446	Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. <i>Blood</i> , 2002, 99, 3319-3325.	0.6	177
447	Seizary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. <i>Blood</i> , 2002, 100, 3287-3294.	0.6	66
448	Cancer Immunotherapy Using Gene-Modified Dendritic Cells. <i>Current Gene Therapy</i> , 2002, 2, 57-78.	0.9	70
449	Adjuvants of Immunity. <i>Journal of Experimental Medicine</i> , 2002, 195, F19-F23.	4.2	150
450	IL- $1\hat{I}^2$ Enhances CD40 Ligand-Mediated Cytokine Secretion by Human Dendritic Cells (DC): A Mechanism for T Cell-Independent DC Activation. <i>Journal of Immunology</i> , 2002, 168, 713-722.	0.4	108
451	Myeloid Dendritic Cells in Non-Obese Diabetic Mice have Elevated Costimulatory and T Helper-1-Inducing Abilities. <i>Journal of Autoimmunity</i> , 2002, 19, 23-35.	3.0	44
452	The Flavonoid Kaempferol Suppresses the Graft-versus-Host Reaction by Inhibiting Type 1 Cytokine Production and CD8+ T Cell Engraftment. <i>Clinical Immunology</i> , 2002, 103, 132-144.	1.4	36
453	Costimulatory Molecules and Autoimmune Thyroid Diseases. <i>Autoimmunity</i> , 2002, 35, 159-167.	1.2	44
454	Genetically modified dendritic cells â€œ a new, promising cancer treatment strategy?. <i>Expert Opinion on Biological Therapy</i> , 2002, 2, 835-845.	1.4	15
455	Antitumor Immune Responses Derived from Transgenic Expression of CD40 Ligand in Myeloma Cells. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2002, 17, 11-18.	0.7	12

#	ARTICLE	IF	CITATIONS
456	Minor Structural Changes in a Mutated Human Melanoma Antigen Correspond to Dramatically Enhanced Stimulation of a CD4+ Tumor-infiltrating Lymphocyte Line. <i>Journal of Molecular Biology</i> , 2002, 319, 449-461.	2.0	32
457	T-Cell costimulatory pathways relevant to transplant rejection and tolerance. <i>Transplantation Reviews</i> , 2002, 16, 205-219.	1.2	4
458	CD40L Blockade Prevents Autoimmune Diabetes by Induction of Bitypic NK/DC Regulatory Cells. <i>Immunity</i> , 2002, 16, 403-415.	6.6	150
459	CD154-Dependent Priming of Diabetogenic CD4+ T Cells Dissociated from Activation of Antigen-Presenting Cells. <i>Immunity</i> , 2002, 16, 719-732.	6.6	40
460	In Vivo Depletion of CD11c+ Dendritic Cells Abrogates Priming of CD8+ T Cells by Exogenous Cell-Associated Antigens. <i>Immunity</i> , 2002, 17, 211-220.	6.6	1,579
461	Tuning tumor-specific T-cell activation: a matter of costimulation?. <i>Trends in Immunology</i> , 2002, 23, 240-245.	2.9	76
462	Cross-priming versus cross-tolerance: are two signals enough?. <i>Trends in Immunology</i> , 2002, 23, 171-173.	2.9	28
463	T helper cells, IL-2 and the generation of cytotoxic T-cell responses. <i>Trends in Immunology</i> , 2002, 23, 465-467.	2.9	37
464	Plasmacytoid dendritic cells: the key to CpG. <i>Human Immunology</i> , 2002, 63, 1111-1119.	1.2	135
465	Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine. <i>Vaccine</i> , 2002, 20, 2857-2865.	1.7	114
466	Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice. <i>Vaccine</i> , 2002, 20, 3123-3129.	1.7	77
467	A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. <i>Vaccine</i> , 2002, 20, A8-A22.	1.7	175
468	Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules—potential benefits in vaccine design. <i>Vaccine</i> , 2002, 21, 231-242.	1.7	28
469	What's the Matter with HIV-directed Killer T Cells?. <i>Journal of Theoretical Biology</i> , 2002, 219, 19-31.	0.8	7
470	Immunotherapy for pancreatic cancer: current concepts. <i>Hematology/Oncology Clinics of North America</i> , 2002, 16, 159-197.	0.9	20
471	Immune escape mechanisms of childhood ALL and a potential countering role for DC-like leukemia cells. <i>Cytotherapy</i> , 2002, 4, 165-175.	0.3	11
472	CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion. <i>Journal of Clinical Pathology</i> , 2002, 55, 110-120.	2.1	58
473	Cd40 Activation as Potential Tool in Malignant Neoplasms. <i>Tumori</i> , 2002, 88, 361-366.	0.6	24

#	ARTICLE	IF	CITATIONS
474	B7-1 (CD80) and B7-2 (CD 86) Expression in Human Tubular Epithelial Cells in vivo and in vitro<footref id="foot01">¹</footref>. Nephron, 2002, 92, 542-556.	0.9	39
475	Mice Deficient in Perforin, CD4 + T Cells, or CD28-Mediated Signaling Maintain the Typical Immunodominance Hierarchies of CD8 + T-Cell Responses to Influenza Virus. Journal of Virology, 2002, 76, 10332-10337.	1.5	50
476	Increased production of pro-inflammatory cytokines and enhanced T cell responses after activation of human dendritic cells with IL-1 and CD40 ligand. BMC Immunology, 2002, 3, 14.	0.9	68
477	The molecular architecture of the TNF superfamily. Trends in Biochemical Sciences, 2002, 27, 19-26.	3.7	788
478	Exhaustion of cytotoxic T cells during adoptive immunotherapy of virus carrier mice can be prevented by B cells or CD4+ T cells. European Journal of Immunology, 2002, 32, 374-382.	1.6	48
479	CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. European Journal of Immunology, 2002, 32, 2356.	1.6	158
480	On cross-priming of MHC class I-specific CTL: rule or exception?. European Journal of Immunology, 2002, 32, 2385-2392.	1.6	133
481	In vivo receptor-mediated delivery of a recombinant invasive bacterial toxoid to CD11c+CD8 β ⁺ CD11b ^{high} dendritic cells. European Journal of Immunology, 2002, 32, 3071-3081.	1.6	50
483	What's the Matter with HIV-directed Killer T Cells?. Journal of Theoretical Biology, 2002, 219, 19-31.	0.8	7
484	Quantification of antigen-reactive T cells by a modified ELISPOT assay based on freshly isolated blood dendritic cells. Journal of Clinical Laboratory Analysis, 2002, 16, 30-36.	0.9	4
485	Critical involvement of CD40 in protection against herpes simplex virus infection in a murine model of genital herpes. Archives of Virology, 2002, 147, 187-194.	0.9	7
486	CD4+ T helper cells and the role they play in viral control. Journal of Molecular Medicine, 2002, 80, 397-405.	1.7	33
487	Naive CD8+ but not CD4+ T cells induce maturation of dendritic cells. Journal of Molecular Medicine, 2002, 80, 533-541.	1.7	12
488	Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines. Cancer Immunology, Immunotherapy, 2002, 51, 327-340.	2.0	15
489	Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunological Reviews, 2002, 188, 177-182.	2.8	94
490	Influence of CD4 T cells and the source of major histocompatibility complex class II-restricted peptides on cytotoxic T-cell priming by dendritic cells. Immunology, 2002, 105, 47-55.	2.0	11
491	Homeostasis of naïve, effector and memory CD8 T cells. Current Opinion in Immunology, 2002, 14, 348-353.	2.4	37
492	Interactions between dead cells and dendritic cells in the induction of antiviral CTL responses. Current Opinion in Immunology, 2002, 14, 471-477.	2.4	56

#	ARTICLE	IF	CITATIONS
493	Mechanisms of transplant tolerance induction using costimulatory blockade. <i>Current Opinion in Immunology</i> , 2002, 14, 592-600.	2.4	158
494	T cell-mediated immune responses in melanoma: implications for immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 43, 1-11.	2.0	26
495	Requirement of the IFN- γ /IFN- β -induced CXCR3 chemokine signalling for CD8+T cell activation. <i>Genes To Cells</i> , 2002, 7, 309-320.	0.5	59
496	Mechanism of antigen presentation after hypertonic loading of soluble antigens. <i>Immunology</i> , 2002, 106, 511-516.	2.0	4
497	The role of dendritic cell subsets in selection between tolerance and immunity. <i>Immunology and Cell Biology</i> , 2002, 80, 463-468.	1.0	76
498	CD40 stimulation in vivo does not inhibit CD4+ T cell tolerance to soluble antigens. <i>Immunology Letters</i> , 2002, 84, 125-132.	1.1	10
499	Optimal cytokine stimulation for the enhanced generation of leukemic dendritic cells in short-term culture. <i>Leukemia Research</i> , 2002, 26, 191-201.	0.4	25
500	Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8+ cytotoxic T-cell activation and antitumor immunity. <i>Cancer Gene Therapy</i> , 2002, 9, 202-208.	2.2	44
501	Efficient genetic modification of murine dendritic cells by electroporation with mRNA. <i>Cancer Gene Therapy</i> , 2002, 9, 787-797.	2.2	100
502	In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154. <i>Cancer Gene Therapy</i> , 2002, 9, 846-853.	2.2	19
503	Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. <i>Gene Therapy</i> , 2002, 9, 833-843.	2.3	56
504	IL-4-secreting CD4+ T cells are crucial to the development of CD8+ T-cell responses against malaria liver stages. <i>Nature Medicine</i> , 2002, 8, 166-170.	15.2	217
505	The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?. <i>Nature Reviews Immunology</i> , 2002, 2, 283-291.	10.6	126
506	Generation of dendritic cell-based vaccines for cancer therapy. <i>British Journal of Cancer</i> , 2002, 86, 1529-1533.	2.9	50
507	Tumour escape from immune surveillance through dendritic cell inactivation. <i>Seminars in Cancer Biology</i> , 2002, 12, 33-42.	4.3	205
508	ANTIGENPRESENTATION ANDT CELLSTIMULATION BYDENDRITICCELLS. <i>Annual Review of Immunology</i> , 2002, 20, 621-667.	9.5	1,577
509	Hybrid-Cell Vaccines for Cancer Immune Therapy. <i>Molecular Biotechnology</i> , 2003, 25, 63-70.	1.3	13
510	Title is missing!. <i>Journal of Neuro-Oncology</i> , 2003, 64, 177-183.	1.4	4

#	ARTICLE	IF	CITATIONS
511	Effector lymphocytes in islet cell autoimmunity. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2003, 4, 271-280.	2.6	12
512	Mediators of Central Nervous System Damage During the Progression of Human T-Cell Leukemia Type I-Associated Myelopathy/Tropical Spastic Paraparesis. <i>Journal of NeuroVirology</i> , 2003, 9, 522-529.	1.0	31
513	CD4-Independent Protective Cytotoxic T Cells Induced in Early Life by a Non-Replicative Delivery System Based on Virus-like Particles. <i>Virology</i> , 2003, 305, 428-435.	1.1	19
514	Kinetic Evolution of a Diabetogenic CD8+ T Cell Response. <i>Annals of the New York Academy of Sciences</i> , 2003, 1005, 88-97.	1.8	12
515	Importance of CD4+ Helper T-cells in Antitumor Immunity. <i>International Journal of Hematology</i> , 2003, 77, 435-438.	0.7	43
516	Human autologous dendritic cell-glioma fusions: feasibility and capacity to stimulate T cells with proliferative and cytolytic activity. <i>Journal of Neuro-Oncology</i> , 2003, 64, 177-183.	1.4	11
517	Experimental autoimmune encephalomyelitis: Cytokines, effector t cells, and antigen-presenting cells in a prototypical th1-mediated autoimmune disease. <i>Current Allergy and Asthma Reports</i> , 2003, 3, 86-93.	2.4	56
518	IL-12: a promising adjuvant for cancer vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 133-144.	2.0	107
519	Dissecting autoimmune diabetes through genetic manipulation of non-obese diabetic mice. <i>Diabetologia</i> , 2003, 46, 1447-1464.	2.9	33
520	CD40 and its viral mimic, LMP1: similar means to different ends. <i>Cellular Signalling</i> , 2003, 15, 9-16.	1.7	111
521	Contrasting Alloreactive CD4+ and CD8+ T Cells: There's More to It Than MHC Restriction. <i>American Journal of Transplantation</i> , 2003, 3, 107-115.	2.6	49
522	Development of a Novel Transgenic Mouse for the Study of Interactions Between CD4 and CD8 T Cells During Graft Rejection. <i>American Journal of Transplantation</i> , 2003, 3, 1355-1362.	2.6	175
523	CD40 ligand-specific antibodies synergize with cyclophosphamide to promote long-term transplantation tolerance across MHC barriers but inhibit graft-vs-leukemia effects of transplanted cells. <i>Experimental Hematology</i> , 2003, 31, 81-88.	0.2	12
524	Induction of human NK cell-mediated cytotoxicity by CD40 triggering on antigen presenting cells. <i>Cellular Immunology</i> , 2003, 221, 81-88.	1.4	14
525	Assessment of cell mediated immunogenicity of Mycobacterium leprae-derived antigens. <i>Cellular Immunology</i> , 2003, 222, 69-77.	1.4	31
526	CD40 can costimulate human memory T cells and favors IL-10 secretion. <i>European Journal of Immunology</i> , 2003, 33, 1094-1104.	1.6	12
527	MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue. <i>European Journal of Immunology</i> , 2003, 33, 1624-1632.	1.6	18
528	Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. <i>European Journal of Immunology</i> , 2003, 33, 1183-1192.	1.6	73

#	ARTICLE	IF	CITATIONS
529	Th2 cells shape the differentiation of developing T cell responses during interactions with dendritic cells in vivo. <i>European Journal of Immunology</i> , 2003, 33, 1697-1706.	1.6	34
530	Instruction of naive CD4+ T cells by polarized CD4+ T cells within dendritic cell clusters. <i>European Journal of Immunology</i> , 2003, 33, 1686-1696.	1.6	20
531	Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming?. <i>European Journal of Immunology</i> , 2003, 33, 2645-2654.	1.6	164
532	Mini-review CD4 T cells are required for CD8 T cell memory generation. <i>European Journal of Immunology</i> , 2003, 33, 3225-3231.	1.6	75
533	Dendritic cells in peripheral tolerance and immunity. <i>Apmis</i> , 2003, 111, 766-775.	0.9	42
534	Against the self: dendritic cells versus cancer. <i>Apmis</i> , 2003, 111, 805-817.	0.9	7
535	Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha. <i>Immunology</i> , 2003, 108, 177-188.	2.0	54
536	Roles for CD40, B7 and major histocompatibility complex in induction of enhanced immunity by cryptococcal polysaccharide-pulsed antigen-presenting cells. <i>Immunology</i> , 2003, 108, 158-166.	2.0	6
537	Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading. <i>Immunology</i> , 2003, 109, 374-383.	2.0	25
538	Immunotherapy Exploiting the Versatility of Dendritic Cells. <i>Therapeutic Apheresis and Dialysis</i> , 2003, 7, 312-317.	0.4	3
539	Cancer immunotherapy using RNA-loaded dendritic cells. <i>Clinical and Experimental Immunology</i> , 2003, 134, 378-384.	1.1	95
540	Generation of mature dendritic cells fully capable of T helper type 1 polarization using OK-432 combined with prostaglandin E2. <i>Cancer Science</i> , 2003, 94, 1091-1098.	1.7	38
541	CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. <i>Nature</i> , 2003, 421, 852-856.	18.7	1,443
542	Prospects for CD40-directed experimental therapy of human cancer. <i>Cancer Gene Therapy</i> , 2003, 10, 1-13.	2.2	160
543	CD8 and B cell memory: same strategy, same signals. <i>Nature Immunology</i> , 2003, 4, 431-432.	7.0	37
544	Linking Toll-like receptors to IFN- β expression. <i>Nature Immunology</i> , 2003, 4, 432-433.	7.0	53
545	Continuous T cell receptor signaling required for synapse maintenance and full effector potential. <i>Nature Immunology</i> , 2003, 4, 749-755.	7.0	366
546	Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. <i>Nature Immunology</i> , 2003, 4, 1009-1015.	7.0	715

#	ARTICLE	IF	CITATIONS
547	Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. <i>Nature Medicine</i> , 2003, 9, 562-567.	15.2	1,157
548	Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. <i>Nature Medicine</i> , 2003, 9, 1469-1476.	15.2	279
549	Cytokine control of memory T-cell development and survival. <i>Nature Reviews Immunology</i> , 2003, 3, 269-279.	10.6	768
550	Mechanisms Inducing or Controlling CD8 ⁺ T Cell Responses against Self- or Non-Self-Antigens. <i>Annals of the New York Academy of Sciences</i> , 2003, 987, 99-106.	1.8	9
551	Not all effector CD8 ⁺ T cells are alike. <i>Microbes and Infection</i> , 2003, 5, 199-204.	1.0	4
552	Current Developments in Cancer Vaccines and Cellular Immunotherapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 2415-2432.	0.8	287
553	Co-stimulation agonists as a new immunotherapy for autoimmune diseases. <i>Trends in Molecular Medicine</i> , 2003, 9, 483-489.	3.5	6
554	CD8 T CELL RESPONSES TO INFECTIOUS PATHOGENS. <i>Annual Review of Immunology</i> , 2003, 21, 29-70.	9.5	367
555	Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects. <i>Vaccine</i> , 2003, 21, 781-786.	1.7	34
556	Induction of cytotoxic T lymphocyte responses by cholera toxin-treated bone marrow-derived dendritic cells. <i>Vaccine</i> , 2003, 21, 1613-1619.	1.7	14
557	CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. <i>Vaccine</i> , 2003, 21, 2268-2272.	1.7	55
558	T-cell immune responses in the brain and their relevance for cerebral malignancies. <i>Brain Research Reviews</i> , 2003, 42, 97-122.	9.1	77
560	CD8 ⁺ T cells induce graft vascular occlusion in a CD40 knockout donor/recipient combination. <i>Journal of Heart and Lung Transplantation</i> , 2003, 22, 177-183.	0.3	22
561	Inducible Transgenic Mice Reveal Resting Dendritic Cells as Potent Inducers of CD8 ⁺ T Cell Tolerance. <i>Immunity</i> , 2003, 18, 713-720.	6.6	283
562	Platelet-Mediated Modulation of Adaptive Immunity. <i>Immunity</i> , 2003, 19, 9-19.	6.6	353
563	CD40 Ligation Releases Immature Dendritic Cells from the Control of Regulatory CD4 ⁺ CD25 ⁺ T Cells. <i>Immunity</i> , 2003, 19, 877-889.	6.6	259
564	Bacterial infection induces expression of functional MHC class II molecules in murine and human osteoblasts. <i>Bone</i> , 2003, 33, 812-821.	1.4	34
565	Bystander Transfer of Functional Human CD40 Ligand from Gene-Modified Fibroblasts to B-Chronic Lymphocytic Leukemia Cells. <i>Human Gene Therapy</i> , 2003, 14, 545-559.	1.4	23

#	ARTICLE	IF	CITATIONS
566	CD4 + T CELL MATTERS IN TUMOR IMMUNITY. <i>International Reviews of Immunology</i> , 2003, 22, 113-140.	1.5	34
567	A Subset of Toll-Like Receptor Ligands Induces Cross-presentation by Bone Marrow-Derived Dendritic Cells. <i>Journal of Immunology</i> , 2003, 170, 4102-4110.	0.4	273
568	A crucial role of CD4 T cells as a functional source of CD154 in the initiation of insulin-dependent diabetes mellitus in the non-obese diabetic mouse. <i>International Immunology</i> , 2003, 15, 351-357.	1.8	12
569	Vaccine Immunity to Pathogenic Fungi Overcomes the Requirement for CD4 Help in Exogenous Antigen Presentation to CD8+ T Cells. <i>Journal of Experimental Medicine</i> , 2003, 197, 1405-1416.	4.2	174
570	CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN- β -Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination. <i>Journal of Immunology</i> , 2003, 171, 5931-5939.	0.4	186
571	Histone Deacetylation, But Not Hypermethylation, Modifies Class II Transactivator and MHC Class II Gene Expression in Squamous Cell Carcinomas. <i>Journal of Immunology</i> , 2003, 170, 4980-4985.	0.4	41
572	CD40-deficient, Influenza-specific CD8 Memory T Cells Develop and Function Normally in a CD40-sufficient Environment. <i>Journal of Experimental Medicine</i> , 2003, 198, 1759-1764.	4.2	86
573	A role for dendritic cells in the priming of antigen-specific CD4+ and CD8+ T lymphocytes by immune-stimulating complexes in vivo. <i>International Immunology</i> , 2003, 15, 711-720.	1.8	23
574	Evidence for Antibody-Mediated Enhancement of Simian Immunodeficiency Virus (SIV) Gag Antigen Processing and Cross Presentation in SIV-Infected Rhesus Macaques. <i>Journal of Virology</i> , 2003, 77, 10-24.	1.5	60
575	Viral Persistence Alters CD8 T-Cell Immunodominance and Tissue Distribution and Results in Distinct Stages of Functional Impairment. <i>Journal of Virology</i> , 2003, 77, 4911-4927.	1.5	1,340
576	OX40 Ligand-Transduced Tumor Cell Vaccine Synergizes with GM-CSF and Requires CD40-Apc Signaling to Boost the Host T Cell Antitumor Response. <i>Journal of Immunology</i> , 2003, 170, 99-106.	0.4	67
577	NKT Cells Provide Help for Dendritic Cell-Dependent Priming of MHC Class I-Restricted CD8+ T Cells In Vivo. <i>Journal of Immunology</i> , 2003, 170, 2540-2548.	0.4	115
578	Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. <i>International Immunology</i> , 2003, 15, 751-763.	1.8	52
579	Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses. <i>Journal of Virology</i> , 2003, 77, 10862-10871.	1.5	127
580	HIV-1 Viremia Prevents the Establishment of Interleukin 2-producing HIV-specific Memory CD4+ T Cells Endowed with Proliferative Capacity. <i>Journal of Experimental Medicine</i> , 2003, 198, 1909-1922.	4.2	402
581	Functional Plasticity of Dendritic Cell Subsets as Mediated by CD40 Versus B7 Activation. <i>Journal of Immunology</i> , 2003, 171, 2581-2587.	0.4	100
582	Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen. <i>Blood</i> , 2003, 102, 36-42.	0.6	59
583	Cooperative B7-1/2 (CD80/CD86) and B7-DC Costimulation of CD4+ T Cells Independent of the PD-1 Receptor. <i>Journal of Experimental Medicine</i> , 2003, 198, 31-38.	4.2	144

#	ARTICLE	IF	CITATIONS
584	CD154-CD40-independent up-regulation of B7-2 on splenic antigen-presenting cells and efficient T cell priming by staphylococcal enterotoxin A. <i>International Immunology</i> , 2003, 15, 817-826.	1.8	4
585	Stochastic Model of T Cell Proliferation: A Calculus Revealing IL-2 Regulation of Precursor Frequencies, Cell Cycle Time, and Survival. <i>Journal of Immunology</i> , 2003, 170, 4963-4972.	0.4	146
586	HER-2 DNA and Protein Vaccines Containing Potent Th Cell Epitopes Induce Distinct Protective and Therapeutic Antitumor Responses in HER-2 Transgenic Mice. <i>Journal of Immunology</i> , 2003, 171, 1588-1595.	0.4	52
587	Measles Virus and Dendritic Cell Functions: How Specific Response Cohabits with Immunosuppression. <i>Current Topics in Microbiology and Immunology</i> , 2003, 276, 103-123.	0.7	48
588	Rational approaches to human cancer immunotherapy. <i>Journal of Leukocyte Biology</i> , 2003, 73, 3-29.	1.5	109
589	Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help. <i>Science</i> , 2003, 300, 339-342.	6.0	1,107
590	Differentiation of Monocytic Cell Clones into CD8 ⁺ Dendritic Cells (DC) Suggests that Monocytes Can Be Direct Precursors for Both CD8 ⁺ and CD8 ⁺ DC in the Mouse. <i>Journal of Immunology</i> , 2003, 170, 5927-5935.	0.4	20
591	Cooperation of TNF Family Members CD40 Ligand, Receptor Activator of NF- κ B Ligand, and TNF- α in the Activation of Dendritic Cells and the Expansion of Viral Specific CD8 ⁺ T Cell Memory Responses in HIV-1-Infected and HIV-1-Uninfected Individuals. <i>Journal of Immunology</i> , 2003, 170, 1797-1805.	0.4	55
592	Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory. <i>Science</i> , 2003, 300, 337-339.	6.0	1,325
593	Newly Activated T Cells Promote Maturation of Bystander Dendritic Cells but Not IL-12 Production. <i>Journal of Immunology</i> , 2003, 171, 6406-6413.	0.4	50
594	Improved Stimulation of Human Dendritic Cells by Receptor Engagement with Surface-modified Microparticles. <i>Journal of Drug Targeting</i> , 2003, 11, 11-18.	2.1	58
595	Deletion of Naive CD8 T Cells Requires Persistent Antigen and Is Not Programmed by an Initial Signal from the Tolerogenic APC. <i>Journal of Immunology</i> , 2003, 171, 6349-6354.	0.4	36
596	CD4 ⁺ Th2 Cell Recognition of HLA-DR-Restricted Epitopes Derived from CAMEL: A Tumor Antigen Translated in an Alternative Open Reading Frame. <i>Journal of Immunology</i> , 2003, 170, 1490-1497.	0.4	48
597	CD4 ⁺ NKT Cells, But Not Conventional CD4 ⁺ T Cells, Are Required to Generate Efferent CD8 ⁺ T Regulatory Cells Following Antigen Inoculation in an Immune-Privileged Site. <i>Journal of Immunology</i> , 2003, 171, 1266-1271.	0.4	110
598	Early IL-2 Production by Mouse Dendritic Cells Is the Result of Microbial-Induced Priming. <i>Journal of Immunology</i> , 2003, 170, 5075-5081.	0.4	161
599	In Vivo Impact of CpG1826 Oligodeoxynucleotide on CD8 T Cell Primary Responses and Survival. <i>Journal of Immunology</i> , 2003, 171, 2995-3002.	0.4	23
600	Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to <i>Plasmodium falciparum</i> Circumsporozoite Protein-Specific CD4 ⁺ and CD8 ⁺ T Cells Producing IFN- γ . <i>Journal of Immunology</i> , 2003, 171, 6961-6967.	0.4	229
601	Role of CD4 T Cell Help and Costimulation in CD8 T Cell Responses During <i>Listeria monocytogenes</i> Infection. <i>Journal of Immunology</i> , 2003, 170, 2053-2063.	0.4	146

#	ARTICLE	IF	CITATIONS
602	Activation of Alloreactive CD8+ T Cells Operates Via CD4-Dependent and CD4-Independent Mechanisms and Is CD154 Blockade Sensitive. <i>Journal of Immunology</i> , 2003, 170, 3024-3028.	0.4	26
603	CD40 Ligand Trimer Enhances the Response of CD8+ T Cells to <i>Mycobacterium tuberculosis</i> . <i>Journal of Immunology</i> , 2003, 170, 3180-3186.	0.4	32
604	Electroporation Enables Plasmid Vaccines to Elicit CD8+ T Cell Responses in the Absence of CD4+ T Cells. <i>Journal of Immunology</i> , 2003, 171, 3379-3384.	0.4	33
605	Cutting Edge: CD4+ T Cell Help Can Be Essential for Primary CD8+ T Cell Responses In Vivo. <i>Journal of Immunology</i> , 2003, 171, 6339-6343.	0.4	145
606	Community-Acquired Poliovirus Infection in Children with Primary Immunodeficiencies in Tunisia. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1203-1211.	1.8	14
607	The Intracellular Granzyme B Inhibitor, Proteinase Inhibitor 9, Is Up-Regulated During Accessory Cell Maturation and Effector Cell Degranulation, and Its Overexpression Enhances CTL Potency. <i>Journal of Immunology</i> , 2003, 170, 805-815.	0.4	141
608	NKT Cells Enhance CD4+ and CD8+ T Cell Responses to Soluble Antigen In Vivo through Direct Interaction with Dendritic Cells. <i>Journal of Immunology</i> , 2003, 171, 5140-5147.	0.4	445
609	Tumor Necrosis Factor Receptor-associated Factor 2 (TRAF2)-deficient B Lymphocytes Reveal Novel Roles for TRAF2 in CD40 Signaling. <i>Journal of Biological Chemistry</i> , 2003, 278, 45382-45390.	1.6	109
610	In Vivo Ligation of CD40 Enhances Priming Against the Endogenous Tumor Antigen and Promotes CD8+ T Cell Effector Function in SV40 T Antigen Transgenic Mice. <i>Journal of Immunology</i> , 2003, 171, 697-707.	0.4	74
611	The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization. <i>International Immunology</i> , 2003, 15, 1161-1171.	1.8	59
612	IL-21 Activates Both Innate and Adaptive Immunity to Generate Potent Antitumor Responses that Require Perforin but Are Independent of IFN- γ . <i>Journal of Immunology</i> , 2003, 171, 608-615.	0.4	169
613	Cellular Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation: Experimental Strategies and Clinical Experiences. <i>Leukemia and Lymphoma</i> , 2003, 44, 583-592.	0.6	1
614	Immuno-gene therapy with adenoviruses expressing fms-like tyrosine kinase 3 ligand and CD40 ligand for mouse hepatoma cells in vivo. <i>International Journal of Oncology</i> , 2003, 22, 345.	1.4	2
615	Stimulation of CD40 inhibits Fas- or chemotherapy-mediated apoptosis and increases cell motility in human gastric carcinoma cells. <i>International Journal of Oncology</i> , 2003, 23, 1697.	1.4	7
616	Distinctive maturation of in vitro versus in vivo anti-CD40 mAb-matured dendritic cells in mice. <i>Journal of Immunotherapy</i> , 2003, 26, 72-84.	1.2	16
617	CD40 Ligand-Dependent Maturation of Human Monocyte-Derived Dendritic Cells by Activated Platelets. <i>International Journal of Immunopathology and Pharmacology</i> , 2003, 16, 225-231.	1.0	61
618	Presentation of Exogenous Antigens on Major Histocompatibility Complex (MHC) Class I and MHC Class II Molecules Is Differentially Regulated during Dendritic Cell Maturation. <i>Journal of Experimental Medicine</i> , 2003, 198, 111-122.	4.2	218
619	Molecular Mechanisms and Biological Significance of CTL Avidity. <i>Current HIV Research</i> , 2003, 1, 287-294.	0.2	71

#	ARTICLE	IF	CITATIONS
620	CD40 in hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 113-114.	0.8	2
621	Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class II-Restricted Peptides from Melanoma-Associated Antigens. <i>Journal of Immunotherapy</i> , 2003, 26, 349-356.	1.2	118
622	Immunology and Immunotherapy in Neurosurgical Disease. <i>Neurosurgery</i> , 2003, 53, 144-153.	0.6	39
623	Breakdown of peripheral T-cell tolerance by chronic interleukin-15 elevation ¹ . <i>Transplantation</i> , 2003, 76, 415-420.	0.5	6
624	Mechanism of allorecognition and skin graft rejection in CD28 and CD40 ligand double-deficient mice. <i>Transplantation</i> , 2003, 76, 854-858.	0.5	8
625	Î²B kinase 2 but not NF-Î²B inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction. <i>Blood</i> , 2003, 101, 983-991.	0.6	64
626	Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell dependent immunity to B-cell lymphoma. <i>Blood</i> , 2003, 102, 1449-1457.	0.6	81
627	Role of CD4+ T lymphocytes in antitumor immunity. <i>Advances in Cancer Research</i> , 2003, 87, 195-249.	1.9	7
629	Carcinoembryonic Antigen as a Target to Induce Anti-Tumor Immune Responses. <i>Current Cancer Drug Targets</i> , 2004, 4, 443-454.	0.8	21
630	Immunopathogenesis and Prevention of Uveitis with the Behçet's Disease-Specific Peptide Linked to Cholera Toxin B. , 2003, 528, 173-180.		5
631	Induction of Humoral and Cellular Immune Responses to Hepatitis Delta Virus Through DNA Immunization in BALB/c Mice. , 2004, 96, 111-128.		0
632	CD40 Ligation In Vivo Induces Bystander Proliferation of Memory Phenotype CD8 T Cells. <i>Journal of Immunology</i> , 2004, 172, 4804-4811.	0.4	26
634	Cytokines and Costimulatory Molecules in the Immune Response to Murine Gammaherpesvirus-68. <i>Viral Immunology</i> , 2004, 17, 3-11.	0.6	14
635	Phenotypic Stability of Mature Dendritic Cells Tuned by TLR or CD40 to Control the Efficiency of Cytotoxic T Cell Priming. <i>Microbiology and Immunology</i> , 2004, 48, 211-219.	0.7	16
636	Cutting Edge: Tumor-Specific CTL Are Constitutively Cross-Armed in Draining Lymph Nodes and Transiently Disseminate to Mediate Tumor Regression following Systemic CD40 Activation. <i>Journal of Immunology</i> , 2004, 173, 5923-5928.	0.4	68
637	The Role of the p38 Mitogen-Activated Protein Kinase, Extracellular Signal-Regulated Kinase, and Phosphoinositide-3-OH Kinase Signal Transduction Pathways in CD40 Ligand-Induced Dendritic Cell Activation and Expansion of Virus-Specific CD8+ T Cell Memory Responses. <i>Journal of Immunology</i> , 2004, 172, 6047-6056.	0.4	125
638	Helper Requirements for Generation of Effector CTL to Islet Î² Cell Antigens. <i>Journal of Immunology</i> , 2004, 172, 5420-5426.	0.4	56
639	A Spontaneously Arising Pancreatic Tumor Does Not Promote the Differentiation of Naive CD8+ T Lymphocytes into Effector CTL. <i>Journal of Immunology</i> , 2004, 172, 6558-6567.	0.4	70

#	ARTICLE	IF	CITATIONS
640	CD4-Directed Peptide Vaccination Augments an Antitumor Response, but Efficacy Is Limited by the Number of CD8+ T Cell Precursors. <i>Journal of Immunology</i> , 2004, 172, 4215-4224.	0.4	28
641	Local Activation of Dendritic Cells Leads to Insulinitis and Development of Insulin-Dependent Diabetes in Transgenic Mice Expressing CD154 on the Pancreatic β -Cells. <i>Diabetes</i> , 2004, 53, 2588-2595.	0.3	14
642	Identification and Characterization of a T-Helper Peptide from Carcinoembryonic Antigen. <i>Clinical Cancer Research</i> , 2004, 10, 2860-2867.	3.2	14
643	Indirect Minor Histocompatibility Antigen Presentation by Allograft Recipient Cells in the Draining Lymph Node Leads to the Activation and Clonal Expansion of CD4+ T Cells That Cause Obliterative Airways Disease. <i>Journal of Immunology</i> , 2004, 172, 3469-3479.	0.4	46
644	A Two-Step Model of Acute CD4 T-Cell Mediated Cardiac Allograft Rejection. <i>Journal of Immunology</i> , 2004, 172, 7451-7458.	0.4	33
645	CD40 Engagement Enhances Antigen-Presenting Langerhans Cell Priming of IFN- γ -Producing CD4+ and CD8+ T Cells Independently of IL-12. <i>Journal of Immunology</i> , 2004, 173, 2443-2452.	0.4	25
646	T-cell epitope peptide vaccines. <i>Expert Review of Vaccines</i> , 2004, 3, 563-575.	2.0	19
647	MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4). <i>International Immunology</i> , 2004, 16, 895-904.	1.8	9
648	Defective Control of Latent Epstein-Barr Virus Infection in Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2004, 172, 1287-1294.	0.4	217
649	A Tumor-Associated Glycoprotein That Blocks MHC Class II-Dependent Antigen Presentation by Dendritic Cells. <i>Journal of Immunology</i> , 2004, 173, 1023-1032.	0.4	26
650	An Evaluation of Enforced Rapid Proteasomal Degradation as a Means of Enhancing Vaccine-Induced CTL Responses. <i>Journal of Immunology</i> , 2004, 173, 3073-3083.	0.4	26
651	Immunological Synapse Formation Licenses CD40-CD40L Accumulations at T-APC Contact Sites. <i>Journal of Immunology</i> , 2004, 173, 3647-3652.	0.4	58
652	The Development of Functional CD8 T Cell Memory after <i>Listeria monocytogenes</i> Infection Is Not Dependent on CD40. <i>Journal of Immunology</i> , 2004, 173, 4084-4090.	0.4	17
653	Aged Mice Develop Protective Antitumor Immune Responses with Appropriate Costimulation. <i>Journal of Immunology</i> , 2004, 173, 4510-4515.	0.4	76
654	Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells. <i>Journal of Leukocyte Biology</i> , 2004, 75, 504-514.	1.5	146
655	Potential of Tumor Eradication by Adoptive Immunotherapy with T-cell Receptor Gene-Transduced T-Helper Type 1 Cells. <i>Cancer Research</i> , 2004, 64, 386-390.	0.4	65
656	Determinations of B Cell Fate in Immunity and Autoimmunity. , 2004, 8, 1-24.		27
657	Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFN. <i>Journal of Experimental Medicine</i> , 2004, 199, 775-784.	4.2	343

#	ARTICLE	IF	CITATIONS
658	Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication. <i>Journal of Immunology</i> , 2004, 173, 6753-6759.	0.4	153
659	Induction of Tumor Regression by Administration of B7-Ig Fusion Proteins: Mediation by Type 2 CD8+ T Cells and Dependence on IL-4 Production. <i>Journal of Immunology</i> , 2004, 172, 1347-1354.	0.4	15
660	Th Cell-Independent Immune Responses to Chimeric Hemagglutinin/Simian Human Immunodeficiency Virus-Like Particles Vaccine. <i>Journal of Immunology</i> , 2004, 173, 1951-1958.	0.4	37
661	Activation-Induced Cell Death Limits Effector Function of CD4 Tumor-Specific T Cells. <i>Journal of Immunology</i> , 2004, 172, 6598-6606.	0.4	22
662	Fully Functional Memory CD8 T Cells in the Absence of CD4 T Cells. <i>Journal of Immunology</i> , 2004, 173, 969-975.	0.4	111
663	Characterization of a <i>Mycobacterium tuberculosis</i> Peptide That Is Recognized by Human CD4+ and CD8+ T Cells in the Context of Multiple HLA Alleles. <i>Journal of Immunology</i> , 2004, 173, 1966-1977.	0.4	82
664	IFN- γ Promotes Fas Ligand- and Perforin-Mediated Liver Cell Destruction by Cytotoxic CD8 T Cells. <i>Journal of Immunology</i> , 2004, 172, 1588-1594.	0.4	58
665	Myeloid Differentiation Factor 88 Is Required for Cross-Priming In Vivo. <i>Journal of Immunology</i> , 2004, 172, 3415-3421.	0.4	42
666	T Cells Signaled by NF- κ B ⁺ Dendritic Cells Are Sensitized Not Anergic to Subsequent Activation. <i>Journal of Immunology</i> , 2004, 173, 1671-1680.	0.4	24
667	Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients. <i>Journal of Immunology</i> , 2004, 172, 3289-3296.	0.4	176
668	Cellular Immune Responses to the Hepatitis B Virus Polymerase. <i>Journal of Immunology</i> , 2004, 173, 5863-5871.	0.4	86
669	Functional Analysis of Tumor-Specific Th Cell Responses Detected in Melanoma Patients after Dendritic Cell-Based Immunotherapy. <i>Journal of Immunology</i> , 2004, 172, 1304-1310.	0.4	70
670	Activation of CD8 T Cells by Mycobacterial Vaccination Protects against Pulmonary Tuberculosis in the Absence of CD4 T Cells. <i>Journal of Immunology</i> , 2004, 173, 4590-4597.	0.4	75
671	IL-6 Regulates In Vivo Dendritic Cell Differentiation through STAT3 Activation. <i>Journal of Immunology</i> , 2004, 173, 3844-3854.	0.4	444
672	Cutting Edge: Long-Lived CD8 Memory and Protective Immunity in the Absence of CD40 Expression on CD8 T Cells. <i>Journal of Immunology</i> , 2004, 172, 3385-3389.	0.4	90
673	The Linkage of Innate to Adaptive Immunity via Maturing Dendritic Cells In Vivo Requires CD40 Ligation in Addition to Antigen Presentation and CD80/86 Costimulation. <i>Journal of Experimental Medicine</i> , 2004, 199, 1607-1618.	4.2	539
674	Cutting Edge: A Critical Role for CD70 in CD8 T Cell Priming by CD40-Licensed APCs. <i>Journal of Immunology</i> , 2004, 173, 6542-6546.	0.4	109
675	Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 9363-9368.	3.3	82

#	ARTICLE	IF	CITATIONS
676	The Impact of Self-Tolerance on the Polyclonal CD8+ T Cell Repertoire. <i>Journal of Immunology</i> , 2004, 172, 2324-2331.	0.4	18
677	CD154 is a negative regulator of autoaggressive CD8+ T cells in type 1 diabetes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 9345-9350.	3.3	14
678	Generation and Targeting of Human Tumor-Specific Tc1 and Th1 Cells Transduced with a Lentivirus Containing a Chimeric Immunoglobulin T-Cell Receptor. <i>Cancer Research</i> , 2004, 64, 1490-1495.	0.4	51
679	Identification of Multiple HLA-DR-Restricted Epitopes of the Tumor-Associated Antigen CAMEL by CD4+ Th1/Th2 Lymphocytes. <i>Journal of Immunology</i> , 2004, 172, 5095-5102.	0.4	20
680	A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 15440-15445.	3.3	226
681	Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules. <i>Journal of Immunology</i> , 2004, 172, 6649-6657.	0.4	182
682	Generation, Maintenance, and Function of Memory T Cells. <i>Advances in Immunology</i> , 2004, 83, 191-231.	1.1	4
683	Dendritic Cell-Based Immunotherapy of Malignant Gliomas. <i>Cancer Investigation</i> , 2004, 22, 405-416.	0.6	27
684	HIV-1 Vpr inhibits the maturation and activation of macrophages and dendritic cells in vitro. <i>International Immunology</i> , 2004, 17, 103-116.	1.8	64
685	Vaccination by Genetically Modified Dendritic Cells Expressing a Truncated neu Oncogene Prevents Development of Breast Cancer in Transgenic Mice. <i>Cancer Research</i> , 2004, 64, 8022-8028.	0.4	86
686	Antigen-independent acquisition of MHC class II molecules by human T lymphocytes. <i>International Immunology</i> , 2004, 16, 1523-1533.	1.8	21
687	NK Cells Regulate CD8+ T Cell Effector Function in Response to an Intracellular Pathogen. <i>Journal of Immunology</i> , 2004, 172, 130-137.	0.4	155
688	A Role for Toll-Like Receptor 4 in Dendritic Cell Activation and Cytolytic CD8+ T Cell Differentiation in Response to a Recombinant Heat Shock Fusion Protein. <i>Journal of Immunology</i> , 2004, 172, 2885-2893.	0.4	36
689	Prognostic value of cytotoxic T-lymphocytes and CD40 in biopsies with early renal allograft rejection. <i>Transplant International</i> , 2004, 17, 293-300.	0.8	17
690	Helper T cells, dendritic cells and CTL Immunity. <i>Immunology and Cell Biology</i> , 2004, 82, 84-90.	1.0	101
691	Human growth hormone presented by K14hGH transgenic skin grafts induces a strong immune response but no graft rejection. <i>Immunology and Cell Biology</i> , 2004, 82, 577-586.	1.0	8
692	CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. <i>British Journal of Haematology</i> , 2004, 127, 404-415.	1.2	65
693	Immunopathogenic mechanisms in psoriasis. <i>Clinical and Experimental Immunology</i> , 2004, 135, 1-8.	1.1	323

#	ARTICLE	IF	CITATIONS
694	CD8alpha+ dendritic cells and immune protection from experimental allergic encephalomyelitis. <i>Clinical and Experimental Immunology</i> , 2004, 137, 486-495.	1.1	14
695	B-Lymphocytes Activated by CD40 Ligand Induce an Antigen-Specific Anti-Tumour Immune Response by Direct and Indirect Activation of CD8+ T-cells. <i>Scandinavian Journal of Immunology</i> , 2004, 60, 543-551.	1.3	35
696	Immune modulation with dendritic cells. <i>Transfusion Medicine</i> , 2004, 14, 81-96.	0.5	4
697	Antigen-immunostimulatory oligonucleotide conjugates: mechanisms and applications. <i>Immunological Reviews</i> , 2004, 199, 217-226.	2.8	43
698	'Educated' dendritic cells act as messengers from memory to naive T helper cells. <i>Nature Immunology</i> , 2004, 5, 615-622.	7.0	129
699	A license to remember. <i>Nature Immunology</i> , 2004, 5, 1097-1098.	7.0	10
700	CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. <i>Nature Immunology</i> , 2004, 5, 927-933.	7.0	589
701	Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity. <i>Nature Immunology</i> , 2004, 5, 1143-1148.	7.0	387
702	Tolerance tag team. <i>Nature Medicine</i> , 2004, 10, 585-587.	15.2	3
703	Helping the CD8+ T-cell response. <i>Nature Reviews Immunology</i> , 2004, 4, 595-602.	10.6	673
704	Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy. <i>Cancer Gene Therapy</i> , 2004, 11, 194-207.	2.2	25
705	Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber. <i>Cancer Gene Therapy</i> , 2004, 11, 227-236.	2.2	15
706	Effective antigen cross-presentation by prostate cancer patients' dendritic cells: implications for prostate cancer immunotherapy. <i>Prostate Cancer and Prostatic Diseases</i> , 2004, 7, 63-72.	2.0	13
707	Earlier Low-Dose TBI or DST Overcomes CD8+ T-Cell-Mediated Alloresistance to Allogeneic Marrow in Recipients of Anti-CD40L. <i>American Journal of Transplantation</i> , 2004, 4, 31-40.	2.6	62
708	Endothelial cells present antigens in vivo. <i>BMC Immunology</i> , 2004, 5, 5.	0.9	64
709	Expression and functional effects of Eph receptor tyrosine kinase A family members on Langerhans like dendritic cells. <i>BMC Immunology</i> , 2004, 5, 9.	0.9	18
710	Responses Against Complex Antigens in Various Models of CD4 T-Cell Deficiency: Surprises From an Anti-CD4 Antibody Transgenic Mouse. <i>Immunologic Research</i> , 2004, 30, 001-014.	1.3	17
711	Osteoblast Responses to Bacterial Pathogens: A Previously Unappreciated Role for Bone-Forming Cells in Host Defense and Disease Progression. <i>Immunologic Research</i> , 2004, 30, 291-308.	1.3	82

#	ARTICLE	IF	CITATIONS
712	CentralMemory andEffectorMemoryT CellSubsets: Function, Generation, and Maintenance. Annual Review of Immunology, 2004, 22, 745-763.	9.5	2,571
713	The role of CD40-CD154 interaction in cell immunoregulation. Journal of Biomedical Science, 2004, 11, 426-438.	2.6	47
714	Towards a cellular definition of CD8+ T-cell memory: the role of CD4+ T-cell help in CD8+ T-cell responses. Current Opinion in Immunology, 2004, 16, 259-263.	2.4	87
715	A graph model for the evolution of specificity in humoral immunity. Journal of Theoretical Biology, 2004, 229, 311-325.	0.8	8
716	Identification of tumor antigens and T-cell epitopes, and its clinical application. Cancer Immunology, Immunotherapy, 2004, 53, 196-203.	2.0	32
717	Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates. Cancer Immunology, Immunotherapy, 2004, 53, 715-22.	2.0	25
718	Prognostic value of cytotoxic T-lymphocytes and CD40 in biopsies with early renal allograft rejection. Transplant International, 2004, 17, 293-300.	0.8	4
719	CD4 T cells guarantee optimal competitive fitness of CD8 memory T cells. European Journal of Immunology, 2004, 34, 91-97.	1.6	29
720	Maintenance of memory CTL responses by Tâ€š,helper cells and CD40-CD40 ligand: antibodies provide the key. European Journal of Immunology, 2004, 34, 317-326.	1.6	64
721	Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA). Glia, 2004, 45, 392-405.	2.5	28
722	Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand. International Journal of Cancer, 2004, 108, 696-703.	2.3	24
723	Protection against MUC1 expressing mouse tumours by intra-muscular injection of MUC1 cDNA requires functional CD8+ and CD4+ T cells but does not require the MUC1 tandem repeat domain. International Journal of Cancer, 2004, 109, 691-697.	2.3	18
724	Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. International Journal of Cancer, 2004, 110, 730-740.	2.3	60
725	CD8+ T-cell memory: only the good ones last. Current Opinion in Immunology, 2004, 16, 451-455.	2.4	47
726	Cellular immunotherapy for cancer: current concepts and clinical perspectives. Clinical Oncology, 2004, 16, 356-365.	0.6	3
727	Neuroimmunology of the paraneoplastic neurological degenerations. Current Opinion in Immunology, 2004, 16, 616-622.	2.4	88
728	Ligation of B7-1/B7-2 by Human CD4+ T Cells Triggers Indoleamine 2,3-Dioxygenase Activity in Dendritic Cells. Journal of Immunology, 2004, 172, 4100-4110.	0.4	426
729	Expansion of human CMV-specific cytotoxic T lymphocytes to a clinical scale: a simple culture system using tetrameric HLAâ€š-peptide complexes. Cytotherapy, 2004, 6, 514-522.	0.3	9

#	ARTICLE	IF	CITATIONS
730	A graph model for the evolution of specificity in humoral immunity. <i>Journal of Theoretical Biology</i> , 2004, 229, 311-311.	0.8	1
731	The Regulation and Maturation of Antiviral Immune Responses. <i>Advances in Virus Research</i> , 2004, 63, 181-238.	0.9	19
732	CD40/CD154 Interactions at the Interface of Tolerance and Immunity. <i>Annual Review of Immunology</i> , 2004, 22, 307-328.	9.5	615
733	An APC for every occasion: induction and expansion of human Ag-specific CD4 and CD8 T cells using cellular and non-cellular APC. <i>Cytotherapy</i> , 2004, 6, 440-449.	0.3	6
734	Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells. <i>Clinical Immunology</i> , 2004, 112, 35-44.	1.4	14
735	The role of the CD40 pathway in the pathogenesis and treatment of cancer. <i>Current Opinion in Pharmacology</i> , 2004, 4, 360-367.	1.7	83
736	Cancer vaccine development: on the way to break immune tolerance to malignant cells. <i>Experimental Cell Research</i> , 2004, 299, 267-278.	1.2	32
737	Differences of soluble CD40L in sera and plasma: Implications on CD40L assay as a marker of thrombotic risk. <i>Thrombosis Research</i> , 2004, 114, 143-148.	0.8	73
738	DC-virus interplay: a double edged sword. <i>Seminars in Immunology</i> , 2004, 16, 147-161.	2.7	50
739	CD8 T cell memory. <i>Seminars in Immunology</i> , 2004, 16, 305-314.	2.7	39
740	The CD154-CD40 costimulation pathway in organ transplantation. <i>Transplantation Reviews</i> , 2004, 18, 10-19.	1.2	4
741	Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice. <i>Vaccine</i> , 2004, 23, 258-266.	1.7	73
742	T-cell receptor-transgenic NOD mice: a reductionist approach to understand autoimmune diabetes. <i>Journal of Autoimmunity</i> , 2004, 22, 121-129.	3.0	5
743	“One size fits it all” translocation of foreign antigens by Yersinia type III secretion system (TTSS) leads to concomitant CD4 and CD8 T-cell priming. <i>International Journal of Medical Microbiology</i> , 2004, 294, 313-317.	1.5	3
744	Roles of lymphoid cells in the differentiation of Langerhans dendritic cells in mice. <i>Immunobiology</i> , 2004, 209, 209-221.	0.8	9
745	CD8+ T-cell priming regulated by cytokines of the innate immune system. <i>Trends in Molecular Medicine</i> , 2004, 10, 366-371.	3.5	17
746	Memory CD8 T-Cell Differentiation during Viral Infection. <i>Journal of Virology</i> , 2004, 78, 5535-5545.	1.5	767
747	Immune Response Against Dying Tumor Cells. <i>Advances in Immunology</i> , 2004, 84, 131-179.	1.1	104

#	ARTICLE	IF	CITATIONS
748	Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens. <i>Blood</i> , 2004, 104, 2704-2713.	0.6	22
749	Highly efficient expression of transgenic proteins by naked DNA-transfected dendritic cells through terminal differentiation. <i>Blood</i> , 2004, 103, 811-819.	0.6	24
750	Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. <i>Blood</i> , 2004, 103, 2238-2247.	0.6	160
751	Functional domains of HSP70 stimulate generation of cytokines and chemokines, maturation of dendritic cells and adjuvanticity. <i>Biochemical Society Transactions</i> , 2004, 32, 629-632.	1.6	84
752	Therapeutic Vaccines for Cervical Cancer: Dendritic Cell-Based Immunotherapy. <i>Current Pharmaceutical Design</i> , 2005, 11, 3485-3500.	0.9	49
753	Large-Scale Depletion of CD25+ Regulatory T Cells from Patient Leukapheresis Samples. <i>Journal of Immunotherapy</i> , 2005, 28, 403-411.	1.2	35
754	Pulmonary Cell-Mediated Immunity (CMI) to <i>Cryptococcus neoformans</i> . , 2005, , 157-180.		2
755	Impaired CD40L signaling is a cause of defective IL-12 and TNF- α production in Sjögren syndrome: circumvention by hexameric soluble CD40L. <i>Blood</i> , 2005, 105, 219-225.	0.6	36
756	Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes. <i>Blood</i> , 2005, 105, 2436-2442.	0.6	51
757	DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. <i>Blood</i> , 2005, 106, 338-344.	0.6	203
758	Critical role of host T cells in experimental acute graft-versus-host disease. <i>Blood</i> , 2005, 106, 749-755.	0.6	67
759	Differential effect of agonistic anti-CD40 on human mature and immature dendritic cells: the Janus face of anti-CD40. <i>Blood</i> , 2005, 106, 2806-2814.	0.6	17
760	Antigen-specific CD4+ regulatory T cells in cancer: implications for immunotherapy. <i>Microbes and Infection</i> , 2005, 7, 1056-1062.	1.0	21
761	Lymphocyte Activation as a Possible Measure of Atherosclerotic Risk in Patients with Sleep Apnea. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 340-350.	1.8	118
762	Immunity in response to particulate antigen-delivery systems. <i>Advanced Drug Delivery Reviews</i> , 2005, 57, 333-355.	6.6	277
763	Intratumoral immunotherapy: using the tumour against itself. <i>Immunology</i> , 2005, 114, 11-22.	2.0	67
764	C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L. <i>Nature Chemical Biology</i> , 2005, 1, 377-382.	3.9	63
765	Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. <i>Nature Medicine</i> , 2005, 11, 130-137.	15.2	79

#	ARTICLE	IF	CITATIONS
766	Psoriasis: emerging therapeutic strategies. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 19-34.	21.5	127
767	Consensual immunity: success-driven development of T-helper-1 and T-helper-2 responses. <i>Nature Reviews Immunology</i> , 2005, 5, 251-260.	10.6	90
768	Immune surveillance of intracellular pathogens via autophagy. <i>Cell Death and Differentiation</i> , 2005, 12, 1519-1527.	5.0	30
770	The emerging role of platelets in adaptive immunity. <i>Cellular Immunology</i> , 2005, 238, 1-9.	1.4	148
771	Maturation of function in dendritic cells for tolerance and immunity. <i>Journal of Cellular and Molecular Medicine</i> , 2005, 9, 643-654.	1.6	76
772	Human papillomavirus type 16 E7 peptide ³⁸⁻⁶¹ linked with an immunoglobulin G fragment provides protective immunity in mice. <i>Gynecologic Oncology</i> , 2005, 96, 475-483.	0.6	14
773	CD8 T cell priming by B lymphocytes is CD4 help dependent. <i>European Journal of Immunology</i> , 2005, 35, 1360-1370.	1.6	26
774	Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells. <i>European Journal of Immunology</i> , 2005, 35, 2826-2839.	1.6	8
775	Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy. <i>Journal of Gene Medicine</i> , 2005, 7, 686-695.	1.4	55
776	Semi-mature IL-12 secreting dendritic cells present exogenous antigen to trigger cytolytic immune responses. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 769-780.	2.0	46
777	Induction of antigen cross-presentation by Toll-like receptors. <i>Seminars in Immunopathology</i> , 2005, 26, 247-255.	4.0	30
778	Immunological ignorance of solid tumors. <i>Seminars in Immunopathology</i> , 2005, 27, 19-35.	4.0	44
779	Mucosal effector memory T cells: the other side of the coin. <i>Cellular and Molecular Life Sciences</i> , 2005, 62, 2853-2866.	2.4	26
780	Death to the bad guys: Targeting cancer via Apo2L/TRAIL. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2005, 10, 35-51.	2.2	110
781	Heat Shock Proteins, Their Cell Surface Receptors and Effect on the Immune System. , 2005, , 160-178.		2
782	Mechanisms of CD8+ T cell peripheral tolerance to our own antigens. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 1628.	3.0	6
783	T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 2908.	3.0	9
784	Immunoregulation of Dendritic Cells. <i>Clinical Medicine and Research</i> , 2005, 3, 166-175.	0.4	118

#	ARTICLE	IF	CITATIONS
785	Simultaneous Generation of CD8+ and CD4+ Melanoma-Reactive T Cells by Retroviral-Mediated Transfer of a Single T-Cell Receptor. <i>Cancer Research</i> , 2005, 65, 1570-1576.	0.4	97
786	The Parent-into-F1 Model of Graft-vs-Host Disease as a Model of In Vivo T Cell Function and Immunomodulation. <i>Current Medicinal Chemistry Immunology, Endocrine & Metabolic Agents</i> , 2005, 5, 575-583.	0.2	21
787	CD4 T Lymphocytes: A Critical Component of Antitumor Immunity. <i>Cancer Investigation</i> , 2005, 23, 413-419.	0.6	32
788	The Innate Functions of Dendritic Cells in Peripheral Lymphoid Tissues. , 2005, 560, 83-97.		54
789	Definition of an Immunogenic Region Within the Ovarian Tumor Antigen Stratum Corneum Chymotryptic Enzyme. <i>Clinical Cancer Research</i> , 2005, 11, 3446-3454.	3.2	15
790	Ag85B of Mycobacteria Elicits Effective CTL Responses through Activation of Robust Th1 Immunity as a Novel Adjuvant in DNA Vaccine. <i>Journal of Immunology</i> , 2005, 175, 2541-2547.	0.4	37
791	Preferential Apoptosis of HIV-1-Specific CD4+ T Cells. <i>Journal of Immunology</i> , 2005, 174, 2196-2204.	0.4	73
792	Dendritic Cells. , 2005, , 173-184.		0
793	Cross-Priming of T Cell Responses by Synthetic Microspheres Carrying a CD8+ T Cell Epitope Requires an Adjuvant Signal. <i>Journal of Immunology</i> , 2005, 174, 3432-3439.	0.4	16
794	Maintenance of Immune Tolerance Depends on Normal Tissue Homeostasis. <i>Journal of Immunology</i> , 2005, 175, 4247-4254.	0.4	11
796	CD40 Ligation Activates Murine Macrophages via an IFN- γ -Dependent Mechanism Resulting in Tumor Cell Destruction In Vitro. <i>Journal of Immunology</i> , 2005, 174, 6013-6022.	0.4	107
797	Salmonella Pathogenicity Island 2-Mediated Overexpression of Chimeric SspH2 Proteins for Simultaneous Induction of Antigen-Specific CD4 and CD8 T Cells. <i>Infection and Immunity</i> , 2005, 73, 334-341.	1.0	29
798	A Novel Viral System for Generating Antigen-Specific T Cells. <i>Journal of Immunology</i> , 2005, 175, 3431-3438.	0.4	40
799	B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors. <i>International Immunology</i> , 2005, 17, 1071-1079.	1.8	3
800	Generation of Antifungal Effector CD8+ T Cells in the Absence of CD4+ T Cells during <i>Cryptococcus neoformans</i> Infection. <i>Journal of Immunology</i> , 2005, 174, 7920-7928.	0.4	81
801	Use of proteomics to define targets of T-cell immunity. <i>Expert Review of Proteomics</i> , 2005, 2, 367-380.	1.3	11
802	Dendritic cell-based immunotherapy for malignant gliomas. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 497-508.	1.4	15
803	Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy. <i>Gene Therapy</i> , 2005, 12, 999-1010.	2.3	16

#	ARTICLE	IF	CITATIONS
804	Nonreplicating Recombinant Vaccinia Virus Expressing CD40 Ligand Enhances APC Capacity to Stimulate Specific CD4+ and CD8+ T Cell Responses. <i>Human Gene Therapy</i> , 2005, 16, 348-360.	1.4	42
805	Lentiviral Transduction of Primary Myeloma Cells with CD80 and CD154 Generates Antimyeloma Effector T Cells. <i>Human Gene Therapy</i> , 2005, 16, 445-456.	1.4	5
806	Memory cytolytic T-lymphocytes: induction, regulation and implications for vaccine design. <i>Expert Review of Vaccines</i> , 2005, 4, 711-723.	2.0	5
807	In Vivo Depletion of CD4+CD25+ Regulatory T Cells Enhances the Antigen-Specific Primary and Memory CTL Response Elicited by Mature mRNA-Electroporated Dendritic Cells. <i>Molecular Therapy</i> , 2005, 12, 922-932.	3.7	31
808	Antibodies and CD8+ T Cells Are Complementary and Essential for Natural Resistance to a Highly Lethal Cytopathic Virus. <i>Journal of Immunology</i> , 2005, 175, 6829-6836.	0.4	103
809	Direct Cross-Priming by Th Lymphocytes Generates Memory Cytotoxic T Cell Responses. <i>Journal of Immunology</i> , 2005, 174, 3967-3977.	0.4	29
810	CD4 T Cell-Dependent Conditioning of Dendritic Cells to Produce IL-12 Results in CD8-Mediated Graft Rejection and Avoidance of Tolerance. <i>Journal of Immunology</i> , 2005, 174, 6909-6917.	0.4	74
811	A New Dynamic Model of CD8+ T Effector Cell Responses via CD4+ T Helper-Antigen-Presenting Cells. <i>Journal of Immunology</i> , 2005, 174, 7497-7505.	0.4	134
812	Linked Foreign T-Cell Help Activates Self-Reactive CTL and Inhibits Tumor Growth. <i>Journal of Immunology</i> , 2005, 175, 329-334.	0.4	20
813	Simultaneous Targeting of CD3 on T Cells and CD40 on B or Dendritic Cells Augments the Antitumor Reactivity of Tumor-Primed Lymph Node Cells. <i>Journal of Immunology</i> , 2005, 175, 1424-1432.	0.4	38
814	Detection of Spontaneous CD4+ T-Cell Responses in Melanoma Patients against a Tyrosinase-Related Protein-2â€Derived Epitope Identified in HLA-DRB1*0301 Transgenic Mice. <i>Clinical Cancer Research</i> , 2005, 11, 5241-5247.	3.2	20
815	License to Heal: Bidirectional Interaction of Antigen-Specific Regulatory T Cells and Tolerogenic APC. <i>Journal of Immunology</i> , 2005, 174, 5907-5914.	0.4	139
816	The Influence of the Major Histocompatibility Complex on Development of Autoimmune Diabetes in RIP-B7.1 Mice. <i>Diabetes</i> , 2005, 54, 2032-2040.	0.3	8
817	Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. <i>Gene Therapy</i> , 2005, 12, 772-782.	2.3	85
818	Maintenance of CD8+T Cells during Acute Viral Infection of the Central Nervous System Requires CD4+T Cells But Not Interleukin-2. <i>Viral Immunology</i> , 2005, 18, 162-169.	0.6	21
820	CD8+T cells produce IL-2, which is required for CD4+CD25+T cell regulation of effector CD8+T cell development for contact hypersensitivity responses. <i>Journal of Leukocyte Biology</i> , 2005, 78, 725-735.	1.5	52
821	The New Immunosuppression: Intervention at the Dendritic Cell-T-Cell Interface. <i>Current Drug Targets Immune, Endocrine and Metabolic Disorders</i> , 2005, 5, 397-411.	1.8	8
822	Differential Expression Regulation of the $\hat{1}$ and $\hat{2}$ Subunits of the PA28 Proteasome Activator in Mature Dendritic Cells. <i>Journal of Immunology</i> , 2005, 174, 7815-7822.	0.4	60

#	ARTICLE	IF	CITATIONS
823	Induction of CD70 on Dendritic Cells through CD40 or TLR Stimulation Contributes to the Development of CD8+ T Cell Responses in the Absence of CD4+ T Cells. <i>Journal of Immunology</i> , 2005, 174, 710-717.	0.4	161
824	Induction of Impaired Antitumor Immunity by Fusion of MHC Class II-Deficient Dendritic Cells with Tumor Cells. <i>Journal of Immunology</i> , 2005, 174, 1274-1280.	0.4	32
825	BCL6b mediates the enhanced magnitude of the secondary response of memory CD8+ T lymphocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 7418-7425.	3.3	76
826	Responses to Human CD40 Ligand/Human Interleukin-2 Autologous Cell Vaccine in Patients with B-Cell Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 6916-6923.	3.2	76
827	The role of apoptosis in the development and function of T lymphocytes. <i>Cell Research</i> , 2005, 15, 749-769.	5.7	126
828	Anti-CD40 monoclonal antibody. <i>Leukemia and Lymphoma</i> , 2005, 46, 1105-1113.	0.6	24
829	HSP110 induces "danger signals" upon interaction with antigen presenting cells and mouse mammary carcinoma. <i>Immunobiology</i> , 2005, 210, 295-303.	0.8	36
830	Cooperation of Human Tumor-Reactive CD4+ and CD8+ T Cells after Redirection of Their Specificity by a High-Affinity p53A2.1-Specific TCR. <i>Immunity</i> , 2005, 22, 117-129.	6.6	136
831	Peripheral Tolerance of CD8 T Lymphocytes. <i>Immunity</i> , 2005, 22, 275-284.	6.6	211
832	Interleukin-12 Increases Proliferation and Interferon- γ Production but Not Cytolytic Activity of Human Antigen-Specific Effector Memory Cytotoxic T Lymphocytes: Power of the Effect Depends on the Functional Avidity of the T Cell and the Antigen Concentration. <i>Human Immunology</i> , 2005, 66, 1137-1145.	1.2	9
833	Humoral autoimmunity in mice overexpressing B cell surface CD19: Vital role for MHC class II. <i>Clinical Immunology</i> , 2005, 116, 257-264.	1.4	6
834	Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. <i>Vaccine</i> , 2005, 23, 1232-1241.	1.7	77
835	Programming of CTL with heat-killed <i>Brucella abortus</i> and antigen allows soluble antigen alone to generate effective secondary CTL. <i>Vaccine</i> , 2005, 23, 1730-1738.	1.7	4
836	CD4+ T cell epitope affinity to MHC II influences the magnitude of CTL responses elicited by DNA epitope vaccines. <i>Vaccine</i> , 2005, 23, 2639-2646.	1.7	2
837	Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. <i>Vaccine</i> , 2005, 23, 2367-2373.	1.7	62
838	Characterization of anti-self CD8 T-cell responses stimulated by recombinant expressing the melanoma antigen TRP-2. <i>Vaccine</i> , 2005, 23, 4263-4272.	1.7	33
839	Synergism between active listeriolysin O and dimethyldioctadecylammonium bromide to activate CD8+ T cells. <i>Vaccine</i> , 2005, 23, 4481-4488.	1.7	3
840	Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors. <i>Vaccine</i> , 2005, 23, 5768-5774.	1.7	30

#	ARTICLE	IF	CITATIONS
841	Immunologic aspect of ovarian cancer and p53 as tumor antigen. <i>Journal of Translational Medicine</i> , 2005, 3, 34.	1.8	31
842	DNA Vaccine. <i>Advances in Genetics</i> , 2005, 54, 257-289.	0.8	79
843	Activation of Thymic Regeneration in Mice and Humans following Androgen Blockade. <i>Journal of Immunology</i> , 2005, 175, 2741-2753.	0.4	431
845	CD4+T Lymphocytes: A Critical Component of Antitumor Immunity. <i>Cancer Investigation</i> , 2005, 23, 413-419.	0.6	77
846	Epstein-Barr virus and rheumatoid arthritis: is there a link?. <i>Arthritis Research and Therapy</i> , 2006, 8, 204.	1.6	81
847	Ins and Outs of Dendritic Cells. <i>International Archives of Allergy and Immunology</i> , 2006, 140, 53-72.	0.9	83
849	Antigen presentation and the regulation of CD4 memory generation to influenza. <i>Expert Review of Clinical Immunology</i> , 2006, 2, 601-611.	1.3	1
850	Effective Induction of Type 1 Cytotoxic T Cell Responses in Mice with DNA Vaccine Encoding Two Hepatitis C Virus Cytotoxic T Lymphocyte Epitopes. <i>Viral Immunology</i> , 2006, 19, 702-711.	0.6	14
851	DNA Vaccines Against Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 613-636.	0.9	18
852	Vaccination for Treatment and Prevention of Cancer in Animal Models. <i>Advances in Immunology</i> , 2006, 90, 175-213.	1.1	75
853	COOPERATION BETWEEN CD4+AND CD8+T CELLS: When, Where, and How. <i>Annual Review of Immunology</i> , 2006, 24, 519-540.	9.5	332
854	Immunodominance and Immunodomination: Critical Factors in Developing Effective CD8+ Tâ€Cellâ€Based Cancer Vaccines. <i>Advances in Cancer Research</i> , 2006, 95, 203-247.	1.9	70
855	Dendritic Cell Immunotherapy for the Treatment of Neoplastic Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 113-125.	2.0	27
856	Migratory Dendritic Cells Transfer Antigen to a Lymph Node-Resident Dendritic Cell Population for Efficient CTL Priming. <i>Immunity</i> , 2006, 25, 153-162.	6.6	637
857	CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope. <i>Vaccine</i> , 2006, 24, 1880-1888.	1.7	15
858	Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help. <i>Vaccine</i> , 2006, 24, 3203-3216.	1.7	32
859	Presentation of the HCV-derived lipopeptide LP20â€44 by dendritic cells enhances function of in vitro-generated CD4+ T cells via up-regulation of TLR2. <i>Vaccine</i> , 2006, 24, 3066-3075.	1.7	8
860	Co-stimulatory agonists as immunological adjuvants. <i>Vaccine</i> , 2006, 24, 3399-3407.	1.7	54

#	ARTICLE	IF	CITATIONS
861	Maintenance of CD8 effector T cells by CD4 helper T cells eradicates growing tumors and promotes long-term tumor immunity. <i>Vaccine</i> , 2006, 24, 6199-6207.	1.7	22
862	The effect of co-administration of DNA carrying chicken interferon- β gene on protection of chickens against infectious bursal disease by DNA-mediated vaccination. <i>Vaccine</i> , 2006, 24, 6955-6965.	1.7	17
863	Endothelial Cell-Mediated Antigen Presentation. <i>Transfusion Medicine and Hemotherapy</i> , 2006, 33, 58-70.	0.7	6
865	Therapeutic potential of immunostimulatory monoclonal antibodies. <i>Clinical Science</i> , 2006, 111, 93-106.	1.8	15
866	Dendritic Cells. , 2006, , 115-126.		0
867	OX40 Ligation of CD4+ T Cells Enhances Virus-Specific CD8+ T Cell Memory Responses Independently of IL-2 and CD4+ T Regulatory Cell Inhibition. <i>Journal of Immunology</i> , 2006, 176, 2486-2495.	0.4	41
868	CD4+ T cell-independent maintenance and expansion of memory CD8+ T cells derived from in vitro dendritic cell activation. <i>International Immunology</i> , 2006, 18, 887-895.	1.8	6
869	Dendritic Cell Immunotherapy for Melanoma. <i>Reviews on Recent Clinical Trials</i> , 2006, 1, 87-102.	0.4	2
870	Subject Index. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 959-963.	1.1	49
871	Blood Dendritic Cells Generated With Flt3 Ligand and CD40 Ligand Prime CD8+ T Cells Efficiently in Cancer Patients. <i>Journal of Immunotherapy</i> , 2006, 29, 499-511.	1.2	62
872	Monocyte-derived DC Primed With TLR Agonists Secrete IL-12p70 in a CD40-dependent Manner Under Hyperthermic Conditions. <i>Journal of Immunotherapy</i> , 2006, 29, 606-615.	1.2	23
873	The Role of Dendritic Cells in T-cell Activation and Differentiation. , 0, , 343-354.		0
874	The Tower of Babel of CD8 + T cell memory: known facts, deserted roads, muddy waters, and possible dead ends. <i>Immunological Reviews</i> , 2006, 211, 182-196.	2.8	31
875	Signals required for programming effector and memory development by CD8 + T cells. <i>Immunological Reviews</i> , 2006, 211, 81-92.	2.8	513
876	Developing and maintaining protective CD8 + memory T cells. <i>Immunological Reviews</i> , 2006, 211, 146-153.	2.8	137
877	p53: A Potential Target Antigen for Immunotherapy of Cancer. <i>Annals of the New York Academy of Sciences</i> , 2000, 910, 223-236.	1.8	45
878	Characterization of T-cell responses against immunodominant epitopes from hepatitis C virus E2 and NS4a proteins. <i>Journal of Viral Hepatitis</i> , 2006, 13, 47-55.	1.0	18
879	Antitumor activity of chimeric immunoreceptor gene-modified Tc1 and Th1 cells against autologous carcinoembryonic antigen-expressing colon cancer cells. <i>Cancer Science</i> , 2006, 97, 920-927.	1.7	11

#	ARTICLE	IF	CITATIONS
880	Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide. <i>Immunology</i> , 2006, 117, 47-58.	2.0	18
881	The regression of a canine Langerhans cell tumour is associated with increased expression of IL-2, TNF-alpha, IFN-gamma and iNOS mRNA. <i>Immunology</i> , 2006, 118, 060608033622002-???.	2.0	22
882	Interleukin 15-dependent crosstalk between conventional and plasmacytoid dendritic cells is essential for CpG-induced immune activation. <i>Nature Immunology</i> , 2006, 7, 740-746.	7.0	138
883	Tumor-infiltrating T lymphocytes: friends or foes?. <i>Laboratory Investigation</i> , 2006, 86, 231-245.	1.7	246
884	Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. <i>Nature</i> , 2006, 440, 890-895.	13.7	752
885	Rapid and efficient nonviral gene delivery of CD154 to primary chronic lymphocytic leukemia cells. <i>Cancer Gene Therapy</i> , 2006, 13, 215-224.	2.2	19
886	Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination. <i>Cancer Gene Therapy</i> , 2006, 13, 318-325.	2.2	22
887	Why Can't the Immune System Control HIV-1? Defining HIV-1-Specific CD4 ⁺ T Cell Immunity in Order to Develop Strategies to Enhance Viral Immunity. <i>Immunologic Research</i> , 2006, 35, 89-102.	1.3	3
888	Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. <i>Advanced Drug Delivery Reviews</i> , 2006, 58, 916-930.	6.6	102
889	Human Dendritic Cell Interactions with Whole Recombinant Yeast: Implications for HIV-1 Vaccine Development. <i>Journal of Clinical Immunology</i> , 2006, 26, 251-264.	2.0	23
890	Chemotherapeutic agents enhance AAV2-mediated gene transfer into breast cancer cells promoting CD40 ligand-based immunotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 787-794.	1.2	9
891	CD40 ligation restores cytolytic T lymphocyte response and eliminates fibrosarcoma in the peritoneum of mice lacking CD4+ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1542-1552.	2.0	6
892	The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines. <i>Cancer Immunology, Immunotherapy</i> , 2006, 56, 70-80.	2.0	26
893	Successful tumor eradication was achieved by collaboration of augmented cytotoxic activity and anti-angiogenic effects following therapeutic vaccines containing helper-activating analog-loaded dendritic cells and tumor antigen DNA. <i>Cancer Immunology, Immunotherapy</i> , 2006, 56, 331-342.	2.0	13
894	Studies of HIV-associated immune responses in lymphoid compartments. <i>Current HIV/AIDS Reports</i> , 2006, 3, 32-38.	1.1	5
895	Dendritic cell activation and function in response to <i>Schistosoma mansoni</i> . <i>International Journal for Parasitology</i> , 2006, 36, 711-721.	1.3	49
896	Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer. <i>Seminars in Cancer Biology</i> , 2006, 16, 73-79.	4.3	58
897	In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire. <i>Journal of Immunological Methods</i> , 2006, 310, 40-52.	0.6	111

#	ARTICLE	IF	CITATIONS
898	CD4 T cell help is required for primary CD8 T cell responses to vesicular antigen delivered to dendritic cells in vivo. <i>European Journal of Immunology</i> , 2006, 36, 1386-1397.	1.6	23
899	IFN- γ -conditioned dendritic cells are highly efficient in inducing cross-priming CD8+ T cells against exogenous viral antigens. <i>European Journal of Immunology</i> , 2006, 36, 2046-2060.	1.6	132
900	Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. <i>International Journal of Cancer</i> , 2006, 119, 317-327.	2.3	276
901	Lymphoid and extralymphoid CD4 T cells that orchestrate the antiviral immune response. <i>Expert Review of Clinical Immunology</i> , 2006, 2, 267-276.	1.3	1
902	Immunotherapy of Cancer Based on DC-Tumor Fusion Vaccine. <i>Current Immunology Reviews</i> , 2006, 2, 291-304.	1.2	2
903	In vivo CD40 ligation can induce T cell-independent antitumor effects that involve macrophages. <i>Journal of Leukocyte Biology</i> , 2006, 79, 1181-1192.	1.5	69
904	Immunological Tolerance Using Synthetic Peptides - Basic Mechanisms and Clinical Application. <i>Current Molecular Medicine</i> , 2006, 6, 631-643.	0.6	18
905	Differential Antigenic Hierarchy Associated with Spontaneous Recovery from Hepatitis C Virus Infection: Implications for Vaccine Design. <i>Journal of Infectious Diseases</i> , 2006, 194, 454-463.	1.9	60
906	Alloantigen Affinity and CD4 Help Determine Severity of Graft-versus-Host Disease Mediated by CD8 Donor T Cells. <i>Journal of Immunology</i> , 2006, 176, 3383-3390.	0.4	31
907	Efficient Immunization and Cross-Priming by Vaccine Adjuvants Containing TLR3 or TLR9 Agonists Complexed to Cationic Liposomes. <i>Journal of Immunology</i> , 2006, 176, 7335-7345.	0.4	229
908	Macaque Multimeric Soluble CD40 Ligand and GITR Ligand Constructs Are Immunostimulatory Molecules In Vitro. <i>Vaccine Journal</i> , 2006, 13, 1223-1230.	3.2	22
909	Effector and Memory CD8+ T Cells Can Be Generated in Response to Alloantigen Independently of CD4+ T Cell Help. <i>Journal of Immunology</i> , 2006, 176, 2316-2323.	0.4	39
910	TRAIL Deficiency Delays, but Does Not Prevent, Erosion in the Quality of "Helpless" Memory CD8 T Cells. <i>Journal of Immunology</i> , 2006, 177, 999-1006.	0.4	56
911	CD4 T cells inhibit the CD8 T cell response during low-dose virus infection. <i>International Immunology</i> , 2006, 18, 1285-1293.	1.8	4
912	Multimeric Soluble CD40 Ligand and GITR Ligand as Adjuvants for Human Immunodeficiency Virus DNA Vaccines. <i>Journal of Virology</i> , 2006, 80, 1762-1772.	1.5	91
913	T Cell-Dependent Activation of Dendritic Cells Requires IL-12 and IFN- γ Signaling in T Cells. <i>Journal of Immunology</i> , 2006, 177, 3625-3634.	0.4	35
914	CIITA-Induced MHC Class II Expression in Mammary Adenocarcinoma Leads to a Th1 Polarization of the Tumor Microenvironment, Tumor Rejection, and Specific Antitumor Memory. <i>Clinical Cancer Research</i> , 2006, 12, 3435-3443.	3.2	79
915	Killing of Normal Melanocytes, Combined with Heat Shock Protein 70 and CD40L Expression, Cures Large Established Melanomas. <i>Journal of Immunology</i> , 2006, 177, 4168-4177.	0.4	39

#	ARTICLE	IF	CITATIONS
916	Roadmap to a Better Therapeutic Tumor Vaccine. <i>International Reviews of Immunology</i> , 2006, 25, 415-443.	1.5	56
917	Enhancement of CD8+ T Cell Immunity in the Lung by CpG Oligodeoxynucleotides Increases Protective Efficacy of a Modified Vaccinia Ankara Vaccine against Lethal Poxvirus Infection Even in a CD4-Deficient Host. <i>Journal of Immunology</i> , 2006, 177, 6336-6343.	0.4	42
918	Synergistic Activation of Macrophages via CD40 and TLR9 Results in T Cell Independent Antitumor Effects. <i>Journal of Immunology</i> , 2006, 176, 309-318.	0.4	79
919	Cell-Associated Double-Stranded RNA Enhances Antitumor Activity through the Production of Type I IFN. <i>Journal of Immunology</i> , 2006, 177, 6122-6128.	0.4	46
920	Immune Complex-Loaded Dendritic Cells Are Superior to Soluble Immune Complexes as Antitumor Vaccine. <i>Journal of Immunology</i> , 2006, 176, 4573-4580.	0.4	104
921	Direct Stimulation of T Cells by Type I IFN Enhances the CD8+ T Cell Response during Cross-Priming. <i>Journal of Immunology</i> , 2006, 176, 4682-4689.	0.4	248
922	Generation of T Cell Help through a MHC Class I-Restricted TCR. <i>Journal of Immunology</i> , 2006, 177, 976-982.	0.4	39
923	Melan-A/MART-1-Specific CD4 T Cells in Melanoma Patients: Identification of New Epitopes and Ex Vivo Visualization of Specific T Cells by MHC Class II Tetramers. <i>Journal of Immunology</i> , 2006, 177, 6769-6779.	0.4	48
924	Requirement for CD70 in CD4+ Th Cell-Dependent and Innate Receptor-Mediated CD8+ T Cell Priming. <i>Journal of Immunology</i> , 2006, 177, 2969-2975.	0.4	53
925	Recombinant Ig-Like Transcript 3-Fc Modulates T Cell Responses via Induction of Th Anergy and Differentiation of CD8+ T Suppressor Cells. <i>Journal of Immunology</i> , 2006, 176, 2790-2798.	0.4	81
926	Human Monocytes as Intermediaries between Allogeneic Endothelial Cells and Allospecific T Cells: A Role for Direct Scavenger Receptor-Mediated Endothelial Membrane Uptake in the Initiation of Alloimmunity. <i>Journal of Immunology</i> , 2006, 176, 750-761.	0.4	43
927	CD8+ Cytotoxic T-APC Stimulate Central Memory CD8+ T Cell Responses via Acquired Peptide-MHC Class I Complexes and CD80 Costimulation, and IL-2 Secretion. <i>Journal of Immunology</i> , 2006, 177, 2976-2984.	0.4	39
928	Cutting Edge: Cognate CD4 Help Promotes Recruitment of Antigen-Specific CD8 T Cells around Dendritic Cells. <i>Journal of Immunology</i> , 2006, 177, 1406-1410.	0.4	58
929	T Helper Lymphocytes Rescue CTL from Activation-Induced Cell Death. <i>Journal of Immunology</i> , 2006, 177, 2862-2872.	0.4	54
930	Differential Requirements of T Cell Subsets for CD40 Costimulation in Immunity to <i>Blastomyces dermatitidis</i> . <i>Journal of Immunology</i> , 2006, 176, 5538-5547.	0.4	15
931	Modulation of Dendritic Cell Function by Naive and Regulatory CD4+ T Cells. <i>Journal of Immunology</i> , 2006, 176, 6202-6210.	0.4	114
932	IL-2 Is Required for the Activation of Memory CD8+ T Cells via Antigen Cross-Presentation. <i>Journal of Immunology</i> , 2006, 176, 7288-7300.	0.4	54
933	CD4+ T Cells Can Protect APC from CTL-Mediated Elimination. <i>Journal of Immunology</i> , 2006, 176, 7379-7384.	0.4	35

#	ARTICLE	IF	CITATIONS
934	Recognition of Prostate and Melanoma Tumor Cells by Six-Transmembrane Epithelial Antigen of Prostate-Specific Helper T Lymphocytes in a Human Leukocyte Antigen Class II-Restricted Manner. <i>Cancer Research</i> , 2007, 67, 5498-5504.	0.4	30
935	Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12837-12842.	3.3	239
936	Defective Alloreactive CD8 T Cell Function and Memory Response in Allograft Recipients in the Absence of CD4 Help. <i>Journal of Immunology</i> , 2007, 179, 4529-4534.	0.4	25
937	Combined TLR/CD40 Stimulation Mediates Potent Cellular Immunity by Regulating Dendritic Cell Expression of CD70 In Vivo. <i>Journal of Immunology</i> , 2007, 178, 1564-1572.	0.4	141
938	A New Class of Reverse Signaling Costimulators Belongs to the TNF Family. <i>Journal of Immunology</i> , 2007, 179, 4307-4312.	0.4	130
939	Disparate Primary and Secondary Allospecific CD8+ T Cell Cytolytic Effector Function in the Presence or Absence of Host CD4+ T Cells. <i>Journal of Immunology</i> , 2007, 179, 80-88.	0.4	20
940	Human Dendritic Cells Acquire a Semimature Phenotype and Lymph Node Homing Potential through Interaction with CD4+CD25+ Regulatory T Cells. <i>Journal of Immunology</i> , 2007, 178, 4184-4193.	0.4	79
941	A Novel Mechanism for TNFR-Associated Factor 6-Dependent CD40 Signaling. <i>Journal of Immunology</i> , 2007, 179, 4645-4653.	0.4	68
942	CD40-CD40 Ligand Interaction between Dendritic Cells and CD8+ T Cells Is Needed to Stimulate Maximal T Cell Responses in the Absence of CD4+ T Cell Help. <i>Journal of Immunology</i> , 2007, 178, 2844-2852.	0.4	88
943	The CD4+ T-cell response to adenovirus is focused against conserved residues within the hexon protein. <i>Journal of General Virology</i> , 2007, 88, 2417-2425.	1.3	31
944	Delivery of Antigen to CD40 Induces Protective Immune Responses against Tumors. <i>Journal of Immunology</i> , 2007, 178, 4169-4176.	0.4	66
945	Dominance and Diversity in the Primary Human CD4 T Cell Response to Replication-Competent Vaccinia Virus. <i>Journal of Immunology</i> , 2007, 178, 6374-6386.	0.4	38
946	Tumors Hamper the Immunogenic Competence of CD4+T Cell-Directed Dendritic Cell Vaccination. <i>Journal of Immunology</i> , 2007, 179, 2899-2909.	0.4	11
947	Chemokine-Guided CD4+T Cell Help Enhances Generation of IL-6R ^{hi} IL-7R ^{hi} Prememory CD8+T Cells. <i>Journal of Immunology</i> , 2007, 178, 778-787.	0.4	90
948	Anthocyanin Prevents CD40-Activated Proinflammatory Signaling in Endothelial Cells by Regulating Cholesterol Distribution. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 519-524.	1.1	92
949	CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cells. <i>British Journal of Cancer</i> , 2007, 96, 1839-1848.	2.9	116
950	The Surprising Kinetics of the T Cell Response to Live Antigenic Cells. <i>Journal of Immunology</i> , 2007, 179, 4988-4995.	0.4	12
951	Helper Function of Memory CD8+ T Cells: Heterologous CD8+ T Cells Support the Induction of Therapeutic Cancer Immunity. <i>Cancer Research</i> , 2007, 67, 10012-10018.	0.4	27

#	ARTICLE	IF	CITATIONS
952	T Cell Memory Generation in the Face of Persistent Antigen Presentation. <i>Current Immunology Reviews</i> , 2007, 3, 240-250.	1.2	1
953	Human Immunodeficiency Virus Type 1 Controllers but Not Noncontrollers Maintain CD4 T Cells Coexpressing Three Cytokines. <i>Journal of Virology</i> , 2007, 81, 12071-12076.	1.5	135
954	The Expansion and Maintenance of Antigen-Selected CD8+ T Cell Clones. <i>Advances in Immunology</i> , 2007, 96, 103-139.	1.1	29
955	Potent CTL Induction by a Whole Cell Pertussis Vaccine in Anti-Tumor Peptide Immunotherapy. <i>Microbiology and Immunology</i> , 2007, 51, 685-699.	0.7	12
956	CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 1774-1779.	0.6	21
957	Th1 and Th2 Cells Help CD8 T-Cell Responses. <i>Infection and Immunity</i> , 2007, 75, 2291-2296.	1.0	49
958	Therapeutic Vaccination against Murine Lymphoma by Intratumoral Injection of Recombinant Fowlpox Virus Encoding CD40 Ligand. <i>Cancer Research</i> , 2007, 67, 7037-7044.	0.4	15
959	CD4 T Cells Are Required for CD8 T Cell Survival during Both Primary and Memory Recall Responses. <i>Journal of Immunology</i> , 2007, 179, 8243-8251.	0.4	115
960	Increasing the Survival of Dendritic Cells In Vivo Does Not Replace the Requirement for CD4+ T Cell Help during Primary CD8+ T Cell Responses. <i>Journal of Immunology</i> , 2007, 179, 5738-5747.	0.4	12
961	Limited Role for CD4 + T-Cell Help in the Initial Priming of Trypanosoma cruzi- Specific CD8 + T Cells. <i>Infection and Immunity</i> , 2007, 75, 231-235.	1.0	39
962	Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody. <i>Journal of Clinical Oncology</i> , 2007, 25, 876-883.	0.8	458
963	Agonistic Anti-CD40 Antibody Profoundly Suppresses the Immune Response to Infection with Lymphocytic Choriomeningitis Virus. <i>Journal of Immunology</i> , 2007, 178, 1662-1670.	0.4	36
964	Systemic Administration of IL-23 Induces Potent Antitumor Immunity Primarily Mediated through Th1-Type Response in Association with the Endogenously Expressed IL-12. <i>Journal of Immunology</i> , 2007, 178, 7571-7580.	0.4	85
965	Cognate CD4+ Help Elicited by Resting Dendritic Cells Does Not Impair the Induction of Peripheral Tolerance in CD8+ T Cells. <i>Journal of Immunology</i> , 2007, 178, 2094-2103.	0.4	38
966	Prospect of Targeting the CD40 Pathway for Cancer Therapy. <i>Clinical Cancer Research</i> , 2007, 13, 1083-1088.	3.2	156
967	Anti-CD40 Conditioning Enhances the TCD8 Response to a Highly Tolerogenic Epitope and Subsequent Immunotherapy of Simian Virus 40 T Antigen-Induced Pancreatic Tumors. <i>Journal of Immunology</i> , 2007, 179, 6686-6695.	0.4	13
968	CD8+T Cells Circumvent Immune Privilege in the Eye and Mediate Intraocular Tumor Rejection by a TNF- α -Dependent Mechanism. <i>Journal of Immunology</i> , 2007, 178, 6115-6122.	0.4	17
969	CD40-CD40 Ligand Interactions Promote Trafficking of CD8 ⁺ T Cells into the Brain and Protection against West Nile Virus Encephalitis. <i>Journal of Virology</i> , 2007, 81, 9801-9811.	1.5	80

#	ARTICLE	IF	CITATIONS
970	MHC Class II α -Transduced Tumor Cells Originating in the Immune-Privileged Eye Prime and Boost CD4+ T Lymphocytes that Cross-react with Primary and Metastatic Uveal Melanoma Cells. <i>Cancer Research</i> , 2007, 67, 4499-4506.	0.4	34
971	TLR3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help. <i>Blood</i> , 2007, 109, 5318-5326.	0.6	57
972	Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. <i>Blood</i> , 2007, 109, 4810-4815.	0.6	103
973	Neutrophils efficiently cross-prime naive T cells in vivo. <i>Blood</i> , 2007, 110, 2965-2973.	0.6	254
974	CD4+ T Helper Cell Response is Required for Memory in CD8+ T Lymphocytes Induced by a Poly(I:C)-adjuvanted MHC I-restricted Peptide Epitope. <i>Journal of Immunotherapy</i> , 2007, 30, 180-189.	1.2	19
975	Anti-CD40 agonist antibodies: Preclinical and clinical experience. <i>Update on Cancer Therapeutics</i> , 2007, 2, 61-65.	0.9	61
976	Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. <i>Vaccine</i> , 2007, 25, 1379-1389.	1.7	46
977	Dendritic cells for active immunotherapy: Optimizing design and manufacture in order to develop commercially and clinically viable products. <i>Vaccine</i> , 2007, 25, B47-B60.	1.7	47
978	Molecular basis for checkpoints in the CD8 T cell response: Tolerance versus activation. <i>Seminars in Immunology</i> , 2007, 19, 153-161.	2.7	38
979	Lipid rafts regulate cellular CD40 receptor localization in vascular endothelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2007, 361, 768-774.	1.0	8
980	Immunology and immunotherapy approaches for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2007, 10, 224-236.	2.0	11
981	Immunologic Approaches to Composite Tissue Allograft. <i>Journal of Hand Surgery</i> , 2007, 32, 1072-1085.	0.7	12
982	Duration, combination and timing: the signal integration model of dendritic cell activation. <i>Trends in Immunology</i> , 2007, 28, 227-233.	2.9	167
983	Engineered promiscuous T helper peptides for the induction of immune responses. <i>Molecular Immunology</i> , 2007, 44, 2205-2212.	1.0	2
984	General Principles of Tumor Immunotherapy. , 2007, , .		3
986	Combination of Protein and Viral Vaccines Induces Potent Cellular and Humoral Immune Responses and Enhanced Protection from Murine Malaria Challenge. <i>Infection and Immunity</i> , 2007, 75, 5819-5826.	1.0	43
987	Epstein-Barr Virus: Environmental Trigger of Multiple Sclerosis?. <i>Journal of Virology</i> , 2007, 81, 6777-6784.	1.5	97
988	Advances in dendritic cell-based therapeutic vaccines for cervical cancer. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1473-1486.	1.1	32

#	ARTICLE	IF	CITATIONS
989	Effector and Memory CTL Differentiation. Annual Review of Immunology, 2007, 25, 171-192.	9.5	776
991	CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund's Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity. Journal of Immunology, 2007, 179, 5033-5040.	0.4	221
992	Design and development of synthetic peptide vaccines: past, present and future. Expert Review of Vaccines, 2007, 6, 591-603.	2.0	130
993	Some Biological Features of Dendritic Cells in the Mouse. , 2007, , 135-154.		2
994	Therapy-induced antitumor vaccination by targeting tumor necrosis factor- α to tumor vessels in combination with melphalan. European Journal of Immunology, 2007, 37, 3381-3392.	1.6	41
995	Silencing invariant chain of DCs enhances Th1 response using small interfering RNA. Cell Biology International, 2007, 31, 663-671.	1.4	2
996	The relative importance of CD4+ and CD8+T cells in immunity to pulmonary paracoccidoidomycosis. Microbes and Infection, 2007, 9, 1078-1088.	1.0	44
997	Dynamic imaging of chemokine-dependent CD8+ T cell help for CD8+ T cell responses. Nature Immunology, 2007, 8, 921-930.	7.0	128
998	Immunosuppressive Activity of 4-O-Methylascochlorin. Journal of Antibiotics, 2007, 60, 20-26.	1.0	9
999	CD4+Th1 cells promote CD8+Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes. Immunology, 2007, 120, 148-159.	2.0	77
1000	Involvement of IL-10 in exhaustion of myeloid dendritic cells and rescue by CD40 stimulation. Immunology, 2007, 120, 28-37.	2.0	29
1001	Generation of Autoreactive CTL by Tumour Vaccines Containing Foreign T Helper Epitopes. Scandinavian Journal of Immunology, 2007, 65, 240-248.	1.3	8
1002	Identification of a novel NY-ESO-1 promiscuous helper epitope presented by multiple MHC class II molecules found frequently in the Japanese population. Cancer Science, 2007, 98, 1092-1098.	1.7	11
1003	Central role of ILT3 in the T suppressor cell cascade. Cellular Immunology, 2007, 248, 59-67.	1.4	53
1004	Adeno-associated virus mediated gene transfer into lung cancer cells promoting CD40 ligand-based immunotherapy. Virology, 2007, 368, 309-316.	1.1	18
1005	Allopeptide-Specific CD4+T Cells Facilitate the Differentiation of Directly Alloreactive Graft-Infiltrating CD8+T Cells. American Journal of Transplantation, 2007, 7, 2269-2278.	2.6	6
1006	Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors. Seminars in Cancer Biology, 2007, 17, 299-308.	4.3	44
1007	Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer. Cytotherapy, 2007, 9, 755-770.	0.3	67

#	ARTICLE	IF	CITATIONS
1008	Patterns of constitutive and IFN- γ inducible expression of HLA class II molecules in human melanoma cell lines. <i>Immunogenetics</i> , 2007, 59, 123-133.	1.2	29
1009	li-Key/HER-2/neu(776-90) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 601-613.	2.0	43
1010	A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1565-1575.	2.0	10
1011	Epstein-Barr virus and multiple sclerosis. <i>Current Neurology and Neuroscience Reports</i> , 2007, 7, 253-258.	2.0	31
1012	CD8 T cell memory development: CD4 T cell help is appreciated. <i>Immunologic Research</i> , 2007, 39, 94-104.	1.3	59
1013	Roles of TRAF6 in CD40 signaling. <i>Immunologic Research</i> , 2007, 39, 105-114.	1.3	38
1014	The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 389-398.	2.0	37
1015	CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1151-1160.	2.0	35
1016	TLR-mediated induction of negative regulatory ligands on dendritic cells. <i>Journal of Molecular Medicine</i> , 2008, 86, 443-455.	1.7	30
1017	CD4 ⁺ T cell help improves CD8 ⁺ T cell memory by retained CD27 expression. <i>European Journal of Immunology</i> , 2008, 38, 1847-1856.	1.6	34
1018	Generating functional CD8 ⁺ T cell memory response under transient CD4 ⁺ T cell deficiency: Implications for vaccination of immunocompromised individuals. <i>European Journal of Immunology</i> , 2008, 38, 1857-1866.	1.6	12
1019	Circumvention of regulatory CD4 ⁺ T cell activity during cross-priming strongly enhances T cell-mediated immunity. <i>European Journal of Immunology</i> , 2008, 38, 1585-1597.	1.6	24
1020	Editorial overview. <i>Current Opinion in Immunology</i> , 2008, 20, 208-210.	2.4	5
1021	Immunotherapy with dendritic cells for cancer. <i>Advanced Drug Delivery Reviews</i> , 2008, 60, 173-183.	6.6	54
1022	Twelve immunotherapy drugs that could cure cancers. <i>Immunological Reviews</i> , 2008, 222, 357-368.	2.8	297
1023	Multiple roles for CD4 ⁺ T cells in anti-tumor immune responses. <i>Immunological Reviews</i> , 2008, 222, 129-144.	2.8	449
1024	Reengineering dendritic cell-based anti-cancer vaccines. <i>Immunological Reviews</i> , 2008, 222, 256-276.	2.8	55
1025	Fine-Tuned Expression of Programmed Death 1 Ligands in Mature Dendritic Cells Stimulated by CD40 Ligand Is Critical for the Induction of an Efficient Tumor Specific Immune Response. <i>Cellular and Molecular Immunology</i> , 2008, 5, 33-39.	4.8	9

#	ARTICLE	IF	CITATIONS
1026	Dendritic cells: driving the differentiation programme of T cells in viral infections. <i>Immunology and Cell Biology</i> , 2008, 86, 333-342.	1.0	39
1027	Determination of T cell fate by dendritic cells. <i>Immunology and Cell Biology</i> , 2008, 86, 389-397.	1.0	82
1028	Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. <i>Nature Reviews Cancer</i> , 2008, 8, 351-360.	12.8	508
1029	Shaping and reshaping CD8+ T-cell memory. <i>Nature Reviews Immunology</i> , 2008, 8, 107-119.	10.6	493
1030	Significant alterations of biodistribution and immune responses in Balb/c mice administered with adenovirus targeted to CD40(+) cells. <i>Gene Therapy</i> , 2008, 15, 298-308.	2.3	29
1031	A WT1 protein-derived, naturally processed 16-mer peptide, WT1 ₃₃₂ , is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4 ⁺ T cells. <i>Microbiology and Immunology</i> , 2008, 52, 591-600.	0.7	20
1032	Adenovirus-mediated CD40L gene therapy induced both humoral and cellular immunity against rat model of hepatocellular carcinoma. <i>Cancer Science</i> , 2008, 99, 2097-2103.	1.7	10
1033	Strategic use of an adenoviral vector for rapid and efficient ex vivo-generation of cytomegalovirus pp65-reactive cytolytic and helper T cells. <i>British Journal of Haematology</i> , 2008, 141, 188-199.	1.2	3
1034	RNA-electroporated CD40-activated B cells induce functional T-cell responses against HepG2 cells. <i>European Journal of Cancer Care</i> , 2008, 17, 404-411.	0.7	11
1035	CD4+T-cell-dependent tumour rejection in an immune-privileged environment requires macrophages. <i>Immunology</i> , 2008, 123, 367-377.	2.0	27
1036	Breaking B cell Tolerance and CTL Tolerance in three OVA-transgenic Mouse Strains Expressing Different Levels of OVA. <i>Scandinavian Journal of Immunology</i> , 2008, 67, 113-120.	1.3	10
1037	Liposome-Encapsulated Antigens Induce a Protective CTL Response against <i>Listeria monocytogenes</i> Independent of CD4+T Cell Help. <i>Scandinavian Journal of Immunology</i> , 2008, 67, 594-602.	1.3	2
1038	Redox modulation inhibits CD8 T cell effector function. <i>Free Radical Biology and Medicine</i> , 2008, 45, 1477-1486.	1.3	59
1039	CD4+ T helper responses in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2008, 44, 870-877.	0.8	15
1040	Chapter 4 CD8+ T Cells in Type 1 Diabetes. <i>Advances in Immunology</i> , 2008, 100, 79-124.	1.1	105
1041	Chapter 2 New Insights into the Roles of Dendritic Cells in Intestinal Immunity and Tolerance. <i>International Review of Cell and Molecular Biology</i> , 2008, 272, 33-105.	1.6	19
1042	CD8+ T suppressor cells and the ILT3 master switch. <i>Human Immunology</i> , 2008, 69, 681-686.	1.2	46
1043	Constitutive Crosspresentation of Tissue Antigens by Dendritic Cells Controls CD8+ T Cell Tolerance In Vivo. <i>Immunity</i> , 2008, 28, 521-532.	6.6	113

#	ARTICLE	IF	CITATIONS
1044	Cancer Immunotherapy by Dendritic Cells. <i>Immunity</i> , 2008, 29, 372-383.	6.6	474
1045	Differential promotion of hematopoietic chimerism and inhibition of alloreactive T cell proliferation by combinations of anti-CD40Ligand, anti-LFA-1, everolimus, and deoxyspergualin. <i>Transplant Immunology</i> , 2008, 20, 106-112.	0.6	5
1046	Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40. <i>Vaccine</i> , 2008, 26, 697-705.	1.7	8
1047	Recombinant fowlpox virus elicits transient cytotoxic T cell responses due to suboptimal innate recognition and recruitment of T cell help. <i>Vaccine</i> , 2008, 26, 3566-3573.	1.7	8
1048	CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals. <i>Vaccine</i> , 2008, 26, 4062-4072.	1.7	48
1049	A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response. <i>Vaccine</i> , 2008, 26, 4006-4014.	1.7	17
1050	Spontaneous Recovery in Acute Human Hepatitis C Virus Infection: Functional T-Cell Thresholds and Relative Importance of CD4 Help. <i>Journal of Virology</i> , 2008, 82, 1827-1837.	1.5	77
1051	The Allogeneic Effect Revisited: Exogenous Help for Endogenous, Tumor-Specific T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 499-509.	2.0	36
1052	T cell precursor frequency differentially affects CTL responses under different immune conditions. <i>Biochemical and Biophysical Research Communications</i> , 2008, 367, 427-434.	1.0	6
1053	Type I interferon as a stimulus for cross-priming. <i>Cytokine and Growth Factor Reviews</i> , 2008, 19, 33-40.	3.2	108
1054	The nature of the lymphopenic environment dictates protective function of homeostatic-memory CD8 ⁺ T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 18484-18489.	3.3	34
1055	CD40L+ CD4+ memory T cells migrate in a CD62P-dependent fashion into reactive lymph nodes and license dendritic cells for T cell priming. <i>Journal of Experimental Medicine</i> , 2008, 205, 2561-2574.	4.2	64
1056	CD40 Engagement on Dendritic Cells, but Not on B or T Cells, Is Required for Long-Term Control of Murine Gammaherpesvirus 68. <i>Journal of Virology</i> , 2008, 82, 11016-11022.	1.5	5
1057	Suppression of Mature Dendritic Cell Function by Regulatory T Cells In Vivo Is Abrogated by CD40 Licensing. <i>Journal of Immunology</i> , 2008, 180, 1405-1413.	0.4	48
1058	CTL-Promoting Effects of CD40 Stimulation Outweigh B Cell-Stimulatory Effects Resulting in B Cell Elimination and Disease Improvement in a Murine Model of Lupus. <i>Journal of Immunology</i> , 2008, 181, 47-61.	0.4	32
1059	CD27 Instructs CD4+ T Cells to Provide Help for the Memory CD8+ T Cell Response after Protein Immunization. <i>Journal of Immunology</i> , 2008, 181, 1071-1082.	0.4	73
1060	Serpins in T cell immunity. <i>Journal of Leukocyte Biology</i> , 2008, 84, 1238-1247.	1.5	27
1061	Cancer Immunotherapy Using <i>In vitro</i> Genetically Modified Targeted Dendritic Cells. <i>Cancer Research</i> , 2008, 68, 3854-3862.	0.4	21

#	ARTICLE	IF	CITATIONS
1062	Maturation of dendritic cells for enhanced activation of anti-HIV-1 CD8+ T cell immunity. <i>Journal of Leukocyte Biology</i> , 2008, 83, 1530-1540.	1.5	26
1063	Progress in dendritic cell immunotherapy: Elucidating the enigma of Th-1 polarization. <i>Hum Vaccin</i> , 2008, 4, 162-164.	2.4	5
1064	Breaking of CD8+ T Cell Tolerance through In Vivo Ligation of CD40 Results in Inhibition of Chronic Graft-versus-Host Disease and Complete Donor Cell Engraftment. <i>Journal of Immunology</i> , 2008, 181, 7380-7389.	0.4	15
1065	Identification of an N-Linked Glycosylation in the C4 Region of HIV-1 Envelope gp120 That Is Critical for Recognition of Neighboring CD4 T Cell Epitopes. <i>Journal of Immunology</i> , 2008, 180, 4011-4021.	0.4	37
1066	Phenotype Switching by Inflammation-Inducing Polarized Th17 Cells, but Not by Th1 Cells. <i>Journal of Immunology</i> , 2008, 181, 7205-7213.	0.4	141
1067	CD40 on APCs Is Needed for Optimal Programming, Maintenance, and Recall of CD8+ T Cell Memory Even in the Absence of CD4+ T Cell Help. <i>Journal of Immunology</i> , 2008, 180, 4382-4390.	0.4	30
1068	Memory CD8+ T Cells Protect Dendritic Cells from CTL Killing. <i>Journal of Immunology</i> , 2008, 180, 3857-3865.	0.4	36
1069	Antigen Persistence Is Required for Dendritic Cell Licensing and CD8+ T Cell Cross-Priming. <i>Journal of Immunology</i> , 2008, 181, 3067-3076.	0.4	44
1070	Kinetic and Mechanistic Requirements for Helping CD8 T Cells. <i>Journal of Immunology</i> , 2008, 180, 1517-1525.	0.4	24
1071	Late Signals from CD27 Prevent Fas-Dependent Apoptosis of Primary CD8+ T Cells. <i>Journal of Immunology</i> , 2008, 180, 2912-2921.	0.4	74
1072	CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 2999-3004.	3.3	121
1073	IL-15 as a mediator of CD4 ⁺ help for CD8 ⁺ T cell longevity and avoidance of TRAIL-mediated apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 5201-5206.	3.3	128
1074	Cutting Edge: CD4+ T Cell-Derived IL-2 Is Essential for Help-Dependent Primary CD8+ T Cell Responses. <i>Journal of Immunology</i> , 2008, 181, 7445-7448.	0.4	80
1075	Active CD4 ⁺ helper T cells directly stimulate CD8 ⁺ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet β -cell ovalbumin antigen leading to diabetes. <i>Autoimmunity</i> , 2008, 41, 501-511.	1.2	9
1076	Combined Triggering of Dendritic Cell Receptors Results in Synergistic Activation and Potent Cytotoxic Immunity. <i>Journal of Immunology</i> , 2008, 181, 3422-3431.	0.4	51
1077	Dissociation of Its Opposing Immunologic Effects Is Critical for the Optimization of Antitumor CD8+ T-Cell Responses Induced by Interleukin 21. <i>Clinical Cancer Research</i> , 2008, 14, 6125-6136.	3.2	18
1078	CD20, CD3, and CD40 Ligand Microclusters Segregate Three-Dimensionally In Vivo at B-Cell-T-Cell Immunological Synapses after Viral Immunity in Primate Brain. <i>Journal of Virology</i> , 2008, 82, 9978-9993.	1.5	17
1079	An Extremely Diverse CD4 Response to Vaccinia Virus in Humans Is Revealed by Proteome-Wide T-Cell Profiling. <i>Journal of Virology</i> , 2008, 82, 7120-7134.	1.5	55

#	ARTICLE	IF	CITATIONS
1080	<i>In vivo</i> Expansion, Persistence, and Function of Peptide Vaccine-Induced CD8 T Cells Occur Independently of CD4 T Cells. <i>Cancer Research</i> , 2008, 68, 9892-9899.	0.4	47
1081	Tumor-Specific CD4 ⁺ T Cells Render the Tumor Environment Permissive for Infiltration by Low-Avidity CD8 ⁺ T Cells. <i>Journal of Immunology</i> , 2008, 180, 3122-3131.	0.4	124
1082	Memory-like CD8 ⁺ and CD4 ⁺ T cells cooperate to break peripheral tolerance under lymphopenic conditions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 19414-19419.	3.3	68
1083	Dendritic cell subtypes as primary targets of vaccines: the emerging role and cross-talk of pattern recognition receptors. <i>Biological Chemistry</i> , 2008, 389, 469-85.	1.2	58
1084	Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN- γ production. <i>Blood</i> , 2008, 111, 4245-4253.	0.6	230
1085	Platelet-derived CD154 enables T-cell priming and protection against <i>Listeria monocytogenes</i> challenge. <i>Blood</i> , 2008, 111, 3684-3691.	0.6	83
1086	Cognate CD4 ⁺ T-cell-dendritic cell interactions induce migration of immature dendritic cells through dissolution of their podosomes. <i>Blood</i> , 2008, 111, 3579-3590.	0.6	23
1087	A functional TNFRSF5 gene variant is associated with risk of lymphoma. <i>Blood</i> , 2008, 111, 4348-4354.	0.6	42
1088	Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway. <i>Blood</i> , 2008, 112, 2149-2155.	0.6	63
1089	Targeting T-cell memory: where do we stand?. <i>Current Opinion in Organ Transplantation</i> , 2008, 13, 344-349.	0.8	19
1090	Deficient TH-1 Responses From TNF- α -matured and β -CD40-matured Dendritic Cells. <i>Journal of Immunotherapy</i> , 2008, 31, 157-165.	1.2	13
1091	Application of a Systems Biology Approach to Skin Allergy Risk Assessment. <i>ATLA Alternatives To Laboratory Animals</i> , 2008, 36, 521-556.	0.7	30
1092	CD40-Independent Engagement of Mammalian hsp70 by Antigen-Presenting Cells. <i>Journal of Immunology</i> , 2009, 182, 6844-6850.	0.4	16
1093	Recall Responses by Helpless Memory CD8 ⁺ T Cells Are Restricted by the Up-Regulation of PD-1. <i>Journal of Immunology</i> , 2009, 182, 4244-4254.	0.4	62
1094	CD8 ⁺ T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability. <i>FASEB Journal</i> , 2009, 23, 3659-3673.	0.2	85
1095	CD154-CD40 Interactions Are Essential for Thymus-Dependent Antibody Production in Zebrafish: Insights into the Origin of Costimulatory Pathway in Helper T Cell-Regulated Adaptive Immunity in Early Vertebrates. <i>Journal of Immunology</i> , 2009, 182, 7749-7762.	0.4	89
1096	Immunity to Murine Prostatic Tumors: Continuous Provision of T-Cell Help Prevents CD8 T-Cell Tolerance and Activates Tumor-Infiltrating Dendritic Cells. <i>Cancer Research</i> , 2009, 69, 6256-6264.	0.4	54
1097	CD4 ⁺ T Cells Are Required for the Priming of CD8 ⁺ T Cells following Infection with Herpes Simplex Virus Type 1. <i>Journal of Virology</i> , 2009, 83, 5256-5268.	1.5	42

#	ARTICLE	IF	CITATIONS
1098	Chronic CD70-Driven Costimulation Impairs IgG Responses by Instructing T Cells to Inhibit Germinal Center B Cell Formation through FasL-Fas Interactions. <i>Journal of Immunology</i> , 2009, 183, 6442-6451.	0.4	21
1099	CD4+ T Cell Help Has an Epitope-Dependent Impact on CD8+ T Cell Memory Inflation during Murine Cytomegalovirus Infection. <i>Journal of Immunology</i> , 2009, 183, 3932-3941.	0.4	69
1100	Influenza Virus and Poly(I:C) Inhibit MHC Class I-Restricted Presentation of Cell-Associated Antigens Derived from Infected Dead Cells Captured by Human Dendritic Cells. <i>Journal of Immunology</i> , 2009, 182, 2766-2776.	0.4	20
1101	Kinetics of Major Histocompatibility Class I Antigen Presentation in Acute Infection. <i>Journal of Immunology</i> , 2009, 182, 902-911.	0.4	5
1102	MHC Class I TCR Engineered Anti-Tumor CD4 T Cells: Implications For Cancer Immunotherapy. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2009, 9, 344-352.	0.6	11
1103	Adeno-Associated Virus Capsid Structure Drives CD4-Dependent CD8+ T Cell Response to Vector Encoded Proteins. <i>Journal of Immunology</i> , 2009, 182, 6051-6060.	0.4	79
1104	Anti-CD40 Monoclonal Antibody Synergizes with CTLA4-Ig in Promoting Long-Term Graft Survival in Murine Models of Transplantation. <i>Journal of Immunology</i> , 2009, 183, 1625-1635.	0.4	73
1105	Expression of Diabetes-Associated Genes by Dendritic Cells and CD4 T Cells Drives the Loss of Tolerance in Nonobese Diabetic Mice. <i>Journal of Immunology</i> , 2009, 183, 1533-1541.	0.4	33
1106	CD4+ Th-APC with Acquired Peptide/MHC Class I and II Complexes Stimulate Type 1 Helper CD4+ and Central Memory CD8+ T Cell Responses. <i>Journal of Immunology</i> , 2009, 182, 193-206.	0.4	53
1107	CD40L gene transfer in immunotherapy of cancer: more than co-stimulation?. <i>Cancer Biology and Therapy</i> , 2009, 8, 143-145.	1.5	0
1109	Programming for CD8 T Cell Memory Development Requires IL-12 or Type I IFN. <i>Journal of Immunology</i> , 2009, 182, 2786-2794.	0.4	185
1110	Role of CD8+T-cell immunity in influenza infection: potential use in future vaccine development. <i>Expert Review of Respiratory Medicine</i> , 2009, 3, 523-537.	1.0	3
1111	Tissue destruction caused by cytotoxic T lymphocytes induces deletional tolerance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 3901-3906.	3.3	19
1112	Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions. <i>International Immunology</i> , 2009, 21, 655-665.	1.8	28
1113	Implication of CD154/CD40 Interaction in Healthy and Autoimmune Responses. <i>Current Immunology Reviews</i> , 2009, 5, 285-299.	1.2	12
1114	Combination approaches to immunotherapy: the radiotherapy example. <i>Immunotherapy</i> , 2009, 1, 1025-1037.	1.0	29
1115	Protective CD8 T Cell Memory Is Impaired during Chronic CD70-Driven Costimulation. <i>Journal of Immunology</i> , 2009, 182, 5352-5362.	0.4	42
1116	Toll-like receptor 7-induced immune response to cutaneous West Nile virus infection. <i>Journal of General Virology</i> , 2009, 90, 2660-2668.	1.3	78

#	ARTICLE	IF	CITATIONS
1117	Role of dopamine in the physiology of T-cells and dendritic cells. <i>Journal of Neuroimmunology</i> , 2009, 216, 8-19.	1.1	110
1118	ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans. <i>Journal of Immunological Methods</i> , 2009, 347, 36-45.	0.6	27
1119	CD40 ligation restores type 1 polarizing capacity in TLR4-activated dendritic cells that have ceased interleukin-12 expression. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 1741-1750.	1.6	13
1120	IL-2 and antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity in antigen specific CD4+ T cells. <i>Cellular Immunology</i> , 2009, 257, 69-79.	1.4	99
1121	Coadministration of chicken GM-CSF with a DNA vaccine expressing infectious bronchitis virus (IBV) S1 glycoprotein enhances the specific immune response and protects against IBV infection. <i>Archives of Virology</i> , 2009, 154, 1117-1124.	0.9	27
1122	Deficiencies in the CD40 and CD154 receptor-ligand system reduce experimental lung metastasis. <i>Clinical and Experimental Metastasis</i> , 2009, 26, 829-837.	1.7	11
1123	Unravelling the mechanisms of help for CD8+ T cell responses. <i>Immunologic Research</i> , 2009, 45, 209-217.	1.3	19
1124	Platelet influence on T- and B-cell responses. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2009, 57, 235-241.	1.0	45
1125	A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 301-308.	2.0	18
1126	Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 887-900.	2.0	46
1127	Soluble HLA/peptide monomers cross-linked with co-stimulatory antibodies onto a streptavidin core molecule efficiently stimulate antigen-specific T cell responses. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1459-1470.	2.0	5
1128	CD8+ T lymphocyte mobilization to virus-infected tissue requires CD4+ T-cell help. <i>Nature</i> , 2009, 462, 510-513.	13.7	495
1129	Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells. <i>British Journal of Cancer</i> , 2009, 100, 1135-1143.	2.9	19
1130	Translating costimulation blockade to the clinic: lessons learned from three pathways. <i>Immunological Reviews</i> , 2009, 229, 294-306.	2.8	119
1131	Virus-specific CD8 T cells: activation, differentiation and memory formation. <i>Apmis</i> , 2009, 117, 356-381.	0.9	58
1132	Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity. <i>Experimental Dermatology</i> , 2009, 18, 78-87.	1.4	19
1133	The hydroxyflavone, fisetin, suppresses mast cell activation induced by interaction with activated T cell membranes. <i>British Journal of Pharmacology</i> , 2009, 158, 907-919.	2.7	16
1134	Selected Toll-like Receptor Ligands and Viruses Promote Helper-Independent Cytotoxic T Cell Priming by Upregulating CD40L on Dendritic Cells. <i>Immunity</i> , 2009, 30, 218-227.	6.6	84

#	ARTICLE	IF	CITATIONS
1135	Turnabout Is Fair Play: T Cell Stimulation by Dendritic Cell-Expressed CD40L. <i>Immunity</i> , 2009, 30, 171-173.	6.6	3
1136	Antiviral Responses: Different Roles for Different Tolls. <i>Immunity</i> , 2009, 30, 173-175.	6.6	6
1137	Peripheral tolerance in CD8+ T cells. <i>Cytokine</i> , 2009, 46, 147-159.	1.4	27
1138	Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. <i>Cytokine and Growth Factor Reviews</i> , 2009, 20, 271-281.	3.2	59
1139	The role of CD4 T cell help for CD8 CTL activation. <i>Biochemical and Biophysical Research Communications</i> , 2009, 384, 405-408.	1.0	88
1140	Functional roles for T cell CD40 in infection and autoimmune disease: The role of CD40 in lymphocyte homeostasis. <i>Seminars in Immunology</i> , 2009, 21, 283-288.	2.7	61
1141	CD40 and the immune response to parasitic infections. <i>Seminars in Immunology</i> , 2009, 21, 273-282.	2.7	29
1142	Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: Prolonged survival. <i>Vaccine</i> , 2009, 27, 1825-1833.	1.7	17
1143	Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens. <i>Vaccine</i> , 2009, 27, 3165-3174.	1.7	39
1144	Gene gun administration of therapeutic HPV DNA vaccination restores the efficacy of prolonged defrosted viral based vaccine. <i>Vaccine</i> , 2009, 27, 7352-7358.	1.7	9
1145	Immunoglobulin-like transcript 3: A crucial regulator of dendritic cell function. <i>Human Immunology</i> , 2009, 70, 340-344.	1.2	41
1146	Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. <i>Molecular Immunology</i> , 2009, 46, 1654-1662.	1.0	47
1147	Cancer immunotherapy. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2009, 46, 167-189.	2.7	95
1148	Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. <i>Journal of Translational Medicine</i> , 2009, 7, 93.	1.8	60
1150	Recent advances in multivalent self adjuvanting glycolipopeptide vaccine strategies against breast cancer. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2009, 57, 409-423.	1.0	13
1151	Dissociated Induction of Cytotoxicity and DTH by CFA and CpG. <i>Journal of Immunotherapy</i> , 2009, 32, 389-398.	1.2	15
1152	Proinflammatory tachykinins that signal through the neurokinin 1 receptor promote survival of dendritic cells and potent cellular immunity. <i>Blood</i> , 2009, 113, 3017-3026.	0.6	69
1153	Cognate CD4 help is essential for the reactivation and expansion of CD8 memory T cells directed against the hematopoietic cell-specific dominant minor histocompatibility antigen, H60. <i>Blood</i> , 2009, 113, 4273-4280.	0.6	27

#	ARTICLE	IF	CITATIONS
1154	Th-1 polarization is regulated by dendritic-cell comparison of MHC class I and class II antigens. <i>Blood</i> , 2009, 113, 4213-4223.	0.6	21
1155	CD40 Expression by Human Melanocytic Lesions and Melanoma Cell Lines and Direct CD40 Targeting With the Therapeutic Anti-CD40 Antibody CP-870,893. <i>Journal of Immunotherapy</i> , 2010, 33, 810-816.	1.2	20
1156	Control of Established Melanoma by CD27 Stimulation Is Associated With Enhanced Effector Function and Persistence, and Reduced PD-1 Expression of Tumor Infiltrating CD8+ T Cells. <i>Journal of Immunotherapy</i> , 2010, 33, 769-779.	1.2	90
1157	Immunology of Î²-Cell Destruction. <i>Advances in Experimental Medicine and Biology</i> , 2010, 654, 537-583.	0.8	27
1158	CD4+ T Cell Epitope Discovery and Rational Vaccine Design. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2010, 58, 121-130.	1.0	63
1159	Reprogrammed Foxp3+ Regulatory T Cells Provide Essential Help to Support Cross-presentation and CD8+ T Cell Priming in Naive Mice. <i>Immunity</i> , 2010, 33, 942-954.	6.6	157
1160	Mechanism of cellular rejection in transplantation. <i>Pediatric Nephrology</i> , 2010, 25, 61-74.	0.9	229
1161	Immunogene therapy against colon cancer metastasis using an adenovirus vector expressing CD40 ligand. <i>Surgery</i> , 2010, 148, 925-935.	1.0	7
1162	Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. <i>Cellular Immunology</i> , 2010, 263, 79-87.	1.4	137
1163	Thymic stromal lymphopoietin plays an adjuvant role in BCG-mediated CD8+ cytotoxic T cell responses through dendritic cell activation. <i>Clinical Immunology</i> , 2010, 136, 205-216.	1.4	8
1164	A new era in anticancer peptide vaccines. <i>Cancer</i> , 2010, 116, 2071-2080.	2.0	85
1165	CIITA-driven MHC-II positive tumor cells: Preventive vaccines and superior generators of antitumor CD4 ⁺ T lymphocytes for immunotherapy. <i>International Journal of Cancer</i> , 2010, 127, 1614-1624.	2.3	28
1166	Steady-state antigen-expressing dendritic cells terminate CD4 ⁺ memory T cell responses. <i>European Journal of Immunology</i> , 2010, 40, 2016-2025.	1.6	31
1167	Enhancement of proliferation and downregulation of TRAIL expression on CD8 ⁺ T cells by IL-21. <i>European Journal of Immunology</i> , 2010, 40, 2990-2992.	1.6	6
1168	Immune memory redefined: characterizing the longevity of natural killer cells. <i>Immunological Reviews</i> , 2010, 236, 83-94.	2.8	100
1169	Generation of effector CD8 ⁺ T cells and their conversion to memory T cells. <i>Immunological Reviews</i> , 2010, 236, 151-166.	2.8	229
1170	Î³Î´ T cells promote the maturation of dendritic cells during West Nile virus infection. <i>FEMS Immunology and Medical Microbiology</i> , 2010, 59, 71-80.	2.7	51
1171	Semi-Allogeneic Dendritic Cells Injected via the Intratumoural Injection Route Show Efficient Antitumour Effects in Cooperation with Host-Derived Professional Antigen-Presenting Cells. <i>Scandinavian Journal of Immunology</i> , 2010, 72, 476-490.	1.3	0

#	ARTICLE	IF	CITATIONS
1172	The potential of CD4 T cell memory. <i>Immunology</i> , 2010, 130, 1-9.	2.0	112
1173	Harnessing the immune response to treat cancer. <i>Oncogene</i> , 2010, 29, 6301-6313.	2.6	72
1174	Mobilizing forces - CD4+ helper T cells script adaptive immunity. <i>Cell Research</i> , 2010, 20, 1-3.	5.7	22
1175	Antiviral immune responses in the genital tract: clues for vaccines. <i>Nature Reviews Immunology</i> , 2010, 10, 699-711.	10.6	152
1176	Once a killer, always a killer: from cytotoxic T cell to memory cell. <i>Immunological Reviews</i> , 2010, 235, 206-218.	2.8	84
1177	Plasticity in programming of effector and memory CD8 ⁺ T cell formation. <i>Immunological Reviews</i> , 2010, 235, 190-205.	2.8	176
1178	Tumor Antigen Presentation by Dendritic Cells. <i>Critical Reviews in Immunology</i> , 2010, 30, 345-386.	1.0	51
1179	The Role of CD8 T Cells and Their Antigen Receptors in Psoriasis. <i>Psoriasis Forum</i> , 2010, 16a, 39-46.	0.1	0
1180	IL-2 Mediates CD4+ T Cell Help in the Breakdown of Memory-Like CD8+ T Cell Tolerance under Lymphopenic Conditions. <i>PLoS ONE</i> , 2010, 5, e12659.	1.1	9
1181	Emerging Evidence for the Role of Neurotransmitters in the Modulation of T Cell Responses to Cognate Ligands. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2010, 10, 65-83.	0.5	49
1182	Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. <i>Journal of Experimental Medicine</i> , 2010, 207, 651-667.	4.2	389
1183	Augmented Antibody Response with Premature Germinal Center Regression in CD40L Transgenic Mice. <i>Journal of Immunology</i> , 2010, 185, 211-219.	0.4	30
1184	CD4+ T Cells Elicit Host Immune Responses to MHC Class II ⁺ Ovarian Cancer through CCL5 Secretion and CD40-Mediated Licensing of Dendritic Cells. <i>Journal of Immunology</i> , 2010, 184, 5654-5662.	0.4	75
1185	Dynamic Regulation of CD8 T Cell Tolerance Induction by Liver Sinusoidal Endothelial Cells. <i>Journal of Immunology</i> , 2010, 184, 4107-4114.	0.4	106
1186	CD4 ⁺ T cell regulation of CD25 expression controls development of short-lived effector CD8 ⁺ T cells in primary and secondary responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 193-198.	3.3	169
1187	IL-21 Deficiency Influences CD8 T Cell Quality and Recall Responses following an Acute Viral Infection. <i>Journal of Immunology</i> , 2010, 185, 4835-4845.	0.4	73
1188	HER-2/neu as a target for cancer vaccines. <i>Immunotherapy</i> , 2010, 2, 213-226.	1.0	47
1189	Activation of Tolerogenic Dendritic Cells in the Tumor Draining Lymph Nodes by CD8+T Cells Engineered to Express CD40 Ligand. <i>Journal of Immunology</i> , 2010, 184, 3394-3400.	0.4	15

#	ARTICLE	IF	CITATIONS
1190	T Cell Polarity at the Immunological Synapse Is Required for CD154-Dependent IL-12 Secretion by Dendritic Cells. <i>Journal of Immunology</i> , 2010, 185, 6809-6818.	0.4	26
1191	Th Cells Act Via Two Synergistic Pathways To Promote Antiviral CD8+ T Cell Responses. <i>Journal of Immunology</i> , 2010, 185, 5188-5197.	0.4	36
1192	Early CD4+ T Cell Help Prevents Partial CD8+ T Cell Exhaustion and Promotes Maintenance of Herpes Simplex Virus 1 Latency. <i>Journal of Immunology</i> , 2010, 184, 277-286.	0.4	72
1193	TLR9 Blockade Inhibits Activation of Diabetogenic CD8+ T Cells and Delays Autoimmune Diabetes. <i>Journal of Immunology</i> , 2010, 184, 5645-5653.	0.4	70
1194	Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8+ T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 4281-4286.	3.3	45
1195	CD70 expression by dendritic cells plays a critical role in the immunogenicity of CD40-independent, CD4+ T cell-dependent, licensed CD8+ T cell responses. <i>Journal of Leukocyte Biology</i> , 2009, 87, 477-485.	1.5	28
1196	Shaping Successful and Unsuccessful CD8 T Cell Responses Following Infection. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-12.	3.0	26
1197	Delivery of Exogenous Antigens to Induce Cytotoxic CD8+ T Lymphocyte Responses. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-10.	3.0	10
1198	Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. <i>Cancer Biology and Therapy</i> , 2010, 10, 983-993.	1.5	135
1199	The Regulatory Natural Killer Cells. , 2010, , 369-389.		2
1200	Polyfunctional CD4+ T cell responses to a set of pathogenic arenaviruses provide broad population coverage. <i>Immunome Research</i> , 2010, 6, 4.	0.1	16
1201	Production and characterization of agonistic monoclonal antibodies against chicken CD40. <i>Developmental and Comparative Immunology</i> , 2010, 34, 1139-1143.	1.0	8
1202	Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses. <i>Vaccine</i> , 2010, 28, 1383-1390.	1.7	44
1203	Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. <i>Vaccine</i> , 2010, 28, 6757-6764.	1.7	52
1204	Considerations in the design of vaccines that induce CD8 T cell mediated immunity. <i>Vaccine</i> , 2010, 28, 7716-7722.	1.7	10
1205	Immunogenicity and protective efficacy of a DNA vaccine encoding a chimeric protein of avian influenza hemagglutinin subtype H5 fused to CD154 (CD40L) in Pekin ducks. <i>Vaccine</i> , 2010, 28, 8147-8156.	1.7	30
1206	Induction of pathogenic cytotoxic T lymphocyte tolerance by dendritic cells: a novel therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 797-824.	1.5	8
1207	CD40-FasL and CTLA-4-FasL Fusion Proteins Induce Apoptosis in Malignant Cell Lines by Dual Signaling. <i>American Journal of Pathology</i> , 2010, 177, 3159-3168.	1.9	12

#	ARTICLE	IF	CITATIONS
1208	Functional assessment of human dendritic cells labeled for in vivo 19F magnetic resonance imaging cell tracking. <i>Cytotherapy</i> , 2010, 12, 238-250.	0.3	87
1210	CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Leukemia and Lymphoma</i> , 2010, 51, 1643-1648.	0.6	11
1211	CD40L co-stimulation from CD8 ⁺ to CD4 ⁺ effector memory T cells supports CD4 ⁺ expansion. <i>Immunology and Cell Biology</i> , 2011, 89, 670-680.	1.0	9
1212	Autocrine IL-2 is required for secondary population expansion of CD8+ memory T cells. <i>Nature Immunology</i> , 2011, 12, 908-913.	7.0	214
1213	Amplified B Lymphocyte CD40 Signaling Drives Regulatory B10 Cell Expansion in Mice. <i>PLoS ONE</i> , 2011, 6, e22464.	1.1	62
1214	CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans. <i>Science</i> , 2011, 331, 1612-1616.	6.0	1,407
1215	Targeting Nanosystems to Human DCs via Fc Receptor as an Effective Strategy to Deliver Antigen for Immunotherapy. <i>Molecular Pharmaceutics</i> , 2011, 8, 104-116.	2.3	85
1217	LAG-3, TGF- β 2, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L. <i>Blood</i> , 2011, 117, 5532-5540.	0.6	38
1218	Harnessing dendritic cells for immunotherapy. <i>Seminars in Immunology</i> , 2011, 23, 2-11.	2.7	57
1219	Chemokines: A New Dendritic Cell Signal for T Cell Activation. <i>Frontiers in Immunology</i> , 2011, 2, 31.	2.2	56
1220	Immunization route dictates cross-priming efficiency and impacts the optimal timing of adjuvant delivery. <i>Frontiers in Immunology</i> , 2011, 2, 71.	2.2	11
1221	Targeting Co-Stimulatory Pathways in Gene Therapy. <i>Frontiers in Microbiology</i> , 2011, 2, 202.	1.5	4
1222	CD4+ T Cells Modulate Expansion and Survival but Not Functional Properties of Effector and Memory CD8+ T Cells Induced by Malaria Sporozoites. <i>PLoS ONE</i> , 2011, 6, e15948.	1.1	51
1223	CD4+ T Cell Effects on CD8+ T Cell Location Defined Using Bioluminescence. <i>PLoS ONE</i> , 2011, 6, e16222.	1.1	5
1224	Chimeric Trop2 Virus-like Particles. <i>Journal of Immunotherapy</i> , 2011, 34, 251-263.	1.2	36
1225	Selective Depletion of Cross-Presenting Dendritic Cells Enhances Islet Allograft Survival. <i>Cell Transplantation</i> , 2011, 20, 467-474.	1.2	9
1226	Redirecting α CD4 T cells against cancer cells by transfer of a broadly tumor-reactive α CD4 T-cell receptor. <i>Blood</i> , 2011, 118, 50-59.	0.6	184
1227	Immunological perspective of self versus tumor antigens: insights from the RIP-Tag model. <i>Immunological Reviews</i> , 2011, 241, 164-179.	2.8	16

#	ARTICLE	IF	CITATIONS
1228	LT β 2R and CD40: working together in dendritic cells to optimize immune responses. <i>Immunological Reviews</i> , 2011, 244, 85-98.	2.8	23
1229	Translating Tumor Antigens into Cancer Vaccines. <i>Vaccine Journal</i> , 2011, 18, 23-34.	3.2	183
1230	A High-Affinity T-Helper Epitope Enhances Peptide-Pulsed Dendritic Cell-Based Vaccine. <i>DNA and Cell Biology</i> , 2011, 30, 883-892.	0.9	4
1231	Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come. <i>Expert Review of Vaccines</i> , 2011, 10, 1553-1568.	2.0	83
1232	Regulation of the Physiological Functions of Human Dendritic Cells by Recombinant Heat Shock Protein Hsp70. <i>Neuroscience and Behavioral Physiology</i> , 2011, 41, 74-82.	0.2	1
1233	Using an agent-based model to analyze the dynamic communication network of the immune response. <i>Theoretical Biology and Medical Modelling</i> , 2011, 8, 1.	2.1	65
1234	The subcellular location of antigen expressed by adenoviral vectors modifies adaptive immunity but not dependency on cross-presenting dendritic cells. <i>European Journal of Immunology</i> , 2011, 41, 2185-2196.	1.6	5
1235	MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response. <i>Journal of Proteomics</i> , 2011, 74, 728-743.	1.2	18
1236	Development of Memory-Like Autoregulatory CD8+ T Cells Is CD4+ T Cell Dependent. <i>Journal of Immunology</i> , 2011, 187, 2859-2866.	0.4	13
1237	T Cells and Adoptive Immunotherapy: Recent Developments and Future Prospects in Gastrointestinal Oncology. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-17.	3.3	16
1238	LT β 2R signaling in dendritic cells induces a type I IFN response that is required for optimal clonal expansion of CD8 ⁺ T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 2046-2051.	3.3	28
1239	CD4 ⁺ T cells support cytotoxic T lymphocyte priming by controlling lymph node input. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 8749-8754.	3.3	80
1240	Antibody-Targeted NY-ESO-1 to Mannose Receptor or DEC-205 In Vitro Elicits Dual Human CD8+ and CD4+ T Cell Responses with Broad Antigen Specificity. <i>Journal of Immunology</i> , 2011, 186, 1218-1227.	0.4	98
1241	Ileal Immune Dysregulation in Necrotizing Enterocolitis: Role of CD40/CD40L in the Pathogenesis of Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2011, 52, 140-146.	0.9	14
1242	CD154-CD40 interactions in the control of murine B cell hematopoiesis. <i>Journal of Leukocyte Biology</i> , 2011, 89, 697-706.	1.5	10
1243	EBV LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine. <i>Journal of Leukocyte Biology</i> , 2011, 90, 389-398.	1.5	11
1244	C-type Lectin Receptors for Tumor Eradication: Future Directions. <i>Cancers</i> , 2011, 3, 3169-3188.	1.7	8
1245	Harnessing Dendritic Cells for Tumor Antigen Presentation. <i>Cancers</i> , 2011, 3, 2195-2213.	1.7	12

#	ARTICLE	IF	CITATIONS
1246	A Temporal Role Of Type I Interferon Signaling in CD8+ T Cell Maturation during Acute West Nile Virus Infection. <i>PLoS Pathogens</i> , 2011, 7, e1002407.	2.1	95
1247	IL-15 ex vivo overcomes CD4+ T cell deficiency for the induction of human antigen-specific CD8+ T cell responses. <i>Journal of Leukocyte Biology</i> , 2011, 90, 205-214.	1.5	12
1248	Heat Shock Proteins, Autoimmunity, and Cancer Treatment. <i>Autoimmune Diseases</i> , 2012, 2012, 1-10.	2.7	69
1249	Human $\hat{\beta}$ T Lymphocytes Are Licensed for Professional Antigen Presentation by Interaction with Oposonized Target Cells. <i>Journal of Immunology</i> , 2012, 188, 1708-1716.	0.4	119
1250	Directed antigen targeting in vivo identifies a role for CD103+ dendritic cells in both tolerogenic and immunogenic T-cell responses. <i>Mucosal Immunology</i> , 2012, 5, 150-160.	2.7	67
1251	Synergistic CD40 signaling on APCs and CD8 T cells drives efficient CD8 response and memory differentiation. <i>Journal of Leukocyte Biology</i> , 2012, 91, 859-869.	1.5	18
1252	Licensing of $\hat{\beta}$ T cells for professional antigen presentation. <i>Oncolmunology</i> , 2012, 1, 1652-1654.	2.1	14
1253	Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia. <i>Leukemia</i> , 2012, 26, 312-322.	3.3	26
1254	Immunoglobulin Fc Fragment Tagging Allows Strong Activation of Endogenous CD4 T Cells To Reshape the Tumor Milieu and Enhance the Antitumor Effect of Lentivector Immunization. <i>Journal of Immunology</i> , 2012, 188, 4819-4827.	0.4	4
1255	Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor. <i>Clinical Cancer Research</i> , 2012, 18, 6284-6295.	3.2	54
1256	CD4+ T Cell-Dependent IFN- $\hat{\beta}$ Production by CD8+ Effector T Cells in <i>Mycobacterium tuberculosis</i> Infection. <i>Journal of Immunology</i> , 2012, 189, 2530-2536.	0.4	53
1257	Cytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Antitumor Effects. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-12.	3.3	45
1258	CD8 T Cell Priming in the Presence of IFN- $\hat{\beta}$ Renders CTLs with Improved Responsiveness to Homeostatic Cytokines and Recall Antigens: Important Traits for Adoptive T Cell Therapy. <i>Journal of Immunology</i> , 2012, 189, 3299-3310.	0.4	36
1259	Dendritic Cell Activation and Memory Cell Development Are Impaired among Mice Administered Medroxyprogesterone Acetate Prior to Mucosal Herpes Simplex Virus Type 1 Infection. <i>Journal of Immunology</i> , 2012, 189, 3449-3461.	0.4	23
1260	CCR5 as a Potential Target in Cancer Therapy: Inhibition or Stimulation?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 1045-1057.	0.9	14
1261	Immunomodulatory Drugs and Active Immunotherapy for Chronic Lymphocytic Leukemia. <i>Cancer Control</i> , 2012, 19, 54-67.	0.7	25
1262	IL-6-inducing Whole Yeast-based Immunotherapy Directly Controls IL-12-dependent CD8 T-cell Responses. <i>Journal of Immunotherapy</i> , 2012, 35, 14-22.	1.2	9
1263	Crosstalk between T Lymphocytes and Dendritic Cells. <i>Critical Reviews in Immunology</i> , 2012, 32, 139-155.	1.0	83

#	ARTICLE	IF	CITATIONS
1264	Nab2 regulates secondary CD8+ T-cell responses through control of TRAIL expression. <i>Blood</i> , 2012, 119, 798-804.	0.6	21
1265	Vaccine-Elicited CD8 ⁺ T Cells Protect against Respiratory Syncytial Virus Strain A2-Line19F-Induced Pathogenesis in BALB/c Mice. <i>Journal of Virology</i> , 2012, 86, 13016-13024.	1.5	46
1266	CD40/CD154 Blockade Inhibits Dendritic Cell Expression of Inflammatory Cytokines but Not Costimulatory Molecules. <i>Journal of Immunology</i> , 2012, 189, 4387-4395.	0.4	30
1267	Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice. <i>Blood</i> , 2012, 119, 2056-2065.	0.6	16
1268	T-cell-independent Antitumor Effects of CD40 Ligation. <i>International Reviews of Immunology</i> , 2012, 31, 267-278.	1.5	47
1269	Targeting Dendritic Cells for Improved HIV-1 Vaccines. <i>Advances in Experimental Medicine and Biology</i> , 2012, 762, 263-288.	0.8	10
1270	Induction of antigen-specific human T suppressor cells by membrane and soluble ILT3. <i>Experimental and Molecular Pathology</i> , 2012, 93, 294-301.	0.9	21
1271	Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1764-1768.	0.6	11
1272	Experience with Synthetic Vaccines for Cancer and Persistent Virus Infections in Nonhuman Primates and Patients. <i>Advances in Immunology</i> , 2012, 114, 77-106.	1.1	33
1273	Dietary Mustard Seeds (<i>Sinapis alba</i> Linn) Suppress 1,2-Dimethylhydrazine-Induced Immuno-Imbalance and Colonic Carcinogenesis in Rats. <i>Nutrition and Cancer</i> , 2012, 64, 464-472.	0.9	12
1274	Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine. <i>Vaccine</i> , 2012, 30, 691-702.	1.7	45
1275	Single chain MHC I trimer-based DNA vaccines for protection against <i>Listeria monocytogenes</i> infection. <i>Vaccine</i> , 2012, 30, 2178-2186.	1.7	10
1276	CD40 triggering induces strong cytotoxic T lymphocyte responses to heat-killed <i>Staphylococcus aureus</i> immunization in mice: A new vaccine strategy for staphylococcal mastitis. <i>Vaccine</i> , 2012, 30, 2116-2124.	1.7	20
1277	T-cell activation and transplantation tolerance. <i>Transplantation Reviews</i> , 2012, 26, 212-222.	1.2	25
1278	Design of CD40 Agonists and Their Use in Growing B Cells for Cancer Immunotherapy. <i>International Reviews of Immunology</i> , 2012, 31, 279-288.	1.5	29
1279	The secret ally: immunostimulation by anticancer drugs. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 215-233.	21.5	591
1280	Identification of a Coordinated CD8 and CD4 T Cell Response Directed Against Mismatched HLA Class I Causing Severe Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 210-219.	2.0	26
1281	Role of CD40 ligation in dendritic cell semimaturation. <i>BMC Immunology</i> , 2012, 13, 22.	0.9	10

#	ARTICLE	IF	CITATIONS
1282	Direct in vivo evidence of CD4 ⁺ T cell requirement for CTL response and memory via pMHC-I targeting and CD40L signaling. <i>Journal of Leukocyte Biology</i> , 2012, 92, 289-300.	1.5	27
1283	Maintaining the balance: Costimulatory TNFRs and control of HIV. <i>Cytokine and Growth Factor Reviews</i> , 2012, 23, 245-254.	3.2	11
1284	ISCOMATRIX vaccines mediate CD8 ⁺ T cell cross-priming by a MyD88-dependent signaling pathway. <i>Immunology and Cell Biology</i> , 2012, 90, 540-552.	1.0	92
1285	Simultaneous Targeting of Toll- and Nod-Like Receptors Induces Effective Tumor-Specific Immune Responses. <i>Science Translational Medicine</i> , 2012, 4, 120ra16.	5.8	125
1286	Adenovirus-Based Immunotherapy of Cancer: Promises to Keep. <i>Advances in Cancer Research</i> , 2012, 115, 147-220.	1.9	16
1287	TLR Ligand-Peptide Conjugate Vaccines. <i>Advances in Immunology</i> , 2012, 114, 177-201.	1.1	71
1288	Foxp4 Is Dispensable for T Cell Development, but Required for Robust Recall Responses. <i>PLoS ONE</i> , 2012, 7, e42273.	1.1	38
1289	The Role of Heat Shock Proteins in Antigen Cross Presentation. <i>Frontiers in Immunology</i> , 2012, 3, 63.	2.2	137
1290	Heat Shock Proteins: Conditional Mediators of Inflammation in Tumor Immunity. <i>Frontiers in Immunology</i> , 2012, 3, 75.	2.2	40
1291	Requirement of CD4 Help for Induction of CD8 T Cell Response Specific for Virally Derived H60. <i>Immune Network</i> , 2012, 12, 118.	1.6	0
1292	Current concepts on the immunopathogenesis of inflammatory bowel disease. <i>Frontiers in Bioscience - Elite</i> , 2012, E4, 1451.	0.9	7
1293	Cells, Molecules and Mechanisms Involved in the Neuro-Immune Interaction. , 2012, , .		7
1294	Human dendritic cells sequentially matured with CD4 ⁺ T cells as a secondary signal favor CTL and long-term T memory cell responses. <i>Biological Research</i> , 2012, 45, 33-43.	1.5	6
1295	Lipopolysaccharide-Activated Dendritic Cells: "Exhausted" or Alert and Waiting?. <i>Journal of Immunology</i> , 2012, 188, 5981-5989.	0.4	67
1296	From crucial to negligible: Functional CD8 ⁺ T cell responses and their dependence on CD4 ⁺ T cell help. <i>European Journal of Immunology</i> , 2012, 42, 1080-1088.	1.6	104
1297	Unlike CD4 ⁺ T cell help, CD28 costimulation is necessary for effective primary CD8 ⁺ T cell influenza-specific immunity. <i>European Journal of Immunology</i> , 2012, 42, 1744-1754.	1.6	14
1298	Multivalent Porous Silicon Nanoparticles Enhance the Immune Activation Potency of Agonistic CD40 Antibody. <i>Advanced Materials</i> , 2012, 24, 3981-3987.	11.1	93
1299	Suppression of antigen-specific CD4 ⁺ T cell activation by SRA/CD204 through reducing the immunostimulatory capability of antigen-presenting cell. <i>Journal of Molecular Medicine</i> , 2012, 90, 413-426.	1.7	26

#	ARTICLE	IF	CITATIONS
1300	Early T-cell and thymus development in Japanese eel <i>Anguilla japonica</i> . <i>Fisheries Science</i> , 2012, 78, 539-547.	0.7	3
1301	Intratumoral interleukin-2/agonist CD40 antibody drives CD4 ⁺ -independent resolution of treated-tumors and CD4 ⁺ -dependent systemic and memory responses. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 549-560.	2.0	38
1302	Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 713-723.	2.0	24
1303	Stroma and pancreatic ductal adenocarcinoma: An interaction loop. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1826, 170-178.	3.3	25
1304	Advances in Direct T-Cell Alloreactivity: Function, Avidity, Biophysics and Structure. <i>American Journal of Transplantation</i> , 2012, 12, 15-26.	2.6	27
1305	Virus-like particles induce robust human T-helper cell responses. <i>European Journal of Immunology</i> , 2012, 42, 330-340.	1.6	69
1306	Pleural Mesothelial Cells Promote Expansion of IL-17-Producing CD8 ⁺ T Cells in Tuberculous Pleural Effusion. <i>Journal of Clinical Immunology</i> , 2013, 33, 775-787.	2.0	12
1307	Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines. , 2013, , .		1
1308	CD40 immunotherapy for pancreatic cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 949-954.	2.0	95
1309	Candida skin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine. <i>Vaccine</i> , 2013, 31, 5806-5813.	1.7	23
1310	Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. <i>Seminars in Immunology</i> , 2013, 25, 182-190.	2.7	44
1311	p53 in the Clinics. , 2013, , .		1
1313	The contextual role of TNFR family members in CD ⁸ ⁺ T-cell control of viral infections. <i>Immunological Reviews</i> , 2013, 255, 125-148.	2.8	77
1314	Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations. <i>Leukemia and Lymphoma</i> , 2013, 54, 2008-2015.	0.6	11
1315	Crafting precise multivalent architectures. <i>MedChemComm</i> , 2013, 4, 493-509.	3.5	37
1316	Human CD1c ⁺ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. <i>Blood</i> , 2013, 122, 932-942.	0.6	300
1317	T Cell and Antigen-Presenting Cell Subsets in the Tumor Microenvironment. , 2013, , 17-44.		0
1318	A West Nile virus NS4B-P38G mutant strain induces adaptive immunity via TLR7-MyD88-dependent and independent signaling pathways. <i>Vaccine</i> , 2013, 31, 4143-4151.	1.7	15

#	ARTICLE	IF	CITATIONS
1319	Influenza-induced, helper-independent CD8+T cell responses use CD40 costimulation at the late phase of the primary response. <i>Journal of Leukocyte Biology</i> , 2013, 93, 145-154.	1.5	9
1320	What Have Dendritic Cells Ever Done for Adjuvant Design? Cellular and Molecular Methods for the Rational Development of Vaccine Adjuvants. , 2013, , 131-154.		0
1321	Novel antibodies targeting immune regulatory checkpoints for cancer therapy. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 233-247.	1.1	38
1323	Transplantation Immunology. <i>Methods in Molecular Biology</i> , 2013, , .	0.4	1
1324	Trial watch. <i>Oncolimmunology</i> , 2013, 2, e23803.	2.1	92
1325	Differential requirements of CD4 ⁺ T cell signals for effector cytotoxic T lymphocyte (CTL) priming and functional memory CTL development at higher CD8 ⁺ T cell precursor frequency. <i>Immunology</i> , 2013, 138, 298-306.	2.0	10
1326	Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases. <i>Cancer Research</i> , 2013, 73, 3566-3577.	0.4	105
1327	CD4 T-cell immunotherapy for chronic viral infections and cancer. <i>Immunotherapy</i> , 2013, 5, 975-987.	1.0	52
1328	CD40 Activation Rescues Antiviral CD8+ T Cells from PD-1-Mediated Exhaustion. <i>PLoS Pathogens</i> , 2013, 9, e1003490.	2.1	127
1329	Genetic Adjuvantation of Recombinant MVA with CD40L Potentiates CD8 T Cell Mediated Immunity. <i>Frontiers in Immunology</i> , 2013, 4, 251.	2.2	12
1330	A Hamster-Derived West Nile Virus Isolate Induces Persistent Renal Infection in Mice. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2275.	1.3	35
1331	Requirement of tumor-associated antigen-specific CD4 ⁺ T cells for an efficient dendritic cell vaccine in antitumor immunotherapy. <i>Immunotherapy</i> , 2013, 5, 565-567.	1.0	7
1332	Agonistic Anti-CD40 Antibody Therapy is Effective Against Postoperative Cancer Recurrence and Metastasis in a Murine Tumor Model. <i>Journal of Immunotherapy</i> , 2013, 36, 365-372.	1.2	17
1333	CD40 Therapy and Surgery. <i>Journal of Immunotherapy</i> , 2013, 36, 359-361.	1.2	5
1334	CD4+ T helper cells use CD154-CD40 interactions to counteract T reg cell-mediated suppression of CD8+ T cell responses to influenza. <i>Journal of Experimental Medicine</i> , 2013, 210, 1591-1601.	4.2	41
1335	Differential Requirements of Cellular and Humoral Immune Responses for Fv2-Associated Resistance to Erythroleukemia and for Regulation of Retrovirus-Induced Myeloid Leukemia Development. <i>Journal of Virology</i> , 2013, 87, 13760-13774.	1.5	11
1336	The Key Role of IL-6-Arginase Cascade for Inducing Dendritic Cell-Dependent CD4+ T Cell Dysfunction in Tumor-Bearing Mice. <i>Journal of Immunology</i> , 2013, 190, 812-820.	0.4	65
1337	Toll-Like Receptor 4 Engagement Drives Differentiation of Human and Murine Dendritic Cells from a Pro- into an Anti-Inflammatory Mode. <i>PLoS ONE</i> , 2013, 8, e54879.	1.1	24

#	ARTICLE	IF	CITATIONS
1338	TLR7 Triggering with Polyuridylic Acid Promotes Cross-Presentation in CD8 ⁺ Conventional Dendritic Cells by Enhancing Antigen Preservation and MHC Class I Antigen Permanence on the Dendritic Cell Surface. <i>Journal of Immunology</i> , 2013, 190, 948-960.	0.4	37
1339	A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 6286-6295.	3.2	382
1340	Agonistic Anti-CD40 Induces Thyrocyte Proliferation and Promotes Thyroid Autoimmunity by Increasing CD40 Expression on Thyroid Epithelial Cells. <i>Journal of Immunology</i> , 2013, 190, 3928-3938.	0.4	13
1341	Inhibition of CD8+ T Cell-Derived CD40 Signals Is Necessary but Not Sufficient for Foxp3+ Induced Regulatory T Cell Generation In Vivo. <i>Journal of Immunology</i> , 2013, 191, 1957-1964.	0.4	18
1342	Regulatory CD8+ T Cells Associated with Erosion of Immune Surveillance in Persistent Virus Infection Suppress In Vitro and Have a Reversible Proliferative Defect. <i>Journal of Immunology</i> , 2013, 191, 312-322.	0.4	10
1343	Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1073-1077.	1.4	20
1344	Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation. <i>Onc Immunology</i> , 2013, 2, e22837.	2.1	24
1345	Effective Anti-Neu ^T -Initiated Antitumor Responses Require the Complex Role of CD4+ T Cells. <i>Clinical Cancer Research</i> , 2013, 19, 1476-1486.	3.2	54
1346	Copresentation of Intact and Processed MHC Alloantigen by Recipient Dendritic Cells Enables Delivery of Linked Help to Alloreactive CD8 T Cells by Indirect-Pathway CD4 T Cells. <i>Journal of Immunology</i> , 2013, 190, 5829-5838.	0.4	51
1347	With(out) a little help from my friends: An IL-2/CD40L-mediated feed-forward loop between CD8 ⁺ T cells and DCs. <i>European Journal of Immunology</i> , 2013, 43, 1445-1448.	1.6	0
1348	CD40L expression permits CD8+ T cells to execute immunologic helper functions. <i>Blood</i> , 2013, 122, 405-412.	0.6	80
1349	Allorecognition Pathways in Transplant Rejection and Tolerance. <i>Transplantation</i> , 2013, 96, 681-688.	0.5	95
1350	Antitumor effects and mechanisms of dendritic cells stimulated by sCD40L on ovarian cancer cells in vitro. <i>OncoTargets and Therapy</i> , 2013, 6, 503.	1.0	1
1351	Th Cells Promote CTL Survival and Memory via Acquired pMHC-I and Endogenous IL-2 and CD40L Signaling and by Modulating Apoptosis-Controlling Pathways. <i>PLoS ONE</i> , 2013, 8, e64787.	1.1	13
1352	NK Cells and Their Ability to Modulate T Cells during Virus Infections. <i>Critical Reviews in Immunology</i> , 2014, 34, 359-388.	1.0	85
1353	Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets. <i>Frontiers in Immunology</i> , 2014, 5, 165.	2.2	127
1354	Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. <i>Immunopharmacology and Immunotoxicology</i> , 2014, 36, 96-104.	1.1	82
1355	Antigen-specific vaccines for cancer treatment. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3332-3346.	1.4	124

#	ARTICLE	IF	CITATIONS
1356	Ikaros Imposes a Barrier to CD8+ T Cell Differentiation by Restricting Autocrine IL-2 Production. <i>Journal of Immunology</i> , 2014, 192, 5118-5129.	0.4	42
1357	CD40L-Adjuvanted DNA/Modified Vaccinia Virus Ankara Simian Immunodeficiency Virus SIV239 Vaccine Enhances SIV-Specific Humoral and Cellular Immunity and Improves Protection against a Heterologous SIVE660 Mucosal Challenge. <i>Journal of Virology</i> , 2014, 88, 9579-9589.	1.5	53
1358	Inhibition of Protein Geranylgeranylation Specifically Interferes with CD40-Dependent B Cell Activation, Resulting in a Reduced Capacity To Induce T Cell Immunity. <i>Journal of Immunology</i> , 2014, 193, 5294-5305.	0.4	29
1359	Human Osteoclasts Are Inducible Immunosuppressive Cells in Response to T cell-Derived IFN- β and CD40 Ligand In Vitro. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 2666-2675.	3.1	36
1360	Fc γ 3 Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization. <i>Journal of Immunology</i> , 2014, 193, 1828-1835.	0.4	56
1361	The Intricate Behavior of T Cells. , 2014, , 141-233.		0
1362	An Autologous In Situ Tumor Vaccination Approach for Hepatocellular Carcinoma. 2. Tumor-Specific Immunity and Cure after Radio-Inducible Suicide Gene Therapy and Systemic CD40-Ligand and Flt3-Ligand Gene Therapy in an Orthotopic Tumor Model. <i>Radiation Research</i> , 2014, 182, 201.	0.7	19
1363	Circulating Type-1 Anti-Tumor CD4 ⁺ T Cells are Preferentially Pro-Apoptotic in Cancer Patients. <i>Frontiers in Oncology</i> , 2014, 4, 266.	1.3	19
1364	Strain-Specific Properties and T Cells Regulate the Susceptibility to Papilloma Induction by Mus musculus Papillomavirus 1. <i>PLoS Pathogens</i> , 2014, 10, e1004314.	2.1	59
1365	Acquired Immunological Tolerance. , 2014, , 235-280.		0
1366	Priming of CD8+ α -T Cell Responses to Liver Stage Malaria Parasite Antigens. <i>Frontiers in Immunology</i> , 2014, 5, 527.	2.2	12
1367	Concurrent interaction of DCs with CD4 ⁺ and CD8 ⁺ T cells improves secondary CTL expansion: It takes three to tango. <i>European Journal of Immunology</i> , 2014, 44, 3543-3559.	1.6	32
1368	Ex Vivo Assays of Dendritic Cell Activation and Cytokine Profiles as Predictors of In Vivo Effects in an Anti-Human CD40 Monoclonal Antibody ChiLob 7/4 Phase I Trial. <i>Cancer Immunology Research</i> , 2014, 2, 229-240.	1.6	21
1369	Helping Themselves: Optimal Virus-Specific CD4 T Cell Responses Require Help via CD4 T Cell Licensing of Dendritic Cells. <i>Journal of Immunology</i> , 2014, 193, 5420-5433.	0.4	9
1370	Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2014, 2, 1051-1058.	1.6	74
1371	The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. <i>Nature Communications</i> , 2014, 5, 5621.	5.8	427
1372	Smarter drugs emerging in pancreatic cancer therapy. <i>Annals of Oncology</i> , 2014, 25, 1260-1270.	0.6	72
1373	T cell help dependence of memory CD8 ⁺ T cell expansion upon vaccinia virus challenge relies on CD40 signaling. <i>European Journal of Immunology</i> , 2014, 44, 115-126.	1.6	7

#	ARTICLE	IF	CITATIONS
1374	CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma. <i>International Journal of Cancer</i> , 2014, 135, 2825-2833.	2.3	12
1375	A CD40/CD40L feedback loop drives the breakdown of CD8 ⁺ T cell tolerance following depletion of suppressive CD4 ⁺ T cells. <i>European Journal of Immunology</i> , 2014, 44, 1099-1107.	1.6	7
1376	Dendritic cells of myeloid lineage. <i>Current Opinion in Organ Transplantation</i> , 2014, 19, 20-27.	0.8	24
1377	Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 19-26.	1.6	77
1378	Liposomes containing NY-ESO-1/tetanus toxoid and adjuvant peptides targeted to human dendritic cells via the Fc receptor for cancer vaccines. <i>Nanomedicine</i> , 2014, 9, 435-449.	1.7	32
1379	Vaccination with a Fusion Protein That Introduces HIV-1 Gag Antigen into a Multimeric CD40L Construct Results in Enhanced CD8 ⁺ T Cell Responses and Protection from Viral Challenge by Vaccinia-Gag. <i>Journal of Virology</i> , 2014, 88, 1492-1501.	1.5	10
1380	Selective antigen-specific CD4 ⁺ T cell, but not CD8 ⁺ T or B cell, tolerance corrupts cancer immunotherapy. <i>European Journal of Immunology</i> , 2014, 44, 1956-1966.	1.6	37
1381	CD154 + CD4 + T cell dependence for effective memory influenza virus-specific CD8 ⁺ T cell responses. <i>Immunology and Cell Biology</i> , 2014, 92, 605-611.	1.0	6
1382	Targeting co-stimulatory pathways: transplantation and autoimmunity. <i>Nature Reviews Nephrology</i> , 2014, 10, 14-24.	4.1	137
1383	Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 80-90.	1.6	78
1384	Longitudinal Requirement for CD4 ⁺ T Cell Help for Adenovirus Vector-Elicited CD8 ⁺ T Cell Responses. <i>Journal of Immunology</i> , 2014, 192, 5214-5225.	0.4	25
1385	Transplantation tolerance: from theory to clinic. <i>Immunological Reviews</i> , 2014, 258, 64-79.	2.8	34
1386	PTPN2 restrains CD8 ⁺ T cell responses after antigen cross-presentation for the maintenance of peripheral tolerance in mice. <i>Journal of Autoimmunity</i> , 2014, 53, 105-114.	3.0	39
1387	Tumor-specific CD4 ⁺ T cells maintain effector and memory tumor-specific CD8 ⁺ T cells. <i>European Journal of Immunology</i> , 2014, 44, 69-79.	1.6	98
1388	Epitope-Specific Regulation of Memory Programming by Differential Duration of Antigen Presentation to Influenza-Specific CD8 ⁺ T Cells. <i>Immunity</i> , 2014, 41, 127-140.	6.6	46
1389	From T Cell Apoptosis to Chronic Immune Activation in Inflammatory Diseases. <i>International Archives of Allergy and Immunology</i> , 2014, 164, 140-146.	0.9	13
1390	Stromal reengineering to treat pancreas cancer. <i>Carcinogenesis</i> , 2014, 35, 1451-1460.	1.3	108
1391	IL-27 is required for shaping the magnitude, affinity distribution, and memory of T cells responding to subunit immunization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 16472-16477.	3.3	53

#	ARTICLE	IF	CITATIONS
1392	A self-adjuvanting vaccine induces cytotoxic T lymphocytes that suppress allergy. <i>Nature Chemical Biology</i> , 2014, 10, 943-949.	3.9	70
1393	Allo-specific CD8 T suppressor cells induced by multiple MLC stimulation or priming in the presence of ILT3.Fc have similar gene expression profiles. <i>Human Immunology</i> , 2014, 75, 190-196.	1.2	11
1394	Vitamin C treatment of mouse bone marrow-derived dendritic cells enhanced CD8+ memory T cell production capacity of these cells in vivo. <i>Immunobiology</i> , 2014, 219, 554-564.	0.8	36
1395	CD40 Ligand Preferentially Modulates Immune Response and Enhances Protection against Influenza Virus. <i>Journal of Immunology</i> , 2014, 193, 722-734.	0.4	35
1398	MHC class II induces memory T cell formation in vivo and inhibits tumour growth. <i>Immunity, Inflammation and Disease</i> , 2014, 2, 181-192.	1.3	4
1399	Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy. <i>Journal of Immunology</i> , 2015, 195, 5816-5826.	0.4	15
1400	Latent virus infection upregulates CD40 expression facilitating enhanced autoimmunity in a model of multiple sclerosis. <i>Scientific Reports</i> , 2015, 5, 13995.	1.6	33
1401	Therapeutic cancer vaccines. <i>Journal of Clinical Investigation</i> , 2015, 125, 3401-3412.	3.9	640
1402	Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. <i>Vaccines</i> , 2015, 3, 490-502.	2.1	43
1403	Development of Cross-Protective Influenza A Vaccines Based on Cellular Responses. <i>Frontiers in Immunology</i> , 2015, 6, 237.	2.2	46
1404	Synergy between CD40 and MyD88 Does Not Influence Host Survival to Salmonella Infection. <i>Frontiers in Immunology</i> , 2015, 6, 460.	2.2	2
1405	Immunotherapy for Bone and Soft Tissue Sarcomas. <i>BioMed Research International</i> , 2015, 2015, 1-11.	0.9	16
1406	CD8+ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity. <i>Critical Reviews in Immunology</i> , 2015, 35, 153-172.	1.0	32
1407	Cell-Mediated Defense against Infection. , 2015, , 50-69.e6.		3
1408	DC-SIGN+ Macrophages Control the Induction of Transplantation Tolerance. <i>Immunity</i> , 2015, 42, 1143-1158.	6.6	144
1409	Cognate CD4 T-Cell Licensing of Dendritic Cells Heralds Anti-Cytomegalovirus CD8 T-Cell Immunity after Human Allogeneic Umbilical Cord Blood Transplantation. <i>Journal of Virology</i> , 2015, 89, 1058-1069.	1.5	36
1410	T cell exhaustion during persistent viral infections. <i>Virology</i> , 2015, 479-480, 180-193.	1.1	251
1411	CD40 Is Required for Protective Immunity against Liver Stage Plasmodium Infection. <i>Journal of Immunology</i> , 2015, 194, 2268-2279.	0.4	25

#	ARTICLE	IF	CITATIONS
1412	Antibody Effector Functions Mediated by Fc γ 3-Receptors Are Compromised during Persistent Viral Infection. <i>Immunity</i> , 2015, 42, 367-378.	6.6	59
1413	Criteria for Dendritic Cell Receptor Selection for Efficient Antibody-Targeted Vaccination. <i>Journal of Immunology</i> , 2015, 194, 2696-2705.	0.4	63
1414	CD40L Induces Functional Tunneling Nanotube Networks Exclusively in Dendritic Cells Programmed by Mediators of Type 1 Immunity. <i>Journal of Immunology</i> , 2015, 194, 1047-1056.	0.4	47
1415	Regulation of the Neurodegenerative Process Associated to Parkinson's Disease by CD4+ T-cells. <i>Journal of NeuroImmune Pharmacology</i> , 2015, 10, 561-575.	2.1	54
1416	Immune outcomes in the liver: Is CD8 T cell fate determined by the environment?. <i>Journal of Hepatology</i> , 2015, 63, 1005-1014.	1.8	45
1417	Role of CD154 in cancer pathogenesis and immunotherapy. <i>Cancer Treatment Reviews</i> , 2015, 41, 431-440.	3.4	23
1418	Inflammation and cancer: advances and new agents. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 584-596.	12.5	901
1419	An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy. <i>Oncolmmunology</i> , 2015, 4, e976052.	2.1	92
1420	Anti-CD40-induced inflammatory E-cadherin+ dendritic cells enhance T cell responses and antitumour immunity in murine Lewis lung carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 11.	3.5	13
1421	Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 325-336.	2.0	3
1422	Innate and Adoptive Immune Cells Contribute to Natural Resistance to Systemic Metastasis of B16 Melanoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 72-78.	0.7	5
1423	Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer. <i>Oncolmmunology</i> , 2015, 4, e968480.	2.1	25
1424	Vaccination strategies in lymphoproliferative disorders: Failures and successes. <i>Leukemia Research</i> , 2015, 39, 1006-1019.	0.4	10
1425	An optimized peptide vaccine strategy capable of inducing multivalent CD8 ⁺ T cell responses with potent antitumor effects. <i>Oncolmmunology</i> , 2015, 4, e1043504.	2.1	24
1426	Generation of a soluble recombinant trimeric form of bovine CD40L and its potential use as a vaccine adjuvant in cows. <i>Veterinary Immunology and Immunopathology</i> , 2015, 168, 1-13.	0.5	4
1427	A Lymphotoxin/Type I IFN Axis Programs CD8+ T Cells To Infiltrate a Self-Tissue and Propagate Immunopathology. <i>Journal of Immunology</i> , 2015, 195, 4650-4659.	0.4	5
1428	CD8 T-cell recognition of acquired alloantigen promotes acute allograft rejection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 12788-12793.	3.3	70
1429	Robust Anti-viral Immunity Requires Multiple Distinct T Cell-Dendritic Cell Interactions. <i>Cell</i> , 2015, 162, 1322-1337.	13.5	299

#	ARTICLE	IF	CITATIONS
1430	Experimental myositis inducible with transfer of dendritic cells presenting a skeletal muscle C protein-derived CD8 epitope peptide. <i>International Immunology</i> , 2015, 27, 327-332.	1.8	10
1431	Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes. <i>Mucosal Immunology</i> , 2015, 8, 211-220.	2.7	41
1432	Immunological Profiles in HIV Positive Patients with or without Opportunistic Infections and the Influence of Highly Active Antiretroviral Therapy: A Systematic Review and Update. <i>Journal of Clinical & Cellular Immunology</i> , 2016, 7, .	1.5	2
1433	Extracellular HSPs: The Complicated Roles of Extracellular HSPs in Immunity. <i>Frontiers in Immunology</i> , 2016, 7, 159.	2.2	155
1434	Unraveling the Role of Allo-Antibodies and Transplant Injury. <i>Frontiers in Immunology</i> , 2016, 7, 432.	2.2	15
1435	Increased CD40 Expression Enhances Early STING-Mediated Type I Interferon Response and Host Survival in a Rodent Malaria Model. <i>PLoS Pathogens</i> , 2016, 12, e1005930.	2.1	29
1436	CD4 T Cells in Antitumor Immunity. , 2016, , 441-450.		2
1437	CD4 ⁺ T cell help amplifies innate signals for primary CD8 ⁺ T cell immunity. <i>Immunological Reviews</i> , 2016, 272, 52-64.	2.8	98
1438	Lymph node – an organ for T cell activation and pathogen defense. <i>Immunological Reviews</i> , 2016, 271, 200-220.	2.8	109
1439	Dendritic cell function and pathogen-specific T cell immunity are inhibited in mice administered levonorgestrel prior to intranasal <i>Chlamydia trachomatis</i> infection. <i>Scientific Reports</i> , 2016, 6, 37723.	1.6	8
1440	CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy. <i>Journal of Immunology</i> , 2016, 197, 179-187.	0.4	48
1441	Suppression of inducible CD4 regulatory cells by MHC class I-restricted human tumor epitope specific TCR engineered multifunctional CD4 T cells. <i>Human Immunology</i> , 2016, 77, 905-911.	1.2	1
1442	Blimp-1-mediated CD4 T cell exhaustion causes CD8 T cell dysfunction during chronic toxoplasmosis. <i>Journal of Experimental Medicine</i> , 2016, 213, 1799-1818.	4.2	73
1443	CD40L expression by CD4 ⁺ but not CD8 ⁺ T cells regulates antiviral immune responses in acute LCMV infection in mice. <i>European Journal of Immunology</i> , 2016, 46, 2566-2573.	1.6	13
1444	Effects of kinsenoside, a potential immunosuppressive drug for autoimmune hepatitis, on dendritic cells/CD8 ⁺ T cells communication in mice. <i>Hepatology</i> , 2016, 64, 2135-2150.	3.6	39
1445	CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 10956-10961.	3.3	106
1446	Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy. <i>Biomaterials</i> , 2016, 104, 310-322.	5.7	114
1447	Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8 ⁺ T Cells. <i>Cancer Immunology Research</i> , 2016, 4, 621-630.	1.6	50

#	ARTICLE	IF	CITATIONS
1448	CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. <i>Cell Reports</i> , 2016, 15, 2719-2732.	2.9	217
1449	The multifaceted role of CD4+ T cells in CD8+ T cell memory. <i>Nature Reviews Immunology</i> , 2016, 16, 102-111.	10.6	440
1450	Lipidomic and metabolomic characterization of a genetically modified mouse model of the early stages of human type 1 diabetes pathogenesis. <i>Metabolomics</i> , 2016, 12, 13.	1.4	45
1451	Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 655-674.	1.4	21
1452	T Cell Help Amplifies Innate Signals in CD8 + DCs for Optimal CD8 + T Cell Priming. <i>Cell Reports</i> , 2016, 14, 586-597.	2.9	62
1453	Light sheet fluorescence microscopy for in situ cell interaction analysis in mouse lymph nodes. <i>Journal of Immunological Methods</i> , 2016, 431, 1-10.	0.6	27
1454	Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8+ and CD4+ T Cells. <i>EBioMedicine</i> , 2016, 5, 46-58.	2.7	59
1455	Linked in: immunologic membrane nanotube networks. <i>Journal of Leukocyte Biology</i> , 2016, 100, 81-94.	1.5	30
1456	Spontaneous Protein Adsorption on Graphene Oxide Nanosheets Allowing Efficient Intracellular Vaccine Protein Delivery. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 1147-1155.	4.0	99
1457	Immunotherapy and tumor microenvironment. <i>Cancer Letters</i> , 2016, 370, 85-90.	3.2	242
1458	CD4+ T-cell dependence of primary CD8+ T-cell response against vaccinia virus depends upon route of infection and viral dose. <i>Cellular and Molecular Immunology</i> , 2016, 13, 82-93.	4.8	24
1459	Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway. <i>Cellular and Molecular Immunology</i> , 2017, 14, 529-545.	4.8	30
1460	Designing therapeutic cancer vaccines by mimicking viral infections. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 203-213.	2.0	36
1461	Inhibition of dopamine receptor D3 signaling in dendritic cells increases antigen cross-presentation to CD8+ T-cells favoring anti-tumor immunity. <i>Journal of Neuroimmunology</i> , 2017, 303, 99-107.	1.1	38
1462	MHC class II restricted neoantigen: A promising target in tumor immunotherapy. <i>Cancer Letters</i> , 2017, 392, 17-25.	3.2	67
1463	Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 969-977.	2.0	22
1464	Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines. <i>Immunobiology</i> , 2017, 222, 989-997.	0.8	34
1465	Deficiency of transcription factor RelB perturbs myeloid and DC development by hematopoietic-extrinsic mechanisms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3957-3962.	3.3	31

#	ARTICLE	IF	CITATIONS
1466	Engaging Natural Killer T Cells as “Universal Helpers”™ for Vaccination. <i>Drugs</i> , 2017, 77, 1-15.	4.9	29
1467	Liver sinusoidal endothelial cell cross-priming is supported by CD4 T cell-derived IL-2. <i>Journal of Hepatology</i> , 2017, 66, 978-986.	1.8	16
1468	Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 175-186.	1.1	96
1469	Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy. <i>Immunotherapy</i> , 2017, 9, 71-82.	1.0	5
1470	Development of a Novel CD4+ TCR Transgenic Line That Reveals a Dominant Role for CD8+ Dendritic Cells and CD40 Signaling in the Generation of Helper and CTL Responses to Blood-Stage Malaria. <i>Journal of Immunology</i> , 2017, 199, 4165-4179.	0.4	37
1471	Intradermal Immunization with rAAV1 Vector Induces Robust Memory CD8+ T Cell Responses Independently of Transgene Expression in DCs. <i>Molecular Therapy</i> , 2017, 25, 2309-2322.	3.7	5
1472	Vaccines targeting helper T cells for cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2017, 47, 85-92.	2.4	145
1473	Cancer Immunity and Immune Evasion Mechanisms. , 2017, , 195-220.		1
1474	Conventional CD4+ T cells present bacterial antigens to induce cytotoxic and memory CD8+ T cell responses. <i>Nature Communications</i> , 2017, 8, 1591.	5.8	26
1475	Histone Acetylation and the Regulation of Major Histocompatibility Class II Gene Expression. <i>Advances in Protein Chemistry and Structural Biology</i> , 2017, 106, 71-111.	1.0	11
1476	Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity. <i>Cancer Immunology Research</i> , 2017, 5, 1109-1121.	1.6	124
1477	Pulmonary immunity to viruses. <i>Clinical Science</i> , 2017, 131, 1737-1762.	1.8	42
1478	Listeria monocytogenes-Induced Cell Death Inhibits the Generation of Cell-Mediated Immunity. <i>Infection and Immunity</i> , 2017, 85, .	1.0	20
1479	Host Defense Mechanisms Against Viruses. , 2017, , 1175-1197.e7.		2
1480	Liver and pancreas transplantation immunobiology. , 2017, , 1726-1736.e3.		0
1481	IL-2-Mediated In Vivo Expansion of Regulatory T Cells Combined with CD154“CD40 Co-Stimulation Blockade but Not CTLA-4 Ig Prolongs Allograft Survival in Naive and Sensitized Mice. <i>Frontiers in Immunology</i> , 2017, 8, 421.	2.2	9
1482	Exploiting Antitumor Immunotherapeutic Novel Strategies by Deciphering the Cross Talk between Invariant NKT Cells and Dendritic Cells. <i>Frontiers in Immunology</i> , 2017, 8, 886.	2.2	19
1483	CD40L Expression Allows CD8+ T Cells to Promote Their Own Expansion and Differentiation through Dendritic Cells. <i>Frontiers in Immunology</i> , 2017, 8, 1484.	2.2	37

#	ARTICLE	IF	CITATIONS
1484	Spontaneous Activation of Antigen-presenting Cells by Genes Encoding Truncated Homo-Oligomerizing Derivatives of CD40. <i>Journal of Immunotherapy</i> , 2017, 40, 39-50.	1.2	12
1485	The function and dysfunction of memory CD8 ⁺ T cells in tumor immunity. <i>Immunological Reviews</i> , 2018, 283, 194-212.	2.8	121
1486	Dysregulated T cells in multiple sclerosis. <i>Clinical and Experimental Neuroimmunology</i> , 2018, 9, 20-29.	0.5	23
1487	Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas. <i>Pancreas</i> , 2018, 47, 142-157.	0.5	19
1488	Innate and adaptive T cells in influenza disease. <i>Frontiers of Medicine</i> , 2018, 12, 34-47.	1.5	67
1489	Peptide-Based Therapeutic Cancer Vaccines. , 2018, , 249-261.		2
1490	Combined sublethal irradiation and agonist anti-CD40 enhance donor T cell accumulation and control of autochthonous murine pancreatic tumors. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 639-652.	2.0	7
1491	CD40 Mediates Maturation of Thymic Dendritic Cells Driven by Self-Reactive CD4 ⁺ Thymocytes and Supports Development of Natural Regulatory T Cells. <i>Journal of Immunology</i> , 2018, 200, 1399-1412.	0.4	22
1492	The opposing roles of CD4 ⁺ T cells in anti-tumour immunity. <i>Immunology</i> , 2018, 154, 582-592.	2.0	92
1493	Cancer vaccines: translation from mice to human clinical trials. <i>Current Opinion in Immunology</i> , 2018, 51, 111-122.	2.4	39
1494	Development, Diversity, and Function of Dendritic Cells in Mouse and Human. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028613.	2.3	71
1495	Enhanced immune response induced by P5 HER2/neu-derived peptide-pulsed dendritic cells as a preventive cancer vaccine. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 558-567.	1.6	15
1496	Cytokines in Cancer Immunotherapy. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028472.	2.3	305
1497	Susceptibility of dendritic cells from individuals with schistosomiasis to infection by <i>Leishmania braziliensis</i> . <i>Molecular Immunology</i> , 2018, 93, 173-183.	1.0	6
1498	T cell Allorecognition Pathways in Solid Organ Transplantation. <i>Frontiers in Immunology</i> , 2018, 9, 2548.	2.2	154
1499	Comparison of Protein and Peptide Targeting for the Development of a CD169-Based Vaccination Strategy Against Melanoma. <i>Frontiers in Immunology</i> , 2018, 9, 1997.	2.2	16
1500	New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661879413.	1.0	35
1501	Tumor Necrosis Factor Receptor Superfamily in T Cell Priming and Effector Function. <i>Advances in Immunology</i> , 2018, 140, 21-57.	1.1	17

#	ARTICLE	IF	CITATIONS
1502	Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. <i>Frontiers in Immunology</i> , 2018, 9, 1878.	2.2	127
1503	Generation of TCR-Expressing Innate Lymphoid-like Helper Cells that Induce Cytotoxic T Cell-Mediated Anti-leukemic Cell Response. <i>Stem Cell Reports</i> , 2018, 10, 1935-1946.	2.3	21
1504	HMGB1 released from intestinal epithelia damaged by cholera toxin adjuvant contributes to activation of mucosal dendritic cells and induction of intestinal cytotoxic T lymphocytes and IgA. <i>Cell Death and Disease</i> , 2018, 9, 631.	2.7	24
1505	CD4+ T cell help in cancer immunology and immunotherapy. <i>Nature Reviews Immunology</i> , 2018, 18, 635-647.	10.6	1,030
1506	Phenotypic and Functional Changes of Peripheral Ly6C+ T Regulatory Cells Driven by Conventional Effector T Cells. <i>Frontiers in Immunology</i> , 2018, 9, 437.	2.2	14
1507	Design of Gold Nanoparticles in Dendritic Cell-Based Vaccines. <i>Particle and Particle Systems Characterization</i> , 2018, 35, 1800109.	1.2	13
1508	Modifying clonal selection theory with a probabilistic cell. <i>Immunological Reviews</i> , 2018, 285, 249-262.	2.8	19
1509	Cytokines in the Treatment of Cancer. <i>Journal of Interferon and Cytokine Research</i> , 2019, 39, 6-21.	0.5	315
1510	Therapeutic cancer vaccine: building the future from lessons of the past. <i>Seminars in Immunopathology</i> , 2019, 41, 69-85.	2.8	56
1511	Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice. <i>European Journal of Immunology</i> , 2019, 49, 2083-2094.	1.6	8
1512	Tuning the Tumor Myeloid Microenvironment to Fight Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1611.	2.2	96
1513	New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5). <i>ESMO Open</i> , 2019, 4, e000510.	2.0	65
1514	STAT3 Activation in Combination with NF-KappaB Inhibition Induces Tolerogenic Dendritic Cells with High Therapeutic Potential to Attenuate Collagen-Induced Arthritis. <i>Journal of Immunology Research</i> , 2019, 2019, 1-12.	0.9	9
1515	Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in the Subretinal Space of the Cat Eye. <i>Stem Cells and Development</i> , 2019, 28, 1151-1166.	1.1	39
1516	Combinatorial Immunophenotyping of Cell Populations with an Electronic Antibody Microarray. <i>Small</i> , 2019, 15, e1904732.	5.2	12
1517	A Viral Nanoparticle Cancer Vaccine Delays Tumor Progression and Prolongs Survival in a HER2 ⁺ Tumor Mouse Model. <i>Advanced Therapeutics</i> , 2019, 2, 1800139.	1.6	25
1518	Tertiary lymphoid structures in the era of cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 307-325.	12.8	879
1519	Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity. <i>Frontiers in Immunology</i> , 2019, 10, 1014.	2.2	74

#	ARTICLE	IF	CITATIONS
1520	Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1. <i>EBioMedicine</i> , 2019, 43, 295-306.	2.7	20
1521	Loss of Neurological Disease HSAN-I-Associated Gene SPTLC2 Impairs CD8+ T Cell Responses to Infection by Inhibiting T Cell Metabolic Fitness. <i>Immunity</i> , 2019, 50, 1218-1231.e5.	6.6	30
1522	GM-CSF Promotes Antitumor Immunity by Inducing Th9 Cell Responses. <i>Cancer Immunology Research</i> , 2019, 7, 498-509.	1.6	24
1523	CD4 ⁺ T help promotes influenza virus-specific CD8 ⁺ T cell memory by limiting metabolic dysfunction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 4481-4488.	3.3	42
1524	Immune Exhaustion: Past Lessons and New Insights from Lymphocytic Choriomeningitis Virus. <i>Viruses</i> , 2019, 11, 156.	1.5	32
1525	Single-cell analysis of CD8 T lymphocyte diversity during adaptive immunity. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2020, 12, e1475.	6.6	3
1526	Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions. <i>Journal of Virology</i> , 2019, 93, .	1.5	20
1527	CD40 Agonist Antibodies in Cancer Immunotherapy. <i>Annual Review of Medicine</i> , 2020, 71, 47-58.	5.0	327
1528	Simultaneous cognate epitope recognition by bovine CD4 and CD8 T cells is essential for primary expansion of antigen-specific cytotoxic T-cells following ex vivo stimulation with a candidate <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> peptide vaccine. <i>Vaccine</i> , 2020, 38, 2016-2025.	1.7	34
1529	CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity. <i>Cancer Immunology Research</i> , 2020, 8, 230-245.	1.6	30
1530	Design and application of oncolytic viruses for cancer immunotherapy. <i>Current Opinion in Biotechnology</i> , 2020, 65, 25-36.	3.3	84
1531	Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. <i>Cancer Letters</i> , 2020, 470, 126-133.	3.2	753
1532	Rationale for CD40 pathway blockade in autoimmune rheumatic disorders. <i>Lancet Rheumatology</i> , The, 2020, 2, e292-e301.	2.2	5
1533	Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model. , 2020, 8, e000772.		36
1534	Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy. <i>Pharmaceutics</i> , 2020, 12, 663.	2.0	24
1535	Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 375-403.	157.7	237
1536	Promoting the activation of T cells with glycopolymer-modified dendritic cells by enhancing cell interactions. <i>Science Advances</i> , 2020, 6, .	4.7	35
1537	Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer. <i>Seminars in Immunology</i> , 2020, 48, 101406.	2.7	44

#	ARTICLE	IF	CITATIONS
1538	CD103+ cDC1 and endogenous CD8+ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function. <i>Nature Communications</i> , 2020, 11, 6171.	5.8	20
1539	The Impact of Malaria Parasites on Dendritic Cell-T Cell Interaction. <i>Frontiers in Immunology</i> , 2020, 11, 1597.	2.2	15
1540	cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity. <i>Nature</i> , 2020, 584, 624-629.	13.7	298
1541	Diverse Routes of Allograft Tolerance Disruption by Memory T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 580483.	2.2	7
1542	Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	77
1543	sLeX Expression Delineates Distinct Functional Subsets of Human Blood Central and Effector Memory T Cells. <i>Journal of Immunology</i> , 2020, 205, 1920-1932.	0.4	3
1544	Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer. , 2020, 8, e001100.		18
1545	Oncolytic Immunotherapy: Can't Start a Fire Without a Spark. <i>Cytokine and Growth Factor Reviews</i> , 2020, 56, 94-101.	3.2	9
1546	A Critical Role of CD40 and CD70 Signaling in Conventional Type 1 Dendritic Cells in Expansion and Antitumor Efficacy of Adoptively Transferred Tumor-Specific T Cells. <i>Journal of Immunology</i> , 2020, 205, 1867-1877.	0.4	19
1547	Accelerator or Brake: Immune Regulators in Malaria. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 610121.	1.8	5
1548	The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma. <i>Annals of Pancreatic Cancer</i> , 2020, 3, 3-3.	1.2	2
1549	IL-15 in the Combination Immunotherapy of Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 868.	2.2	119
1550	MR1-Restricted T Cells Are Unprecedented Cancer Fighters. <i>Frontiers in Immunology</i> , 2020, 11, 751.	2.2	22
1551	Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity. <i>Cancer Cell</i> , 2020, 37, 850-866.e7.	7.7	42
1552	Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4441.	1.8	20
1553	Adjuvant Postoperative CD40 Agonist and PD-1 Antagonist Combination Therapy in Syngeneic Tongue Cancer Mouse Model. <i>Anticancer Research</i> , 2020, 40, 2707-2713.	0.5	1
1554	Dissecting cellular crosstalk by sequencing physically interacting cells. <i>Nature Biotechnology</i> , 2020, 38, 629-637.	9.4	187
1555	New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection. <i>Biomedicines</i> , 2020, 8, 55.	1.4	11

#	ARTICLE	IF	CITATIONS
1556	Harnessing neoantigen specific CD4 T cells for cancer immunotherapy. <i>Journal of Leukocyte Biology</i> , 2020, 107, 625-633.	1.5	40
1557	Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle. <i>Seminars in Cancer Biology</i> , 2020, 65, 38-50.	4.3	34
1558	CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation. <i>Scientific Reports</i> , 2020, 10, 342.	1.6	13
1559	Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials. <i>Immunity</i> , 2020, 52, 36-54.	6.6	127
1560	Insights into CD8 T Cell Activation and Exhaustion from a Mouse Gammaherpesvirus Model. <i>Viral Immunology</i> , 2020, 33, 215-224.	0.6	5
1561	Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	8
1562	Tumor-associated tertiary lymphoid structure predicts postoperative outcomes in patients with primary gastrointestinal stromal tumors. <i>Oncolmmunology</i> , 2020, 9, 1747339.	2.1	30
1563	Revisiting the role of CD4+ T cells in cancer immunotherapyâ€”new insights into old paradigms. <i>Cancer Gene Therapy</i> , 2021, 28, 5-17.	2.2	444
1564	An Improved DNA Vaccine Against Bovine Herpesvirus-1 Using CD40L and a Chemical Adjuvant Induces Specific Cytotoxicity in Mice. <i>Viral Immunology</i> , 2021, 34, 68-78.	0.6	5
1565	Macrophage-Based Approaches for Cancer Immunotherapy. <i>Cancer Research</i> , 2021, 81, 1201-1208.	0.4	327
1566	Highâ€”and lowâ€”molecularâ€”weight chitosan act as adjuvants during singleâ€”dose influenza A virus protein vaccination through distinct mechanisms. <i>Biotechnology and Bioengineering</i> , 2021, 118, 1224-1243.	1.7	14
1567	Organized immune cell interactions within tumors sustain a productive T-cell response. <i>International Immunology</i> , 2021, 33, 27-37.	1.8	8
1568	CD4 T Cell Help Prevents CD8 T Cell Exhaustion and Promotes Control of <i>Mycobacterium tuberculosis</i> </i>. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1569	Enhancing the Efficacy of Tumor Vaccines Based on Immune Evasion Mechanisms. <i>Frontiers in Oncology</i> , 2020, 10, 584367.	1.3	8
1570	Heterodimeric IL-15 in Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 837.	1.7	25
1571	HIV mRNA Vaccinesâ€”Progress and Future Paths. <i>Vaccines</i> , 2021, 9, 134.	2.1	45
1572	Targeting Innate Immunity in Cancer Therapy. <i>Vaccines</i> , 2021, 9, 138.	2.1	57
1574	Enhancing the immunogenicity of cancer vaccines by harnessing CLEC9A. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-5.	1.4	4

#	ARTICLE	IF	CITATIONS
1575	Agonistic Anti-CD40 Antibody Triggers an Acute Liver Crisis With Systemic Inflammation in Humanized Sickle Cell Disease Mice. <i>Frontiers in Immunology</i> , 2021, 12, 627944.	2.2	1
1576	Memory T-Cell Heterogeneity and Terminology. <i>Cold Spring Harbor Perspectives in Biology</i> , 2021, 13, a037929.	2.3	26
1577	Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 459-469.	2.0	27
1578	Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. <i>Nature Reviews Cancer</i> , 2021, 21, 298-312.	12.8	553
1580	CD8 ⁺ T-Cell Memory: The Why, the When, and the How. <i>Cold Spring Harbor Perspectives in Biology</i> , 2021, 13, a038661.	2.3	7
1581	Defining Immunogenic and Radioimmunogenic Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 667075.	1.3	22
1582	Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer. <i>Cancer Medicine</i> , 2021, 10, 3129-3138.	1.3	21
1583	Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment. <i>Cancer Letters</i> , 2021, 503, 151-162.	3.2	1
1584	CD4+ T Cells in Chronic Hepatitis B and T Cell-Directed Immunotherapy. <i>Cells</i> , 2021, 10, 1114.	1.8	27
1585	Delivery of nanoparticle antigens to antigen-presenting cells: from extracellular specific targeting to intracellular responsive presentation. <i>Journal of Controlled Release</i> , 2021, 333, 107-128.	4.8	22
1586	Designing biomaterials for the modulation of allogeneic and autoimmune responses to cellular implants in Type 1 Diabetes. <i>Acta Biomaterialia</i> , 2021, 133, 87-101.	4.1	22
1587	Inflammasomes in dendritic cells: Friend or foe?. <i>Immunology Letters</i> , 2021, 234, 16-32.	1.1	19
1588	Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Therapeutic Opportunities and Clinical Challenges. <i>Cancers</i> , 2021, 13, 2860.	1.7	39
1589	Emerging Treatment Strategies in Pancreatic Cancer. <i>Pancreas</i> , 2021, 50, 773-787.	0.5	3
1590	CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies. <i>Cellular and Molecular Immunology</i> , 2022, 19, 14-22.	4.8	31
1592	Mechanistic understanding of innate and adaptive immune responses in SARS-CoV-2 infection. <i>Molecular Immunology</i> , 2021, 135, 268-275.	1.0	15
1593	Possible Immunotherapeutic Strategies Based on Carcinogen-Dependent Subgroup Classification for Oral Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 717038.	1.6	2
1594	Dendritic cells in cancer immunology. <i>Cellular and Molecular Immunology</i> , 2022, 19, 3-13.	4.8	91

#	ARTICLE	IF	CITATIONS
1595	CD4 T cell help prevents CD8 T cell exhaustion and promotes control of Mycobacterium tuberculosis infection. Cell Reports, 2021, 36, 109696.	2.9	69
1596	Pharmacologically Modified Dendritic Cells: A Route to Tolerance-associated Genes. , 0, , 619-647.		1
1597	Role of CD4 T cell helper subsets in immune response and deviation of CD8 T cells in mice*. European Journal of Immunology, 2017, 47, 2059-2069.	1.6	5
1598	Antigen Processing and Presentation. , 2005, 123, 3-36.		2
1599	Peptide Vaccines Against Cancer. Cancer Treatment and Research, 2005, 123, 115-136.	0.2	15
1600	DNA Vaccination in Immunotherapy of Cancer. Cancer Treatment and Research, 2005, 123, 137-156.	0.2	12
1601	T Cell Memory. , 2006, 311, 85-115.		13
1602	T Cell Tolerance to Tumors and Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2007, 601, 357-368.	0.8	11
1603	The Lymphotoxin Pathway as a Novel Regulator of Dendritic Cell Function. Advances in Experimental Medicine and Biology, 2011, 691, 363-374.	0.8	2
1604	CD40L Pathway Blockade as an Approach to Immunotherapy. Advances in Experimental Medicine and Biology, 2001, 489, 135-152.	0.8	33
1605	Immunotherapy of Cancer by Dendritic Cell-Targeted Gene Transfer. , 2005, , 143-172.		2
1606	Balancing Tolerance and Immunity. Methods in Molecular Biology, 2007, 380, 25-46.	0.4	13
1607	Tolerogenic Dendritic Cells and Induction of T Suppressor Cells in Transplant Recipients. Methods in Molecular Biology, 2013, 1034, 359-371.	0.4	3
1608	Antigen in the Presence of DAMPs Induces Immunostimulatory Dendritic Cells to Promote Destructive Adaptive Immune Responses. , 2018, , 749-790.		2
1609	Immunocytotherapy. Current Topics in Microbiology and Immunology, 2002, 263, 43-65.	0.7	12
1610	Tolerance Induction Post In Utero Stem Cell Transplantation. , 2001, , 145-171.		10
1611	The Relationship of Inflammation and Initiation of Autoimmune Disease: Role of TNF Super Family Members. Current Topics in Microbiology and Immunology, 2002, 266, 1-9.	0.7	30
1612	Cross-Presentation of Cell-Associated Antigens by Dendritic Cells. Current Topics in Microbiology and Immunology, 2003, 276, 261-275.	0.7	30

#	ARTICLE	IF	CITATIONS
1613	Dendritic Cell-Based Immunotherapy. <i>Current Topics in Microbiology and Immunology</i> , 2003, 276, 163-197.	0.7	28
1615	Immunogenicity of tumour associated antigens. , 2001, , 1-26.		1
1617	Pathogenesis of Systemic Lupus Erythematosus. , 2009, , 1233-1262.		4
1618	Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms. <i>Cellular and Molecular Immunology</i> , 2020, 17, 576-586.	4.8	12
1619	Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8+ cytotoxic T-cell activation and antitumor immunity. , 0, .		1
1620	Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 3485-90.	3.3	101
1621	Mediators of Central Nervous System Damage During the Progression of Human T-Cell Leukemia Type I-Associated Myelopathy/Tropical Spastic Paraparesis. <i>Journal of NeuroVirology</i> , 2003, 9, 522-529.	1.0	2
1622	Genealogical Evidence for Positive Selection in the nef Gene of HIV-1. <i>Genetics</i> , 1999, 153, 1077-1089.	1.2	113
1623	COSTIMULATION PATHWAYS IN HOST IMMUNE RESPONSES TO ALLOGENEIC HEPATOCYTES ^{1,2} . <i>Transplantation</i> , 1998, 66, 1841-1845.	0.5	33
1624	CD40 LIGATION INDUCED PHENOTYPIC AND FUNCTIONAL EXPRESSION OF CD80 BY HUMAN CARDIAC MICROVASCULAR ENDOTHELIAL CELLS ¹ . <i>Transplantation</i> , 1999, 68, 430-439.	0.5	28
1625	INDUCTION OF XENOREACTIVE CD4+ T-CELL ANERGY BY SUPPRESSOR CD8+CD28 ^{???} T CELLS ¹ . <i>Transplantation</i> , 2000, 69, 1304-1310.	0.5	80
1626	HLA-C MISMATCHES INDUCE STRONG CYTOTOXIC T-CELL REACTIVITY IN THE PRESENCE OF AN ADDITIONAL DRB/DQB MISMATCH AND AFFECT NK CELL ^{???} MEDIATED ALLOREACTIVITY. <i>Transplantation</i> , 2001, 72, 923-929.	0.5	23
1627	KINETICS OF LEUKOCYTE AND MYELOID CELL TRAFFIC IN THE MURINE CORNEAL ALLOGRAFT RESPONSE ¹ . <i>Transplantation</i> , 2001, 72, 1292-1298.	0.5	32
1628	INDIRECT ALLORECOGNITION CAN PLAY AN IMPORTANT ROLE IN THE DEVELOPMENT OF TRANSPLANT ARTERIOSCLEROSIS ¹ . <i>Transplantation</i> , 2002, 73, 279-286.	0.5	38
1629	Blockade of costimulatory pathways of T-cell activation: the solution to acute and chronic rejection?. <i>Current Opinion in Nephrology and Hypertension</i> , 1999, 8, 675-680.	1.0	5
1630	Dendritic cells: expansion and differentiation with hematopoietic growth factors. <i>Current Opinion in Hematology</i> , 1999, 6, 135.	1.2	19
1631	Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus.. <i>Journal of General Virology</i> , 1999, 80, 187-193.	1.3	32
1632	Virus interactions with dendritic cells.. <i>Journal of General Virology</i> , 1999, 80, 823-833.	1.3	99

#	ARTICLE	IF	CITATIONS
1633	High numbers of IL-2-producing CD8+ T cells during viral infection: correlation with stable memory development. <i>Journal of General Virology</i> , 2002, 83, 2123-2133.	1.3	55
1636	CD4 + T cells support polyfunctionality of cytotoxic CD8 + T cells with memory potential in immunological control of tumor. <i>Cancer Science</i> , 2020, 111, 1958-1968.	1.7	19
1637	Dissecting the Immune Response to Moloney Murine Sarcoma/Leukemia Virus-Induced Tumors by Means of a DNA Vaccination Approach. <i>Journal of Virology</i> , 1999, 73, 2280-2287.	1.5	14
1638	Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Macaques by Using a Multiepitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen. <i>Journal of Virology</i> , 1999, 73, 7524-7532.	1.5	288
1639	The role of CD40-CD154 interaction in cell immunoregulation. , 2004, 11, 426.		1
1640	Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity. <i>Journal of Clinical Investigation</i> , 2002, 109, 261-267.	3.9	36
1641	Short-circuiting long-lived humoral immunity by the heightened engagement of CD40. <i>Journal of Clinical Investigation</i> , 2002, 109, 613-620.	3.9	76
1642	Rescue of CD8 T cell-mediated antimicrobial immunity with a nonspecific inflammatory stimulus. <i>Journal of Clinical Investigation</i> , 2002, 110, 1493-1501.	3.9	12
1643	EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. <i>Journal of Clinical Investigation</i> , 2001, 107, 121-130.	3.9	109
1644	CD4 T cell-mediated cardiac allograft rejection requires donor but not host MHC class II. <i>Journal of Clinical Investigation</i> , 2000, 106, 1003-1010.	3.9	167
1645	Emerging strategies for combination checkpoint modulators in cancer immunotherapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 3209-3218.	3.9	170
1646	Heterologous prime-boost vaccination protects against EBV antigen-expressing lymphomas. <i>Journal of Clinical Investigation</i> , 2019, 129, 2071-2087.	3.9	48
1647	Short-circuiting long-lived humoral immunity by the heightened engagement of CD40. <i>Journal of Clinical Investigation</i> , 2002, 109, 613-620.	3.9	54
1648	In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8+ T cell responses. <i>Journal of Clinical Investigation</i> , 2003, 111, 1673-1681.	3.9	77
1649	Blockade of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in control of SIV replication. <i>Journal of Clinical Investigation</i> , 2004, 113, 836-845.	3.9	32
1650	High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. <i>Journal of Clinical Investigation</i> , 2001, 108, 1677-1685.	3.9	72
1651	In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8+ T cell responses. <i>Journal of Clinical Investigation</i> , 2003, 111, 1673-1681.	3.9	123
1652	Blockade of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in control of SIV replication. <i>Journal of Clinical Investigation</i> , 2004, 113, 836-845.	3.9	41

#	ARTICLE	IF	CITATIONS
1653	Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. <i>Journal of Clinical Investigation</i> , 2008, 118, 1691-1699.	3.9	55
1654	Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. <i>Journal of Clinical Investigation</i> , 2010, 120, 4546-4557.	3.9	276
1655	Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndrome. <i>Journal of Clinical Investigation</i> , 1999, 103, 1151-1158.	3.9	101
1656	Asialo GM1+ CD8+ T cells play a critical role in costimulation blockade-resistant allograft rejection. <i>Journal of Clinical Investigation</i> , 1999, 104, 1715-1722.	3.9	329
1657	Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 1971-1984.	3.9	73
1658	Transfusion Medicine: New Clinical Applications of Cellular Immunotherapy. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 356-375.	0.9	1
1659	Transfusion Medicine: New Clinical Applications of Cellular Immunotherapy. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 356-375.	0.9	2
1660	Dendritic Cells Derived In Vitro From Acute Myelogenous Leukemia Cells Stimulate Autologous, Antileukemic T-Cell Responses. <i>Blood</i> , 1999, 93, 780-786.	0.6	6
1661	Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. <i>Blood</i> , 2000, 95, 3162-3167.	0.6	154
1662	Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. <i>Blood</i> , 2000, 95, 3162-3167.	0.6	21
1663	Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. <i>Blood</i> , 2000, 96, 91-99.	0.6	15
1664	Efficient priming of protein antigen-specific human CD4+ T cells by monocyte-derived dendritic cells. <i>Blood</i> , 2000, 96, 3490-3498.	0.6	27
1665	Ligation of E-cadherin on in vitro-generated immature Langerhans-type dendritic cells inhibits their maturation. <i>Blood</i> , 2000, 96, 4276-4284.	0.6	3
1666	Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes. <i>Blood</i> , 2000, 96, 647-654.	0.6	7
1667	Impaired function of circulating HIV-specific CD8+ T cells in chronic human immunodeficiency virus infection. <i>Blood</i> , 2000, 96, 3094-3101.	0.6	89
1668	DNA vaccination: antigen presentation and the induction of immunity. <i>Journal of Leukocyte Biology</i> , 2000, 68, 793-806.	1.5	187
1669	Selective expansion of perforin-positive CD8+ T cells by immature dendritic cells infected with live <i>Bacillus Calmette-Guérin</i> mycobacteria. <i>Journal of Leukocyte Biology</i> , 2002, 72, 115-124.	1.5	12
1670	Optimal induction of antigen-specific CD8+ T cell responses requires bystander cell participation. <i>Journal of Leukocyte Biology</i> , 2002, 72, 1164-1171.	1.5	7

#	ARTICLE	IF	CITATIONS
1671	The role of cDC1s in vivo: CD8 T cell priming through cross-presentation. <i>F1000Research</i> , 2017, 6, 98.	0.8	56
1672	Tumor-Shed PGE2 Impairs IL2R β c-Signaling to Inhibit CD4+ T Cell Survival: Regulation by Theaflavins. <i>PLoS ONE</i> , 2009, 4, e7382.	1.1	27
1673	CD4+ T Cell-Derived IL-2 Signals during Early Priming Advances Primary CD8+ T Cell Responses. <i>PLoS ONE</i> , 2009, 4, e7766.	1.1	34
1674	Liposome-Coupled Peptides Induce Long-Lived Memory CD8+ T Cells Without CD4+ T Cells. <i>PLoS ONE</i> , 2010, 5, e15091.	1.1	18
1675	Ex Vivo Expansion of Human CD8+ T Cells Using Autologous CD4+ T Cell Help. <i>PLoS ONE</i> , 2012, 7, e30229.	1.1	31
1676	CD154 and IL-2 Signaling of CD4+ T Cells Play a Critical Role in Multiple Phases of CD8+ CTL Responses Following Adenovirus Vaccination. <i>PLoS ONE</i> , 2012, 7, e47004.	1.1	12
1677	MELOE-1 Antigen Contains Multiple HLA Class II T Cell Epitopes Recognized by Th1 CD4+ T Cells from Melanoma Patients. <i>PLoS ONE</i> , 2012, 7, e51716.	1.1	10
1678	CD8 T Cell Memory Recall Is Enhanced by Novel Direct Interactions with CD4 T Cells Enabled by MHC Class II Transferred from APCs. <i>PLoS ONE</i> , 2013, 8, e56999.	1.1	27
1679	scFv from Antibody That Mimics gp43 Modulates the Cellular and Humoral Immune Responses during Experimental Paracoccidiodomycosis. <i>PLoS ONE</i> , 2015, 10, e0129401.	1.1	6
1680	NADPH Oxidase 1 Is Associated with Altered Host Survival and T Cell Phenotypes after Influenza A Virus Infection in Mice. <i>PLoS ONE</i> , 2016, 11, e0149864.	1.1	17
1681	Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7. <i>Cell Stress and Chaperones</i> , 2000, 5, 401.	1.2	35
1682	Tumors and the danger model.. <i>Acta Biochimica Polonica</i> , 2002, 49, 295-302.	0.3	16
1683	Cancer immunotherapy using cells modified with cytokine genes.. <i>Acta Biochimica Polonica</i> , 2003, 50, 613-624.	0.3	19
1684	The circadian clock regulates cisplatin-induced toxicity and tumor regression in melanoma mouse and human models. <i>Oncotarget</i> , 2018, 9, 14524-14538.	0.8	49
1685	Characterization of CD4+ T cells primed and boosted by MHCII primary uveal melanoma cell-based vaccines. <i>Oncotarget</i> , 2019, 10, 1812-1828.	0.8	7
1686	Mucosal Tolerance to Prevent Type 1 Diabetes: Can the Outcome Be Improved in Humans?. <i>Review of Diabetic Studies</i> , 2004, 1, 113-113.	0.5	16
1687	Immunity to avian influenza A viruses. <i>OIE Revue Scientifique Et Technique</i> , 2009, 28, 175-185.	0.5	12
1688	Immunotherapy of viral infections. <i>Immunotherapy</i> , 2009, 1, 691-711.	1.0	11

#	ARTICLE	IF	CITATIONS
1689	Expression of FasR, Fas-L and Bcl-2 in CD4+ and CD8+ subpopulations of T lymphocytes in the cord blood of healthy full-term newborns, is gender of influence?. <i>Advances in Medical Sciences</i> , 2009, 54, 99-103.	0.9	2
1691	Construction of recombinant eukaryotic expression plasmid containing murine CD40 ligand gene and its expression in H22 cells. <i>World Journal of Gastroenterology</i> , 2005, 11, 182.	1.4	6
1692	Mass Cytometry Defines Virus-Specific CD4+ T Cells in Influenza Vaccination. <i>ImmunoHorizons</i> , 2020, 4, 774-788.	0.8	3
1693	The Roles of CD4 ⁺ T Cells in Tumor Immunity. <i>ISRN Immunology</i> , 2011, 2011, 1-6.	0.7	33
1694	CD28/CTLA-4/B7 and CD40/CD40L costimulation and activation of regulatory T cells. <i>World Journal of Immunology</i> , 2014, 4, 63.	0.5	3
1695	Evaluation of CD40, its ligand CD40L and Bcl-2 in psoriatic patients. <i>Folia Histochemica Et Cytobiologica</i> , 2012, 50, 75-79.	0.6	11
1696	Immunity Versus Immunopathology in West Nile Virus Induced Encephalitis. , 0, , .		2
1697	T-Zell Immunreaktionen gegen Melanome – Rolle von CD4+ Lymphozyten. , 2000, , 479-481.		0
1698	Blockade of cytokine activity by soluble cytokine receptors. , 2000, , 157-176.		0
1699	The Hybrid Cell Vaccination Approach to Cancer Immunotherapy. , 2000, , 155-166.		1
1700	Glioma Immunology and Immunotherapy. <i>Neurosurgery</i> , 2000, 46, 778-792.	0.6	89
1701	Blockade of CD86 and CD40 induces alloantigen-specific immunoregulatory T cells that remain anergic even after reversal of hyporesponsiveness. <i>Blood</i> , 2000, 95, 3153-3161.	0.6	8
1702	Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures. <i>Blood</i> , 2000, 96, 2219-2225.	0.6	0
1703	ã, ã,ãf«ã,1è,ç,Žã®è,éšœã®³æ©Ÿãº: <i>Acta Hepatologica Japonica</i> , 2001, 42, 175-184.	0.0	0
1704	Immunology of Transplantation. , 2001, , 1403-1428.		0
1705	Cells of the monocyte/macrophage lineage. , 2001, , 263-274.		1
1706	Factors Contributing to Autoimmune Disease. <i>Advances in Experimental Medicine and Biology</i> , 2001, 490, 7-19.	0.8	0
1707	Principles of Genetic Immunization. , 2001, , 177-200.		1

#	ARTICLE	IF	CITATIONS
1708	Immunostimulatory DNA sequences help to eradicate intracellular pathogens. , 2001, , 147-152.		4
1709	Phagocytosis of apoptotic cells. , 2001, , 627-cp3.		0
1710	Introduction to Dendritic Cells. , 2002, , 167-177.		0
1711	Principles of Immunology. , 2002, , 3-27.		0
1712	Melanoma antigens recognized by CD4+ T cells. , 2003, , 141-158.		0
1713	Contrasting Roles of Dendritic Cells and B Cells in the Immune Control of Epstein-Barr Virus. Current Topics in Microbiology and Immunology, 2003, 276, 55-76.	0.7	6
1714	Dendritic Cells: Important Adjuvants During DNA Vaccination. , 2003, , 39-59.		2
1715	Mechanisms of CD40 Signaling in the Immune System. , 2003, , 319-322.		0
1716	Role of CD4 T lymphocytes in antitumor immunity. Advances in Cancer Research, 2003, 87, 195-249.	1.9	1
1717	Host Defense Mechanisms Against Viruses. , 2004, , 1490-1511.		0
1718	APPLICATION OF GENETICALLY ENGINEERED TUMOR-SPECIFIC TH1 CELLS TO ADOPTIVE TUMOR IMMUNOTHERAPY. Annals of Cancer Research and Therapy, 2004, 12, 71-86.	0.1	0
1720	Host-derived molecules as adjuvants. , 2006, , 35-55.		0
1721	Psoriasis: Etiopathogenesis. , 2007, , 37-47.		0
1722	Liver and Pancreatic Transplantation Immunobiology. , 2007, , 1693-1702.		0
1723	Approaches to the Induction of Tolerance. , 2008, , 361-382.		0
1724	Immunology of Transplantation. , 2008, , 1705-1736.		0
1725	Adenovirus-mediated CD40L gene therapy induced both humoral and cellular immunity against rat model of hepatocellular carcinoma. Cancer Science, 2008, , .	1.7	0
1726	Targeting Immunological Synapse: New Horizons in Immunotherapy for Cancer. , 2009, , 575-590.		0

#	ARTICLE	IF	CITATIONS
1727	CD40 Stimulation and Antitumor Effects. , 2009, , 227-239.		0
1728	Transplantation Immunobiology. , 2009, , 1835-1866.		1
1730	The Prognostic Significance of Tumor-Infiltrating Lymphocytes. , 2010, , 385-407.		0
1731	Cell-Mediated Defense against Infection. , 2010, , 129-150.		1
1732	Host Defense Mechanisms Against Viruses. , 2011, , 1570-1595.		0
1733	Treatment of Melanoma with Agonist Immune Costimulatory Agents. , 2012, , 307-331.		0
1734	Liver and pancreas transplantation immunobiology. , 2012, , 1652-1661.e3.		0
1735	p53 Immunotherapy of Cancer. , 2013, , 275-287.		0
1736	Activation of Immune-Mediated Tumor Cell Death by Chemotherapy. , 2013, , 373-399.		0
1737	Recognition of Foreign Antigen and Foreign Major Histocompatibility Complex. , 0, , 175-189.		0
1738	Dendritic Cells and their Clinical Applications. Cancer Treatment and Research, 1999, 101, 283-310.	0.2	0
1739	Protective Versus Harmful Responses and Immune Regulation. , 1999, , 1-6.		0
1740	Antigen-delivery system for CTL vaccine.. Drug Delivery System, 1999, 14, 459-469.	0.0	0
1741	Cellular Immune Responses to Xenografts. , 0, , 99-115.		0
1742	Overcoming Cancer Tolerance with Immune Checkpoint Blockade. , 2015, , 87-129.		0
1743	Cytotoxic T Lymphocytes and Their Granzymes: An Overview. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 91-112.	0.1	1
1744	T-Lymphocytes. , 2016, , 167-198.		0
1745	CD4 T Cell Immunity to Viral Infection. , 2016, , 291-299.		1

#	ARTICLE	IF	CITATIONS
1747	Targeting the Tumor Microenvironment. , 2018, , 235-256.		0
1748	Tumor-Promoting/Associated Inflammation and the Microenvironment: A State of the Science and New Horizons. , 0, , 473-510.		0
1749	Modification of Antitumor Immunity by Supernatants of oncoytic Herpes Simplex Virus-Infected Squamous Cell Carcinoma Cells. International Journal of Vaccine Research, 2018, 3, 1-6.	0.4	1
1750	Treatment of Advanced Pancreatic Carcinoma. , 2019, , 255-268.		0
1751	Overcoming Cancer Tolerance with Immune Checkpoint Blockade. , 2021, , 85-128.		0
1752	Cancer Immunology and Immuno-Oncology (Innate vs. Adaptive Cell Immunity). Digestive Disease Interventions, 2021, 05, 032-049.	0.3	0
1753	Immune modulation by CD40L blockade. , 2008, , 71-86.		0
1754	Thymic Accessory Cells, Including Dendritic Type Antigen Presenting Cells, within the Mammalian Thymic Microenvironment. , 2004, , 115-145.		0
1756	DNA Vaccines Against Cancer. , 2007, , 193-215.		0
1757	High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. Journal of Clinical Investigation, 2001, 108, 1677-1685.	3.9	30
1758	Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity. Journal of Clinical Investigation, 2002, 109, 261-267.	3.9	17
1759	Rescue of CD8 T cell-mediated antimicrobial immunity with a nonspecific inflammatory stimulus. Journal of Clinical Investigation, 2002, 110, 1493-1501.	3.9	6
1760	Wilms' Tumor 1 (WT1): The Vaccine for Cancer. Journal of Immunotherapy and Precision Oncology, 2020, 3, 165-171.	0.6	6
1766	Mechanism of dichotomy between CD8+ responses elicited by apoptotic and necrotic cells. Cancer Immunity, 2013, 13, 2.	3.2	6
1769	Silencing c-Kit expression in human DCs suppresses Th2, Th17 response but enhances Th1 response. American Journal of Translational Research (discontinued), 2015, 7, 1499-509.	0.0	1
1771	Platelets: essential components of the immune system. Current Trends in Immunology, 2015, 16, 65-78.	4.0	83
1772	Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges. Frontiers in Cell and Developmental Biology, 2021, 9, 775462.	1.8	59
1773	The Emerging Interplay Between Recirculating and Tissue-Resident Memory T Cells in Cancer Immunity: Lessons Learned From PD-1/PD-L1 Blockade Therapy and Remaining Gaps. Frontiers in Immunology, 2021, 12, 755304.	2.2	2

#	ARTICLE	IF	CITATIONS
1774	Donor-derived alloantigen-presenting cells persist in the liver allograft during tolerance induction. <i>Transplant International</i> , 2000, 13, 12-20.	0.8	8
1775	An Overview of the Tumor Microenvironment and Response to Immunotherapy in Gastrointestinal Malignancies. , 2021, , 3-28.		0
1776	Regression of Triple-Negative Breast Cancer in a Patient-Derived Xenograft Mouse Model by Monoclonal Antibodies against IL-12 p40 Monomer. <i>Cells</i> , 2022, 11, 259.	1.8	6
1777	The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity. <i>Cancers</i> , 2022, 14, 299.	1.7	11
1778	Neoantigens as potential vaccines in hepatocellular carcinoma. , 2022, 10, e003978.		16
1779	Direct and indirect engagement of dendritic cell function by antibodies developed for cancer therapy. <i>Clinical and Experimental Immunology</i> , 2022, 209, 64-71.	1.1	5
1780	IL15 and Anti-“PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 2082-2093.	3.2	4
1781	Aluminum nanoparticles deliver a dual-epitope peptide for enhanced anti-tumor immunotherapy. <i>Journal of Controlled Release</i> , 2022, 344, 134-146.	4.8	21
1782	Convection-enhanced delivery for high-grade glioma. <i>Neuro-Oncology Practice</i> , 2022, 9, 24-34.	1.0	6
1783	Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment. <i>Cancers</i> , 2022, 14, 141.	1.7	8
1792	DCs at the center of help: Origins and evolution of the three-cell-type hypothesis. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	18
1793	Impact of Early Viral Kinetics on T-Cell Reactivity during Antiviral Therapy in Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2007, 12, 705-718.	0.6	35
1795	CD4 ⁺ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy. , 2022, 10, e004022.		7
1796	Immunocyte Populations Observed from Birth to Weaning in Blood, Spleen and Mesenteric Lymph Nodes of Piglets. <i>Animals</i> , 2022, 12, 1445.	1.0	1
1799	Recent Advances and Challenges in Uveal Melanoma Immunotherapy. <i>Cancers</i> , 2022, 14, 3094.	1.7	23
1801	Mapping the Tumor Microenvironment in TNBC and Deep Exploration for M1 Macrophages-Associated Prognostic Genes. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1802	Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms. <i>Pharmaceutics</i> , 2022, 14, 1448.	2.0	6
1803	The IL-2A receptor pathway and its role in lymphocyte differentiation and function. <i>Cytokine and Growth Factor Reviews</i> , 2022, 67, 66-79.	3.2	14

#	ARTICLE	IF	CITATIONS
1804	Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 398-409.	0.8	4
1805	The paradox of radiation and T cells in tumors. <i>Neoplasia</i> , 2022, 31, 100808.	2.3	9
1806	Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes. <i>Frontiers in Oral Health</i> , 0, 3, .	1.2	3
1807	The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. <i>Hepatology</i> , 2023, 77, 1773-1796.	3.6	101
1808	Immune profiles in mouse brain and testes infected by Zika virus with variable pathogenicity. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	2
1809	Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive Macrophages. <i>Cancer Research</i> , 2022, 82, 3785-3801.	0.4	9
1810	Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2022, 14, 4209.	1.7	9
1811	Exogenous signaling repairs defective T cell signaling inside the tumor microenvironment for better immunity. <i>JCI Insight</i> , 2022, 7, .	2.3	1
1812	Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64). , 2022, 10, e005424.		7
1813	The implications of IL-15 trans-presentation on the immune response. <i>Advances in Immunology</i> , 2022, , 103-132.	1.1	5
1814	Class II transactivator induces expression of MHC-I and MHC-II in transmissible Tasmanian devil facial tumours. <i>Open Biology</i> , 2022, 12, .	1.5	4
1815	Mechanisms of CD40-dependent cDC1 licensing beyond costimulation. <i>Nature Immunology</i> , 2022, 23, 1536-1550.	7.0	23
1819	Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies. , 2022, 10, e005018.		6
1820	Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity. <i>European Journal of Immunology</i> , 2023, 53, .	1.6	5
1822	Durable CD8 T Cell Memory against SARS-CoV-2 by Prime/Boost and Multi-Dose Vaccination: Considerations on Inter-Dose Time Intervals. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14367.	1.8	4
1823	A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2023, 41, 93-104.	1.2	6
1824	Retrovirally Transduced Bone Marrow-Derived Dendritic Cells Require CD4+ T Cell Help to Elicit Protective and Therapeutic Antitumor Immunity. <i>Journal of Immunology</i> , 1999, 162, 144-151.	0.4	64
1825	Specific Suppression of Human CD4+ Th Cell Responses to Pig MHC Antigens by CD8+CD28 ^{hi} Regulatory T Cells. <i>Journal of Immunology</i> , 1998, 161, 5193-5202.	0.4	148

#	ARTICLE	IF	CITATIONS
1826	Acute Hepatotoxicity of <i>Pseudomonas aeruginosa</i> Exotoxin A in Mice Depends on T Cells and TNF. <i>Journal of Immunology</i> , 1998, 161, 5745-5754.	0.4	71
1827	The Role of the CD40 Pathway in Alloantigen-Induced Hyporesponsiveness In Vivo. <i>Journal of Immunology</i> , 1998, 161, 5331-5337.	0.4	57
1828	Cutting Edge Commentary: Immune Responses in the Absence of Costimulation: Viruses Know the Trick. <i>Journal of Immunology</i> , 1998, 161, 5791-5794.	0.4	92
1829	Cutting Edge: Linked Suppression of Skin Graft Rejection Can Operate Through Indirect Recognition. <i>Journal of Immunology</i> , 1998, 161, 5813-5816.	0.4	120
1830	Cytotoxic T Cell Responses to DNA Vaccination: Dependence on Antigen Presentation via Class II MHC. <i>Journal of Immunology</i> , 1998, 161, 6532-6536.	0.4	92
1831	CD40 Activation Boosts T Cell Immunity In Vivo by Enhancing T Cell Clonal Expansion and Delaying Peripheral T Cell Deletion. <i>Journal of Immunology</i> , 1999, 162, 2024-2034.	0.4	69
1832	Development of CD8+ Effector T Cells Is Differentially Regulated by IL-18 and IL-12. <i>Journal of Immunology</i> , 1999, 162, 3202-3211.	0.4	95
1833	Differential Effects of CD40 Ligand/Trimer Stimulation on the Ability of Dendritic Cells to Replicate and Transmit HIV Infection: Evidence for CC-Chemokine-Dependent and -Independent Mechanisms. <i>Journal of Immunology</i> , 1999, 162, 3711-3717.	0.4	45
1834	TGF- β 1 Prevents the Noncognate Maturation of Human Dendritic Langerhans Cells. <i>Journal of Immunology</i> , 1999, 162, 4567-4575.	0.4	268
1835	Cutting Edge: Sustained Expansion of CD8+ T Cells Requires CD154 Expression by Th Cells in Acute Graft Versus Host Disease. <i>Journal of Immunology</i> , 1999, 162, 4373-4376.	0.4	78
1836	Pancreatic Infiltration But Not Diabetes Occurs in the Relative Absence of MHC Class II-Restricted CD4 T Cells: Studies Using NOD/CIITA-Deficient Mice. <i>Journal of Immunology</i> , 1999, 162, 4576-4588.	0.4	53
1837	Utilization of MHC Class I Transgenic Mice for Development of Minigene DNA Vaccines Encoding Multiple HLA-Restricted CTL Epitopes. <i>Journal of Immunology</i> , 1999, 162, 3915-3925.	0.4	131
1838	Triggering of Murine NK Cells by CD40 and CD86 (B7-2). <i>Journal of Immunology</i> , 1999, 162, 5910-5916.	0.4	59
1839	Induction of Primary Human CD8+ T Lymphocyte Responses In Vitro Using Dendritic Cells. <i>Journal of Immunology</i> , 1999, 162, 5197-5204.	0.4	38
1840	Human Vascular Endothelial Cells Favor Clonal Expansion of Unusual Alloreactive CTL. <i>Journal of Immunology</i> , 1999, 162, 7022-7030.	0.4	46
1841	Mice Deficient in CD4 T Cells Have Only Transiently Diminished Levels of IFN- γ , Yet Succumb to Tuberculosis. <i>Journal of Immunology</i> , 1999, 162, 5407-5416.	0.4	367
1842	Maturation of Dendritic Cells Accompanies High-Efficiency Gene Transfer by a CD40-Targeted Adenoviral Vector. <i>Journal of Immunology</i> , 1999, 162, 6378-6383.	0.4	140
1843	Impaired Ability of MHC Class II ⁺ Dendritic Cells to Provide Tumor Protection is Rescued by CD40 Ligation. <i>Journal of Immunology</i> , 1999, 163, 77-81.	0.4	41

#	ARTICLE	IF	CITATIONS
1844	Activation of the Janus Kinase 3-STAT5a Pathway After CD40 Triggering of Human Monocytes But Not of Resting B Cells. <i>Journal of Immunology</i> , 1999, 163, 787-793.	0.4	33
1845	Priming MHC-I-Restricted Cytotoxic T Lymphocyte Responses to Exogenous Hepatitis B Surface Antigen Is CD4+ T Cell Dependent. <i>Journal of Immunology</i> , 1999, 163, 1880-1887.	0.4	77
1846	Normal Immune Function of Monocyte-Derived Dendritic Cells from HIV-Infected Individuals: Implications for Immunotherapy. <i>Journal of Immunology</i> , 1999, 163, 1666-1673.	0.4	59
1847	CD28, IL-2-Independent Costimulatory Pathways for CD8 T Lymphocyte Activation. <i>Journal of Immunology</i> , 1999, 163, 1133-1142.	0.4	61
1848	On the Lifespan of Virgin T Lymphocytes. <i>Journal of Immunology</i> , 1999, 163, 1253-1257.	0.4	43
1849	CD40-CD40 Ligand Costimulation Is Required for Generating Antiviral CD4 T Cell Responses But Is Dispensable for CD8 T Cell Responses. <i>Journal of Immunology</i> , 1999, 163, 3194-3201.	0.4	127
1850	Disruption of CD154:CD40 Blocks Generation of Allograft Immunity Without Affecting APC Activation. <i>Journal of Immunology</i> , 1999, 163, 2470-2477.	0.4	27
1851	Role of CD28 in the Generation of Effector and Memory Responses Required for Resistance to <i>Toxoplasma gondii</i> . <i>Journal of Immunology</i> , 1999, 163, 3344-3353.	0.4	54
1852	Adjuvant Effect of IL-12: Conversion of Peptide Antigen Administration from Tolerizing to Immunizing for CD8+ T Cells In Vivo. <i>Journal of Immunology</i> , 1999, 163, 2561-2567.	0.4	110
1853	Autocrine IL-12 Is Involved in Dendritic Cell Modulation Via CD40 Ligation. <i>Journal of Immunology</i> , 1999, 163, 2517-2521.	0.4	49
1854	4-1BB Ligand, a Member of the TNF Family, Is Important for the Generation of Antiviral CD8 T Cell Responses. <i>Journal of Immunology</i> , 1999, 163, 4859-4868.	0.4	187
1855	CD40 Ligand Blockade Induces CD4+ T Cell Tolerance and Linked Suppression. <i>Journal of Immunology</i> , 1999, 163, 4805-4810.	0.4	179
1856	CD4+ T Cell Responses to CD40-Deficient APCs: Defects in Proliferation and Negative Selection Apply Only with B Cells as APCs. <i>Journal of Immunology</i> , 1999, 163, 5250-5256.	0.4	26
1857	Visualization, Fate, and Pathogenicity of Antigen-Specific CD8+ T Cells in the Graft-Versus-Host Reaction. <i>Journal of Immunology</i> , 1999, 163, 4780-4787.	0.4	14
1858	Targeting of Human Dendritic Cells by Autologous NK Cells. <i>Journal of Immunology</i> , 1999, 163, 6365-6370.	0.4	144
1859	MHC Class I-Restricted Cytotoxic Lymphocyte Responses Induced by Enterotoxin-Based Mucosal Adjuvants. <i>Journal of Immunology</i> , 1999, 163, 6502-6510.	0.4	64
1860	CD8+ T-cell immunity orchestrated by iNKT cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1861	CD40-CD40L Blockade: Update on Novel Investigational Therapeutics for Transplantation. <i>Transplantation</i> , 0, Publish Ahead of Print, .	0.5	2

#	ARTICLE	IF	CITATIONS
1864	Combined phospholipids adjuvant augments anti-tumor immune responses through activated tumor-associated dendritic cells. <i>Neoplasia</i> , 2023, 39, 100893.	2.3	1
1866	On the Biology and Therapeutic Modulation of Macrophages and Dendritic Cells in Cancer. <i>Annual Review of Cancer Biology</i> , 2023, 7, 291-311.	2.3	5
1867	A Pilot Study to Develop Paraneoplastic Cerebellar Degeneration Mouse Model. <i>Cerebellum</i> , 2024, 23, 181-196.	1.4	0
1868	Immunotoxin- $\hat{\pm}$ CD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	3
1869	I-Ag7 $\hat{\pm}$ 56/57 polymorphisms regulate non-cognate negative selection to CD4+ T cell orchestrators of type 1 diabetes. <i>Nature Immunology</i> , 2023, 24, 652-663.	7.0	4
1870	SARS-CoV-2 versus Influenza A Virus: Characteristics and Co-Treatments. <i>Microorganisms</i> , 2023, 11, 580.	1.6	1
1871	Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles. <i>Acta Biomaterialia</i> , 2023, 161, 213-225.	4.1	3
1872	Immunization against Zika by entrapping live virus in a subcutaneous self-adjuvanting hydrogel. <i>Nature Biomedical Engineering</i> , 2023, 7, 928-942.	11.6	13
1874	Synthesis and Biological Evaluation of Peptide-Adjuvant Conjugate Vaccines with Increasing Antigen Content. <i>Bioconjugate Chemistry</i> , 0, , .	1.8	1
1875	Interrogating the CD27:CD70 axis in $\hat{\pm}$ CD40-dependent control of pancreatic adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	0
1876	Tumor resident memory CD8 T cells and concomitant tumor immunity develop independently of CD4 help. <i>Scientific Reports</i> , 2023, 13, .	1.6	4
1877	Growth Factors and Cancer. , 2023, , 187-241.		0
1880	T cells in health and disease. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	36
1886	Advances in Therapeutic Targeting of the Tumor Necrosis Factor Receptor Superfamily Members for Cancer Immunotherapy. , 2023, , 1-73.		0
1892	Immunity to <i>Cryptosporidium</i> : insights into principles of enteric responses to infection. <i>Nature Reviews Immunology</i> , 0, , .	10.6	3
1895	Systemic Oncosphere: Host Innate Immune System. , 2023, , 419-442.		0
1900	Fc $\hat{\pm}$ 3 receptors and immunomodulatory antibodies in cancer. <i>Nature Reviews Cancer</i> , 2024, 24, 51-71.	12.8	3